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InTRoDuCTIon
Diabetes is a group of metabolic diseases characterized by hyperglycemia. It affects 
approximately 3% of the population worldwide (1). The criteria for the diagnosis of 
diabetes have been proposed by the American Diabetes Association (2) and comprise the 
presence of one of the following conditions: 1. symptoms of diabetes with a concurrent 
casual plasma glucose of ≥11.1 mmol/l, 2. a fasting plasma glucose concentration of 
≥7.0  mmol/l or 3. a two hour glucose post-load level of ≥11.1 during an oral glucose 
tolerance test.
Several pathogenic processes are involved in the development of diabetes (3,4). The vast 
majority of patients with diabetes fall into two broad etiopathogenic categories: type 1- 
and type 2 diabetes. In type 1 diabetes hyperglycemia is caused by an absolute insulin 
deficiency, and can be identified by serological evidence of a pathologic autoimmune 
process in the pancreatic islets and by genetic markers (4). The far more prevalent type 2 
diabetes, which accounts for 90-95% of cases, encompasses individuals who have insulin 
resistance and often have relative (rather than absolute) insulin deficiency. Type  2 
diabetes is frequently associated with overweight and other components of metabolic 
syndrome (hypertension and dyslipidemia).
In diabetes, cardiovascular disease constitutes a major cause of morbidity and 
mortality  (5). Long term complications include microvascular impairment in organs 
(e.g. eyes, heart, kidneys and nerves), as well as macrovascular injuries of the cerebral, 
coronary and peripheral arterial vasculature.
PATHoPHysIoloGy of CoRonARy ARTERy DIsEAsE In DIAbETEs
Previous studies on diabetes and related heart disease have mainly focused on type 2 
diabetes (6,7). The metabolic abnormalities that characterize type 2 diabetes, particularly 
hyperglycemia, free fatty acids, and insulin resistance, provoke various molecular 
mechanisms: increased oxidative stress, disturbances of intracellular signal transduction 
(such as activation of protein kinase C), and activation of receptor for advanced glycation 
endproducts (RAGE) (8,9). Consequently, there is decreased availability of nitric 
oxide, increased production of endothelin, activation of transcription factors such as 
nuclear factor-κB and activation protein-1, and increased production of pro-thrombotic 
factors such as tissue factor and plasminogen activator inhibitor-1 (8,9). In turn, these 
abnormalities contribute to the cellular events that result in endothelial dysfunction, 
atherosclerosis and a pro-thrombotic state. In addition, the increased prevalence of 
coronary artery disease (CAD) in type 2 diabetes is associated with a constellation of 
risk factors. Patients with type 2 diabetes are frequently obese, and often suffer from 
hypertension and exhibit dyslipidemia.
Chapter 1
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The pathophysiology of atherosclerosis in type 1 diabetes has not been fully elucidated 
(10). However, current thinking supports a model similar to type 2 diabetes in which 
hyperglycemia, glycation, and oxidation products cause endothelial dysfunction, pro-
inflammatory, and pro-thrombotic changes. Also, endothelial and smooth muscle 
dysfunction can be a precursor for hypertension, which is in turn a major risk factor for 
CAD. Lipoprotein disturbances are less apparent in type 1 diabetes.
nATuRE of CAD In DIAbETEs
CAD in diabetic patients is suggested to be distinct from the non-diabetic patients (11). 
In type 2 diabetes, evaluation of atheroscleotic plaques in post-mortem studies as well as 
patients undergoing coronary atherectomy suggest more diffuuse CAD, more vulnerable 
eccentric plaques, with greater inflammatory cell infiltration (12). However, prior studies 
often have selection biases, as they are event or procedure driven. Even less information 
is available concerning CAD in type 1 diabetes (10). A detailed investigation of the 
nature of CAD, in a representative general population of type 1- and type 2 diabtetes is 
therefore warranted.
RIsk of CAD In DIAbETEs
The level of incremental risk for CAD disease in diabetes has been a topic of discussion 
in the last decades (13-15). Based on data collected in 1982-1990, Haffner et al. suggested 
the risk of myocardial infarction to be similar in diabetic patients without previous 
myocardial infarction as compared to non-diabetic patients with prior myocardial 
infarction (13). That initial study formed the basis for implementation of aggressive 
medical treatment of all diabetic patients. Accordingly, the 2007 ADA/AHA guidelines 
recommended treatment with statins and blood pressure lowering medication (16). Also, 
the use of aspirin in form of primary prevention was suggested in diabetic patients 
>40 years of age. However, replications of the findings by Haffner et al. have been 
inconsistent, and recent data suggest a more moderate risk of CAD in diabetes (14-15). 
It should also be pointed out that major advances have developed in glucose regulation 
and treatment approaches to diabetes, likely modifying risk of complications. A more 
recent meta-analysis comparing CAD risk in individuals with diabetes with those with 
previous myocardial infarction but without diabetes reported lower overall relative 
odds of CAD events in the individuals with diabetes (14). Of the 13 studies included, 
11 reported significantly lower odds of incident CAD among individuals with diabetes 
(14). Moreover, a recent prospective population-based study in Spain, found a hazard 
ratio of 0.33 for myocardial infarction in individuals with type 2 diabetes compared 
with nondiabetic individuals with a prior myocardial infarction (15). Therefore, it seems 
General Introduction
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diabetes is not the equivalent of previous myocardial infarction with respect to future 
risk of CAD.
Nevertheless, the incremental risk of CAD in diabetes is high and confers worse 
prognosis. As compared to the general population, the risk of CAD events is two to four 
fold in type 2 diabetes. Simillar risk has been reported men with type 1 diabetes (hazard 
ratio 3.0) (17). Whereas a relative higher risk of CAD events has been observed in women 
with type 1 diabetes (hazard ratio 7.6). Considering the wide ranging inter-individual 
variability the question remains how to identify the high-risk diabetic patient.
RIsk sTRATIfICATIon foR CAD In DIAbETEs
In diabetes, a wide ranged routine screening strategy of all patients by non-invasive 
cardiac imaging does not seem cost-effective, and was not shown to influence treatment 
or outcome (18). A pivotal role could be expected for hyperglycemia in development 
of vascular damage. Nevertheless, epidemiological evidence does not directly link the 
level of glycemic control (hemoglobin A 1C) or the duration of hyperglycemia with 
CAD events. Also, an expert based suggestion by the ADA/AHA in 2000 to consider 
the presence of ≥ two additional cardiovascular risk factors as a threshold for increased 
risk of CAD has not been confirmed. This selection strategy was shown to be ineffective 
in the DIAD study (6), wherein 41% of asymptomatic diabetic patients with abnormal 
myocardial perfusion did not have ≥ two risk factors.
The clinical utility of risk prediction models may also be limited. The Framingham score 
has been shown to underestimate event rates in diabetes as compared to the general 
population (19). Prospective evaluation of the diabetes specific UKPDS suggested less 
underestimation, but showed a poor relation between actual and predicted CAD events 
on an individual basis. The SCORE and DECODE models incorporate diabetes in a 
categorical fashion and do not discriminate risk level in presence of diabetes.
It is assumable that direct estimation of atherosclerosis by means of surrogate markers 
may provide more accurate risk stratification for the prevalence and incidence of CAD. 
Indeed, an increased carotid intima media thickness (CIMT) and increased vascular 
stiffness as assessed by pulse wave velocity (PWV), have been observed in diabetic 
patients with established CAD (20,21). In a limited number of studies an increased 
CIMT has also been related with a higher incident rate of CAD events (22,23). However 
the relation of surrogate markers with silent CAD has not been evaluated in an overall 
asymptomatic population of diabetic patients. Furthermore, the incremental value of 
these markers above age and modified risk models, for the prediction of prevalent CAD 
and CAD events has not been evaluated.
Novel serum biomarkers may convey the additional advantage of reflecting on an 
individual’s predisposition to develop CAD in an early stage. Thereby, patients at risk 
Chapter 1
14
Djaberi.indd   14 5-8-2014   15:28:33
for CAD, could be distinguished, prior to evident atherosclerosis and treated more 
aggressively. In addition, application of a biomarker may provide a more general 
estimation of atherosclerotic risk, opposing diagnostic techniques which are often 
restricted to a certain aspect of vascular disease or a specific organ. On the other hand, 
clinical utility of biomarkers is often limited by their low specificity. Research to attain a 
single biomarker with sufficient sensitivity as well as specificity for early recognition of 
atherosclerosis in various sub-populations continues.
Considering the growing number of patients with diabetes, an optimal risk stratification 
strategy for the selection of the high-risk diabetic patient should convey a number of 
characteristics to enable wide range implementation: sufficient sensitivity and specificity, 
low costs and limited side-effects (e.g. radiation) as well as a non-invasive nature.
DIAbETEs CARDIovAsCulAR RIsk MAnAGEMEnT: DIACARM
The diabetes cardiovascular risk management (DIACARM) project is a clinical protocol 
founded on a cooperation of the departments of endocrinology, cardiology, nephrology, 
radiology and nuclear medicine at the Leiden University Medical Center. Herein, 
asymptomatic patients with type 1- or type 2 diabetes, who visit the diabetes outpatient 
clinic are referred to the cardiology department for a cardiac risk stratification.
Initially, the asymptomatic status of the patients is confirmed. The medical history and 
presence of cardiovascular risk factors is registered. Physical examination is performed 
to assess blood pressure, presence of heart failure, peripheral arterial disease and/or 
neuropathy. Blood samples are taken, which are partly used to assess kidney function and 
lipid profile in the clinical setting. Additional plasma and DNA is collected and stored 
General Introduction
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for later analysis in study setting, approved by the institutional review committee of 
the Leiden University Medical Center, Leiden. Non-invasive multi-slice CT angiography 
(CTA) of the coronaries and myocardial perfusion imaging using SPECT is performed as 
part of clinical work up. Concurrent non-invasive vascular measurements are performed 
in a study setting, also approved by the institutional review committee of the Leiden 
University Medical Center, Leiden. Surrogate markers of atherosclerosis comprising of 
CIMT and vascular stiffness parameters are assessed by ultrasound and applanation 
tonometry. Endothelial function is evaluated by the ultrasound assessment of the 
brachial flow mediated dilatation. Furthermore, a novel imaging technique, sidestream 
dark field imaging was applied to study the labial microcirculation at capillary level. All 
obtained data is prospectively recorded in a database. The database was the basis for 
the studies presented in this thesis. The DIACARM is an ongoing protocol and registry 
continues as this thesis is written.
Chapter 1
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objECTIvE AnD ouTlInE of THE THEsIs
The primary objective of the thesis is to evaluate and compare various techniques and 
strategies for risk stratification of CAD in asymptomatic patients with diabetes.
In Part 1 of the thesis CAD and its correlation with various parameters of metabolic 
syndrome are described. Furthermore the nature of CAD in diabetes is assessed. 
Chapter 2 describes the relation of epicardial adipose tissue with CAD as determined by 
CTA. In Chapter 3 the relation of adipose tissue product, adiponectin, with the parameters 
of CAD on CTA is evaluated. Chapter 4 describes and compares the extent, degree and 
morphology of CAD as assessed by CTA in asymptomatic patients with type 1- and 
type 2 diabetes. In Chapter 4, the relation of abnormal myocardial perfusion on SPECT 
in absence of epicardial obstructive CAD with endothelial dysfunction is evaluated. 
Part 2 of the thesis is dedicated to the risk assessment for CAD in asymptomatic patients 
with diabetes. A review of this topic is provided in Chapter 6. In Chapter 7 the relation 
of CIMT with prevalent CAD on CTA is explored. Chapter 8 further describes the 
relation between an increased CIMT with abnormal myocardial perfusion on SPECT. 
In Chapter 9, the parameters of vascular stiffness are evaluated for the prediction of 
abnormal myocardial perfusion on SPECT. The incremental value of coronary artery 
calcium scoring over micro-albuminuria for the prediction of asymptomatic myocardial 
ischemia on SPECT in type 1 diabetes is described in Chapter 10. In Chapter 11, risk 
stratification techniques, comprising the Framingham risk model, CIMT, PWV and 
coronary calcium scoring are compared for the identification of obstructive CAD 
accompanied by abnormal myocardial perfusion. Part 3 of the thesis describes a novel 
technique, sidestream dark field imaging, for the assessment of the microcirculation 
at capillary level. In Chapter 12, the sidestream dark field imaging device is validated 
for the assessment of the labial microcirculation parameters comprising of the capillary 
density and tortuosity. Chapter 13, firstly compares the microcirculation parameters 
in the healthy non-diabetic individuals with that in diabetic patients. Thereafter, the 
relation between microcirculation parameters with the presence of CAD on CTA is 
described in diabetic patients.
Chapter 1
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PART I
Coronary artery disease in 
adiposity and in diabetes
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CHAPTER 2
Relation of Epicardial Adipose Tissue to Coronary Atherosclerosis
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AbsTRACT
Adipose tissue surrounding the coronary arteries has been suggested to induce 
development of atherosclerosis. We explored the relation between epicardial adipose 
tissue (EAT) volume and coronary atherosclerosis using multislice computed tomography. 
The study population consisted of 190 patients who had undergone multislice computed 
tomographic coronary angiography. Coronary artery calcium score was assessed. In 
addition, patients were classified as having (1) no atherosclerosis, (2) nonobstructive 
atherosclerosis (luminal narrowing <50%), (3) obstructive atherosclerosis (luminal 
narrowing ≥50%) in a single vessel or (4) obstructive atherosclerosis in the left main 
and/or multiple vessels. Cross-sectional tomographic cardiac slices (3.00 mm thickness, 
range 35-40 slices per heart) were traced semi-automatically from the border of EAT 
below the apex to a point at the center of the left atrium. Tissue ranging from -250 HU to 
-30 HU was assigned as EAT. EAT volume within the traced area was then automatically 
quantified. Mean EAT volume was 84 ± 41 ml. Patients with a coronary artery calcium 
score >10 had significantly higher average EAT volume (100 ml ± 40) compared to 
patients with calcium scores ≤10 (59 ml ± 27), (P<0.001). Sensitivity and specificity for 
prediction of a calcium score >10 were 77% and 70% with a cut-off EAT value of 73 ml. In 
patients with normal coronaries mean EAT volume (63 ml ±31) was significantly lower 
than in patients with atherosclerosis (99 ml ± 40), (P<0.001). Using a cut-off EAT volume 
of 75 ml, the sensitivity and specificity for presence of atherosclerosis were 72% and 70%. 
Interestingly, the quantity of EAT did not significantly increase with increasing extent 
or severity of atherosclerosis. After adjustments for risk factors EAT volume remained 
a significant predictor of coronary atherosclerosis (P=0.001). In conclusion, a significant 
relation was shown between EAT volume and the presence of coronary atherosclerosis. 
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InTRoDuCTIon
The relation between abdominal adipose tissue and predisposition to coronary artery 
disease (CAD) has been well established. Recent data suggest that epicardial adipose 
tissue (EAT) may also be associated with CAD. In particular, a local inflammatory effect 
has been suggested since EAT directly surrounds the coronary arteries.1,2 To date, several 
modalities have been applied to quantify EAT. Ahn et al observed a good correlation 
between EAT thickness as determined on echocardiography and the presence of 
angiographic CAD.3 However, assessment of EAT by echocardiography is limited to 
measurements of thickness of the adipose tissue on the free wall of the right ventricle. 
As a result, contradictory results have been reported by other investigators.4 multislice 
computed tomography may provide a more accurate and reproducible quantification of 
EAT due to its higher spatial resolution. In addition the technique allows quantification 
of peri-coronary fat thickness and total EAT volume.5 Reproducibility of volumetric 
EAT measurements have shown to be superior to thickness measurements.5 Two 
recent studies have evaluated the association between EAT assessed by multislice 
computed tomography and coronary artery calcium (CAC) scores. A positive association 
was observed between EAT quantity and coronary calcium.6,7 However, the direct 
relationship between EAT quantity assessed by MSCT and the presence of coronary 
atherosclerosis has not been analyzed thus far. This study explores the relation between 
EAT volume assessed by MSCT and the presence of coronary atherosclerosis. The 
association between EAT volume and CAC scores and with the presence and degree of 
coronary atherosclerosis was determined.
METHoDs
The study population consisted of 190 patients who were clinically referred for non-
invasive multislice computed tomographic (MSCT) coronary angiography for the 
evaluation of CAD. Standard exclusion criteria for MSCT coronary angiography were 
ventricular and supraventricular arrhythmia and contraindications for the use of 
iodinated contrast media. In addition patients with poor image quality (n=6) and 
previous cardiac surgery were excluded from the study.
MSCT coronary angiography was performed with a 64-slice MSCT scanner (Toshiba 
Medical Systems, Japan and Lightspeed VR 64, General Electrics, Milwaukee, MI, USA). 
If the heart rate was ≥ 65 beats per minute, oral beta-blockers (metoprolol 50 mg or 100 
mg) were provided 1 hour preceding the scan, if tolerated. Initially, a triggered CAC 
scan was obtained. Hereafter, MSCT angiography was performed using the following 
parameters: collimation 64x0.5 mm or 64x0.625, tube rotation time 350, 400, 450 or 500 
ms depending on the heart rate, tube current 300, 350 or 600 mA, tube voltage 120 kV. 
Non-ionic contrast material was administered in the antecubital vein in an amount of 
27
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80–100 ml, depending on the total scan time, and a flow rate of 5 ml/s, followed by a 
saline solution flush of 50 ml. Automated bolus-tracking in the aortic root was used 
for the timing of the scan. Images were acquired with simultaneous electrocardiogram 
registration during a single breath hold of approximately 10 seconds. Images were 
reconstructed in the cardiac phase showing least motion artifacts. In general, the end-
diastolic phase was used. However, additional reconstructions were made throughout 
the entire cardiac cycle if necessary. Reconstructed images were transferred to remote 
workstations (Advantage, GE Healthcare, USA; and Vitrea 2, Vital Images, USA) for post-
processing.
The CAC score was assessed with the application of dedicated software (Vitrea2, Vital 
Images, USA). Coronary calcium was identified as a dense area in the coronary artery 
exceeding the threshold of 130 Hounsfield units (HU). An overall Agatston score was 
registered for each patient.
All coronary angiograms were evaluated by 2 experienced observers. The presence of 
coronary atherosclerosis was assessed by scrolling through axial images, followed by 
visual assessment of curved multiplanar reconstructions in at least 2 orthogonal planes. 
Patients were classified as having 1. no atherosclerosis 2. non-obstructive atherosclerosis 
(luminal narrowing <50% in diameter) 3. obstructive atherosclerosis (luminal narrowing 
≥50%) in a single vessel or 4. obstructive atherosclerosis in the left main and/or multiple 
vessels.
EAT was quantified using dedicated software (Advantage, GE Healthcare, USA) using the 
same ECG-gated MSCT reconstructions. EAT was defined as the adipose tissue between 
the surface of myocardium and the epicardium. Short axis reconstruction slices (3 mm 
thickness) were created semi-automatically ranging from the surface of epicardium at 
the apex to a cut-off point at the center of the left atrium for each patient. The number of 
slices ranged between 35 and 40 per heart. The outer border of epicardium was traced 
manually on each slice. The total volume within the selected areas (in ml) was produced 
automatically by the computer software program by adding up the EAT areas and taking 
the slice thickness into account. Hounsfield Units ranging from -250 to -30 were assigned 
to isolate adipose tissue within the total selected volume. Adipose tissue within the 
selected volume was then automatically quantified by the software (Figure 1).
Firstly, the relationship between CAC score and EAT volume was analyzed. The study 
population was divided into four groups according to CAC scores: patients with a CAC 
score 0-10, CAC score 11-100, CAC score 101-400 and those with a CAC score >400. Average 
EAT volume and standard deviation were calculated in each group. The independent 
T-test was used to assess the difference in mean EAT volume between the groups. 
ROC curve analysis was used to select a cut-off value for EAT volume. Consequently 
sensitivity and specificity for predicting a CAC score >10 were calculated.
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figure 1.  Quantification of EAT using dedicated software. The outer border of epicardium was 
traced manually on short axis slices from the surface of epicardium at the apex to a cut-off point at 
the center of the left atrium. (a to d) Hounsfield Units (HU) ranging from -250 to -30 were assigned to 
isolate adipose tissue within the total selected volume. Adipose tissue within the selected volume 
was then automatically identified (e) and quantified (f).
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To evaluate the relationship between coronary atherosclerosis and EAT volume, the 
study population was classified into four groups according to the results of the non-
invasive MSCT angiography: patients with normal coronary arteries, patients with non-
obstructive atherosclerosis, patients with obstructive atherosclerosis in a single coronary 
artery and patients with obstructive atherosclerosis in the left main coronary artery and/
or multiple vessels. Average EAT volume and standard deviation were calculated for 
each group, and the independent T-test was applied to evaluate the difference in mean 
EAT volume between the groups. Using ROC analysis a cut-off value was chosen for EAT 
volume. Subsequently sensitivity and specificity for predicting coronary atherosclerosis 
were calculated. Univariate analysis of baseline characteristics was performed to identify 
potential predictors of coronary atherosclerosis. Hazard ratios were calculated with 95% 
confidence interval as an estimate of the risk associated with coronary atherosclerosis. 
To determine the independent predictors of atherosclerosis, multivariate analysis of risk 
factors with p ≤0.05 in the univariate analysis was performed which corrected for the 
baseline characteristics with p ≤0.05 in the univariate analysis.
REsulTs
Patient characteristics are provided in Table 1. Mean age of the study population was 
56 years (± 12). The majority of patients were male (55%).
Mean CAC score was 358 ± 906 in the total population. CAC was absent or ≤10 in 
71 patients (37%) and >10 in 119 patients (63%). Within this group, 45 patients (24%) had 
a CAC score in the range 11-100, 33 patients (17%) had a CAC score in the range 101-
400 and 41 patients (22%) had a CAC score >400. MSCT coronary angiography showed 
normal coronaries in 76 patients (40%). A total of 45 patients (24%) had non-obstructive 
atherosclerosis (luminal narrowing <50%), and obstructive coronary atherosclerosis 
Table 1. Characteristics of the study population (n=190)
Age (years) 56  ± 12
Men 104  (55%)
Body Mass Index (kg/m2) 27  ± 4
Smokers 51  (27%)
Family history of Coronary Artery Disease 87  (46%)
Hypercholesterolemia* 143  (75%)
Hypertension** 134  (71%)
Diabetes Mellitus 20  (11%)
Data are averages ± standard deviation or numbers of patients (%). 
* Total cholesterol level >5.0 mmol/L or use of cholesterol lowering medication.
** Blood pressure > 140/90 mmHg or treatment with antihypertensive medication.
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figure 2. (A) Example of coronary artery calcium scoring with MSCT. Diffuse calcification can be 
observed in the left anterior ascending coronary artery, first diagonal and left circumflex coronary 
artery (arrows). (B) Pearson correlation showed a significant but only moderate correlation between 
EAT volume (milliliters) and CAC scores (r=0.33, p=0.002). Mean EAT volume in patients with a 
CAC score 0-10 and in those with a CAC score >10. (C) Mean EAT volume was significantly higher 
in patients with a CAC score >10. However, it did not significantly differ between patients with 
CAC scores 11-100, 101-400 and >400. (D) Sensitivity and specificity of EAT volume with a cut-off 
value of 73 ml for predicting a CAC score >10 were 77% and 70%, respectively.
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figure 3. Relationship between EAT volume and coronary atherosclerosis. (A) Mean EAT volume 
in patients with no atherosclerosis, non-obstructive atherosclerosis, obstructive single vessel 
atherosclerosis and obstructive left main and/or multi-vessel atherosclerosis. (B) Sensitivity and 
specificity of EAT volume with a cut-off value of 75 ml for predicting coronary atherosclerosis 
were 72% and 70%, respectively.
Table 2. Predictors of Atherosclerosis
univariate Analysis Multivariate Analysis
Characteristic HR (95% CI) P value HR (95% CI) P value 
EAT volume 1.03 (1.02-1.05) <0.001 1.03 (1.01-1.05) 0.001
Age 1.10  (1.06-1.13) <0.001 1.05 (1.00-1.09) 0.03
Hypertension 0.09 (0.04-0.22) <0.001 0.12 (0.03-0.45) 0.002
Hypercholesterolemia 0.09 (0.03-0.25) <0.001 0.06 (0.01-0.24) <0.001
Body Mass Index (kg/m2) 1.11 (1.03-1.20) 0.01 1.04 (0.91-1.18) 0.56
Diabetes Mellitus 1.58 (0.62-4.00) 0.34 - -
Smoking 0.79 (0.40-1.56) 0.46 - -
Family history of 
cardiovascular disease
1.18 (0.63-2.19) 0.61 - -
Male gender 1.06 (0.59-1.89) 0.86 - -
CI= confidence interval, HR= hazard ratio.
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defined as luminal narrowing ≥ 50% was observed in 69 patients (36%). Obstructive 
single vessel atherosclerosis was observed in 43 patients (22%) and 26 patients (14%) had 
obstructive left main and/or multi-vessel atherosclerosis.
EAT volume ranged between 15 ml and 267 ml with an average of 84 ± 41 ml. EAT volume 
showed a tendency to increase with coronary calcium (r=0.33, p=0.002) (Fig 2A). Indeed, 
average EAT volume was significantly higher in patients with a CAC score >10 (100 ml ± 
40) as compared to patients with calcium scores ≤10 (59 ml ± 27), (P<0.001) (Fig 2B). Mean 
EAT volume did not differ significantly between patients with a CAC score 11-100 (94 
ml ±35), CAC score 101-400 (103 ml ± 40) and those with a CAC score >400 (102 ml ± 44) 
(Figure 2B). Using ROC analysis a cut-off value of 73 ml was identified for EAT volume. 
This cut-off value yielded a sensitivity and specificity of respectively 77% and 70% for 
predicting a calcium score >10 (Fig 2C).
In patients with normal coronaries mean EAT volume (63 ml ± 31) was significantly lower 
than in those with atherosclerosis (99 ml ± 40), (P<0.001) (Fig 3A). However, quantity of 
EAT did not significantly differ between patients with non-obstructive and obstructive 
coronary atherosclerosis (P= 0.29). In patients with obstructive atherosclerosis no 
significant difference was observed in mean EAT volume between patients with 
single vessel atherosclerosis (102 ml ± 37) as compared to those with left main and/or 
multi-vessel atherosclerosis  (101 ml ± 50) (P=0.95) (Fig 3A). ROC analysis resulted in a 
sensitivity and specificity of respectively 72% and 70% with an EAT cut-off volume of 
77 ml, for predicting coronary atherosclerosis (Fig 3B).
In a univariate model, age, EAT volume, BMI, hypercholesterolemia and hypertension 
were shown to be predictors of coronary atherosclerosis (Table 2). After adjustment for 
age, BMI, hypertension and hypercholesterolemia in a multivariate model, EAT volume 
remained a significant predictor of coronary atherosclerosis (Table 2).
DIsCussIon
In the present study a relation was shown between EAT volume and the presence of 
CAC and atherosclerosis. Mean EAT volume was significantly higher in patients with 
CAC and/or coronary atherosclerosis on MSCT angiography in comparison to those 
with normal coronaries. Importantly, EAT volume was shown to be an independent 
predictor of coronary atherosclerosis.
Most previous studies which have examined the relationship between CAD and EAT have 
used echocardiography for the quantification of EAT. Thus far, results of these studies 
have been controversial. Ahn et al studied the association between thickness of EAT on 
the free wall of the right ventricle and CAD in patients who underwent conventional 
coronary angiography due to chest pain.3 A positive association was found between 
thickness of EAT and presence of significant coronary stenosis (luminal narrowing 
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≥50%) and with the number of coronary arteries with significant stenosis. In contrast, 
analysis by Chaowalit and colleagues in 139 patients who were referred for conventional 
coronary angiography did not show a significant correlation between EAT thickness 
and the number of atherosclerotic coronary segments.4 The discrepancy between these 
findings may be due to the limitations of echocardiography in quantification of EAT 
including inaccuracy of measurements due to lower resolution (especially in adiposity) 
while also difficulties in the delineation of EAT and pericardial fat may be frequently 
encountered.8 In addition, echocardiographic estimation of EAT quantity is limited to the 
measurement of the EAT thickness on the free wall of the right ventricle, whereas it has 
been shown that the pattern of distribution of EAT surrounding the myocardium may 
vary significantly amongst individuals.9 It is therefore likely that EAT thickness on the 
free wall of the right ventricle may not always be a reliable and accurate representative 
of total EAT quantity.
Multislice computed tomography provides an accurate and reproducible quantification 
of EAT due to its high temporal and spatial resolution. Quantification of both peri-
coronary fat thickness and total EAT volume are possible.5 Reproducibility of volumetric 
EAT measurements has been shown to be superior to thickness measurements.5 Two 
previous studies have analyzed the association between EAT assessed by MSCT using 
CAC as a marker of atherosclerosis. De Vos et al. studied the relation between peri-
coronary fat thickness assessed by MSCT and CAC scores in a female population 
and found a graded relationship.7 Similarly, in a substudy of the Framingham Heart 
investigation (n=1155 individuals) EAT volume was shown to be associated with CAC.6 
The results of the current study are in line with these investigations. Additionally, in 
the current study the presence and extent of coronary atherosclerosis was directly 
assessed by MSCT angiography and studied in relation to the quantity of EAT volume. 
We observed significantly higher mean volume of EAT in patients with coronary 
calcifications. Importantly mean EAT volume was also significantly higher in patients 
with coronary atherosclerosis as compared to those with normal coronaries. However, 
in patients with atherosclerosis no significant relation was observed between mean EAT 
volume and the extent or degree of coronary atherosclerosis.
In our current study EAT volume was shown to be an independent predictor of 
coronary atherosclerosis in addition to the established cardiovascular risk factors. Of 
interest, EAT volume remained a significant predictor even after correction for BMI 
suggesting that EAT volume is not purely a reflection of BMI in the predisposition of 
atherosclerosis. Rather, EAT may stimulate atherosclerosis due to a direct local effect on 
the coronaries. This notion is supported by several studies exploring the inflammatory 
responses of EAT. Mazurek et al. compared the local concentration and expression of 
inflammatory markers between EAT and subcutaneous fat in patients who underwent 
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coronary artery bypass graft surgery.1 Increased expressions and protein levels of 
interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha mRNA were observed 
in the EAT as compared to subcutaneous fat. Thus, inflammatory EAT response was 
not associated with plasma inflammatory biomarkers. In another study by Iacobellis 
and colleagues suppressed levels of the anti-inflammatory adiponectin were observed 
in the EAT samples of high risk cardiac patients.2 However, it could also be argued that 
the inflammatory responses observed in the above studies may be a result of coronary 
atherosclerosis rather than a cause. Accordingly, plaque rupture in the coronary 
arteries and regional myocardial ischemia have been shown to trigger an inflammatory 
reaction in the adjacent adipose tissue stores.10,11 Thus, the precise pathophysiological 
interaction between EAT and the coronary wall with respect to development of coronary 
atherosclerosis remains to be further elucidated.
Several limitations need to be acknowledged. The present study was performed in a 
heterogeneous study population. The current analysis was restricted to evaluation of 
the association between coronary atherosclerosis and EAT quantity. The proatherogenic 
process, which relates EAT and predisposition to atherosclerosis, was not investigated. 
Furthermore, no follow-up data were available. Indeed, whether EAT quantity may have 
a prognostic value needs to be evaluated in prospective follow up studies.
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CHAPTER 3
Reduced Plasma Adiponectin is Associated with Extent, 
Degree and Morphology of Coronary Artery Disease 
in Asymptomatic Patients with Type 2 Diabetes
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AbsTRACT
objective
Reduced plasma adiponectin has been linked to coronary artery disease (CAD). 
However, little is known concerning this relation in type 2 diabetes. We explored the 
relation between plasma adiponectin and the parameters of coronary atherosclerosis in 
asymptomatic patients with type 2 diabetes.
Methods
Prospectively, multi-slice CT angiography (CTA) of the coronaries was performed in 103 
asymptomatic patients with type 2 diabetes. The following parameters of atherosclerosis 
were assessed: presence of any atherosclerosis and obstructive atherosclerosis, athero-
sclerotic plaque burden (number of plaques), and plaque phenotype (number of non-
calcified, mixed, calcified). Parameters of atherosclerosis were studied in relation to 
traditional cardiovascular risk factors, high sensitivity C-reactive protein and plasma 
adiponectin.
Results
An independent inverse relation was observed between plasma adiponectin and the 
presence of any atherosclerosis (P=0.02) and obstructive atherosclerosis (P=0.003). 
Accordingly, an adiponectin cut-off value of <4.5 mcg/ml resulted in a sensitivity and 
specificity of 80% and 71% for predicting obstructive atherosclerosis. An independent 
inverse relation was also observed between plasma adiponectin and the atherosclerotic 
plaque burden (P=0.02). Further analysis demonstrated low plasma adiponectin to be 
independently associated with the quantity of non-calcified (P=0.04), but not with mixed 
or calcified plaques.
Conclusion
Low plasma adiponectin was independently related with the parameters of coronary 
atherosclerosis in asymptomatic patients with type 2 diabetes. A predominant 
association was observed with the presence of non-calcified plaques, which have 
been associated with unstable disease. Assessment of plasma adiponectin conveys the 
potential to augment risk for CAD in asymptomatic patients with type 2 diabetes.
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InTRoDuCTIon
Early identification of patients prone to develop coronary artery disease (CAD) and 
prompt initiation of appropriate therapy has become a main focus in the last decades. In 
consequence, prognosis of CAD has improved in the general population [1]. However, in 
patients with diabetes, excess CAD mortality and morbidity persist despite preventive 
guidelines [1]. Improved ability to gauge risk in the individual patient with diabetes, 
may motivate physicians and patients to adhere preventive therapy, and define those 
who may benefit from more aggressive risk-reduction strategies and further screening 
for CAD.
Nevertheless, the optimal approach for the identification of the high risk patient with 
diabetes remains unclear. In contrast with the general population, risk assessment 
methods based on the traditional clinical cardiovascular risk factors have shown 
limited incremental value in diabetes [2,3]. As a result, the use of surrogate markers 
of atherosclerosis and novel serum biomarkers has gained recent attention for this 
purpose [4,5]. Validated novel serum biomarkers may convey the additional advantage 
of reflecting on an individual’s predisposition to develop CAD in an early stage, prior to 
evident atherosclerosis, enabling successful preventive therapy.
The serum biomarker adiponectin is the most abundant adipocytokine secreted by the 
adipose tissue cells [6]. Synthesis of adiponectin is reduced in obesity, insulin resistance, 
and type 2 diabetes [6,7]. Low levels of serum adiponectin have also been related to the 
presence of atherosclerosis [6]. In line with these observations, genetic and experimental 
studies suggest adiponectin to have an array of anti-atherosclerotic effects [8]. However, 
based on existing epidemiological data in the general population, the prognostic value 
of adiponectin remains controversial [9-11]. Interestingly, cross-sectional studies in 
general patient populations with manifest CAD suggest adiponectin to be related with 
atherosclerosis only below a certain serum threshold [12,13]. Hence, adiponectin may be 
most strongly related with CAD in the presence of type 2 diabetes where low ranges of 
the biomarker are reported [14]. Thus far, only limited information is available on the 
association of plasma adiponectin and CAD in patients with type 2 diabetes [14-16].
In the current study, we explored the relation between plasma adiponectin and 
parameters of coronary atherosclerosis as assessed by multi-slice CT, in asymptomatic 
patients with type 2 diabetes. The association between plasma adiponectin and the 
presence of any atherosclerosis and obstructive atherosclerosis, atherosclerotic plaque 
burden, and plaque phenotype was determined.
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METHoDs
study Design and Patient Characteristics
The study population comprised of 103 asymptomatic patients with type 2 diabetes. 
Patients were included prospectively from an ongoing registry at the diabetes 
outpatient clinic. Diagnosis and classification of diabetes was performed using the 
American Diabetes Association criteria [17]. Accordingly, presence of type 2 diabetes 
(prominent insulin resistance) was distinguished from primary insulinopenia and 
immune destruction of beta pancreas cells by determining plasma levels of C-peptide 
and auto-antibodies to islet cells, insulin and glutamic-acid-decarboxylase. Consecutive 
patients with type 2 diabetes were referred to the cardiology outpatient clinic for risk 
stratification and cardiovascular screening. Anginal symptoms were ruled out using 
a self-completed questionnaire for encountered chest pain [18]. Patients underwent 
clinical and laboratory evaluation. Non-invasive multi-slice CT angiography (CTA), of 
the coronaries was performed as part of clinical work up. Concurrently, plasma was 
collected and stored for later analysis in a study setting, approved by the institutional 
review committee of the Leiden University Medical Center, Leiden. All patients gave 
written consent. Patients not eligible for CTA due to arrhythmia or contraindications for 
the use of iodinated contrast media were excluded.
Cardiovascular risk factors
Presence of cardiovascular risk factors was defined as: 1. smoking (current smoking 
or smoking in the last 2 years), 2. positive family history of CAD (CAD in first degree 
family members <55 years in men or <65 years of age in women), 3. body mass 
index (BMI) as kg/m2, 4. hypertension (blood pressure >140/90 mmHg or treatment 
with antihypertensive medication), 5. hypercholesterolemia (total cholesterol level 
>5.0  mmol/L or use of lipid lowering medication),  and 5. glycosylated hemoglobin 
A1c (HbA1c) as a measure of glycemic control, 6. micro-albuminuria (urine albumin/
creatinine ratio ≥3.5 mg/mmol).
MsCT data acquisition
Imaging was performed using a 64-slice multi-slice CT scanner (Aquilion64, Toshiba 
Medical Systems, Japan). If necessary and tolerated, oral beta-blockers (metoprolol 
50  mg or 100 mg) were provided 1 hour preceding the scan to achieve a heart rate 
<65 beats per minute. First, a non-enhanced prospective electrocardiographically gated 
scan, triggered at 75% of the R-R interval with 4 x 3.0 mm collimation was obtained to 
determine the start and end position of the helical scan.
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Second, CTA was performed using the following parameters: collimation 64 x 0.5 mm, 
tube rotation time 400, 450 or 500 ms depending on the heart rate, tube current 300 
or 350 mA, tube voltage 120 kV. Non-ionic contrast material was administered in the 
antecubital vein at a flow rate of 5 ml/L and the amount of 90–105 ml (depending on the 
total scan time), followed by 50 ml of saline solution flush. Automated bolus-tracking 
in the aortic root was applied for the timing of the scan. Images were acquired with 
simultaneous ECG registration during a single breath hold of approximately 10 seconds. 
Segmental reconstruction algorithm was applied to generate a single image from the 
data of one, two or three consecutive heartbeats. Images were reconstructed in the 
cardiac phase showing least motion artifacts. In general, the end-diastolic phase was 
used. However, additional reconstructions were made throughout the entire cardiac 
cycle if necessary to improve image quality. Subsequently, the images were transferred 
to a remote workstation (Vitrea 2, Vital Images, Minnetonka, USA) for post-processing.
CTA data analysis
All CTA’s were interpreted by two experienced observers blinded to patient characteristics. 
Discrepancies in interpretation were immediately resolved by consensus. The presence 
of coronary atherosclerosis was evaluated by scrolling through axial images, followed 
by visual assessment of curved multiplanar reconstructions in at least two orthogonal 
planes. Coronary plaques were defined as structures of >1 mm2 within and/or adjacent 
to the coronary artery lumen, which could be vividly discriminated from the vessel 
lumen and the surrounding pericardial tissue [19].
Initially, the presence of any atherosclerosis (≥1 plaque in the coronary tree), and 
that of obstructive atherosclerosis (luminal narrowing ≥50%) were evaluated in each 
patient. Thereafter, plaque burden was obtained by determining the total number of 
atherosclerotic plaques and obstructive plaques per patient [19].
Finally, plaques were classified according to phenotype: 1. non-calcified plaques (plaques 
with lower density than contrast-enhanced lumen), 2. calcified plaques (plaques with 
higher density than contrast-enhanced lumen), and 3. mixed plaques (plaques with 
components of low- and high density plaques) [19].
laboratory Analysis
From all patients, blood and urine were collected after fasting overnight. Plasma total 
cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) 
cholesterol, triglycerides, HbA1c and urine albumin/creatinine ratio were determined 
in the hospital laboratory, following clinical evaluation.
Blood samples collected for later analysis of high sensitivity C-reactive protein (hsCRP) 
and adiponectin in study setting were centrifuged. Separated plasma was stored at 
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-80ºC until assayed. All subsequent laboratory analyses were performed blind to patient 
characteristics.
Plasma levels of hsCRP were determined using the Tina-quant immunoassay (Roche 
Diagnostics, United Kingdom) by a Cobas Integra 800 analyzer. The method has a 
detection limit of 0.15 mg/L and a functional sensitivity of 0.3 mg/L. The inter-assay 
and intra-assay coefficients of variation are <3%.
Plasma adiponectin was measured with a commercially available radioimmunoassay 
(Linco Research, Inc, St Charles, Missouri, USA). The sensitivity cut-off was 1 ng/ml. 
The intra-assay and the inter-assay coefficients of variability were 6.21% and 6.90%, for 
mid-range concentrations of adiponectin respectively. Plasma adiponectin results are 
reported in micrograms per millimeter.
statistical Analysis
Variables were expressed as means ± standard deviation, medians (lower quartile – 
upper quartile) or as numbers (percentages) if categorical.
First, the correlation between plasma adiponectin and traditional cardiovascular risk 
factors as well as hsCRP was determined using the Pearsons correlation.
Second, the relations between plasma adiponectin and the presence and degree 
of coronary atherosclerosis were evaluated. For this purpose the median plasma 
adiponectin levels were determined and compared in patients with no atherosclerosis, 
non-obstructive atherosclerosis and obstructive coronary atherosclerosis. The Mann-
Whitney U test was applied to evaluate the difference in plasma adiponectin levels 
between the groups.
Thereafter, the potential predictors of the presence of any coronary atherosclerosis 
and obstructive coronary atherosclerosis on CTA were studied in univariate logistic 
regression models. All baseline traditional cardiovascular risk factors, as well as 
plasma hsCRP and adiponectin levels were included in the analyses. Variables with a 
P value <0.05 were included in a multivariate logistic regression model to identify the 
independent predictors.
Similarly, the predictors of extent of atherosclerosis represented by the number 
of atherosclerotic plaques, and the predictors of obstructive plaques on CTA were 
determined using univariate- and subsequent multivariate linear regression analyses.
Finally, the predictors of plaque phenotype (number of non-calcified, mixed and calcified 
plaques) on CTA were evaluated using univariate- and subsequent multivariate linear 
regression analyses.
Statistical analyses were performed using SPSS software (version 16.0, Inc., Chicago, 
Illinois). P values <0.05 were considered statistically significant.
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REsulTs
study Population
In total, 103 asymptomatic patients with type 2 diabetes, with a mean age of 54±11 years 
were included. Fifty-three patients (51%) were men. Further baseline characteristics and 
traditional cardiovascular risk factors of the patient population are provided in Table 1. 
Diabetes treatment comprised of only diet in 5 patients (5%), oral agents in 69 patients 
(67%) and insulin in 65 patients (63%). At the time of referral, 69 patients (67%) had 
hypertension, of which 58 patients were treated with anti-hypertensive medication. 
Ace-inhibitors were used in 32 (31%), beta-blockers in 16 (16%), angiotensin-II receptor 
antagonists in 23 (22%), calcium channel blockers in 10 (10%) and diuretics in 16 patients 
(16%). Seventy-nine patients (77%) had hypercholesterolemia, and 55 patients (53%) 
were treated with statins. Furthermore, a minority of 26 patients (26%) received aspirin 
therapy at referral.
Table 1. Characteristics of the patient population (N=103)
Age (years) 54  ± 11 
Male sex 53  (51%)
Diabetes mellitus duration (years) 9   ±  7
Smoking 23  (22%)
Family history of CAD 50  (49%)
BMI (kg/m2) 28  (25-34)  
Hypertension 69  (67%)
Anti-hypertensive medication use 58  (56%)
Systolic blood pressur (mmHg) 130 (125-145)
Diastolic blood pressure (mmHg) 80  (79-85)
HbA1c (mmol/L) 8.3 (7.3-9.5) 
Fasting glucose (mmol/L) 9.6  (7.6-12.6)
Hypercholesterolemia 79  (77%)
Statin use 55  (53%)
Total cholesterol (mmol/L) 4.6 (3.8-5.5)
LDL-cholesterol (mmol/L) 2.9 (2.3-3.6)
HDL-cholesterol (mmol/L) 1.2 (1.0-1.5)
Triglycerides (mmol/L) 1.4 (1.0-2.5)
Micro-albuminuria 31  (30%)
Data are averages ± standard deviation, median (lower quartile – upper quartile) or number of patients 
(%).CAD: coronary artery disease, BMI: body mass index, HbA1c: glycosylated hemoglobin A1c, LDL: 
Low-density lipoprotein, HDL: high-density lipoprotein.
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Assessment of coronary atherosclerosis by CTA
As shown in Appendix 1 (page 59), CTA revealed normal coronaries in 36 patients (35%), 
whereas the remaining 67 patients (65%) were shown to have coronary atherosclerosis. 
Within this group, 39 patients (38%) had non-obstructive atherosclerosis and 28 patients 
(27%) had obstructive atherosclerosis.
Overall, the mean number of plaques was 9.3±11.3, and the mean number of obstructive 
plaques was 1.5±3.2. Analysis of plaque phenotype in the total population showed a 
predominance of non-calcified plaques (62%), as compared to a minority of mixed (13%) 
and calcified plaques (25%) (Appendix 1).
Plasma hsCRP and adiponectin levels
Measurement of plasma hsCRP resulted in an overall median value of 2.3 mg/L with an 
inter-quartile range of 1.1 – 5.8 mg/L.
The overall median plasma adiponectin was determined to be 6.6 mcg/ml (3.8 – 11.2). The 
term of interaction was not significant between adiponectin and age, duration of diabetes, 
smoking, family history of CAD, BMI, HbA1c, total cholesterol, LDL-cholesterol or 
hsCRP levels. A positive significant relation was observed between plasma adiponectin 
levels and HDL-cholesterol (Spearman’s correlation coefficient 0.45, P<0.001). An inverse 
relation was observed between plasma adiponectin and triglycerides (Spearman’s 
correlation coefficient -0.16, P=0.01) as well as with the male sex (Spearman’s correlation 
coefficient -0.25, P=0.01).
Relation of plasma adiponectin with coronary atherosclerosis on CTA
As illustrated in Appendix 2 (page 60), median plasma adiponectin decreased only 
modestly from 9.6 mcg/ml (5.4-13.2) in patients with no atherosclerosis to 7.5 mcg/ml 
(4.7-11.1) in presence of non-obstructive atherosclerosis on CTA (P=0.23). Importantly, a 
significant further decrease was observed in the median plasma adiponectin of patients 
with obstructive coronary atherosclerosis (3.8 mcg/ml (2.8-4.7)) (P<0.001) (Appendix 2).
Predictors of the presence of any atherosclerosis and obstructive atherosclerosis
Using univariate logistic regression analysis, age, a positive family history for CAD, 
hypertension, low HDL-cholesterol, triglycerides, micro-albuminuria and low plasma 
adiponectin were identified as potential predictors of the presence of any coronary 
atherosclerosis on CTA (Table 2). Of note, plasma adiponectin maintained a significant 
inverse relation with the presence of coronary atherosclerosis (P=0.02), after correction 
for other predictors of any coronary atherosclerosis.
Similarly, age, male sex, low HDL-cholesterol, micro-albuminuria and low plasma 
adiponectin were shown to have a significant relation with the presence of obstructive 
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coronary atherosclerosis (Table 2). Importantly, analysis in a multiple logistic regression 
model, revealed low plasma adiponectin to be an independent predictor of the presence 
of obstructive coronary atherosclerosis on CTA (P=0.003).
Using ROC curve analysis a cut-off value of 4.50 mcg/ml was identified for plasma 
adiponectin level. This cut-off value yielded a sensitivity and a specificity of 80% and 
71% for predicting obstructive coronary atherosclerosis on CTA, in asymptomatic 
patients with type 2 diabetes (Figure 1).
Predictors of the extent of coronary atherosclerosis
Age, HbA1c, micro-albuminuria, hsCRP and low plasma adiponectin were significantly 
related with the extent of coronary atherosclerosis, as represented by the number of 
atherosclerotic plaques on CTA, in a univariate linear regression model (Table 3). The 
Plasma Adiponectin (mcg/ml)
SpecicitySensitivity








figure 1. Predictive value of plasma adiponectin for the presence of obstructive coronary 
atherosclerosis. ROC curve analysis yielded a sensitivity and specificity of 80% and 71% with 
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inverse relation between plasma adiponectin with the extent of coronary atherosclerosis 
remained significant after correction in a multivariate linear regression model (P=0.02).
Likewise, as shown in Table 3, low plasma adiponectin was shown to be independently 
associated with the number of obstructive coronary atherosclerotic plaques on CTA 
(P=0.04).
Predictors of atherosclerotic plaque phenotype
The relation of the traditional cardiovascular risk factors, hsCRP and plasma adiponectin 
with coronary atherosclerotic plaque phenotype is provided in Table 4. Briefly, hsCRP 
(P=0.001) and low plasma adiponectin (P=0.04) were shown to be independently 
associated with the number of non-calcified coronary atherosclerotic plaques on CTA. 
Age, duration of diabetes, hypertension, micro-albuminuria and hsCRP were associated 
with mixed atherosclerotic plaques, but all lost significance in a multi-variate linear 
regression model. Age was shown to be the only independent factor associated with the 
number of calcified coronary atherosclerotic plaques on CTA (P=0.002).
In consequence, plasma adiponectin was independently associated with the quantity of 
non-calcified, but not with mixed or calcified coronary atherosclerotic plaques (Table 4).
DIsCussIon
In the current study of asymptomatic patients with type 2 diabetes, an inverse 
relation was observed between plasma adiponectin and the presence and extent of 
coronary atherosclerosis. Of note, the relation between low adiponectin and coronary 
atherosclerosis remained significant after correction for traditional cardiovascular risk 
factors and hsCRP. Low adiponectin was strongly related with obstructive atherosclerosis. 
Accordingly, an adiponectin cut-off value of <4.5 mcg/ml resulted in a sensitivity of 80% 
for predicting obstructive atherosclerosis in asymptomatic patients with type 2 diabetes. 
Whereas no relation was observed between adiponectin and mixed or calcified coronary 
atherosclerotic plaques, an inverse association was shown between adiponectin and 
the quantity of non-calcified plaques. Thereby, in asymptomatic patients with type 2 
diabetes, low plasma adiponectin predominantly contributed to the presence and extent 
of coronary atherosclerosis by predisposing non-calcified coronary atherosclerotic 
plaques.
Assessment of coronary atherosclerosis by CTA
CTA provides imaging of the structure and composition of the coronary arteries, thus 
allowing the evaluation of atherosclerosis. Importantly, in diabetic patients the diagnostic 
accuracy of CTA for the detection of obstructive atherosclerosis has been shown to 
be excellent, with a sensitivity of approximately 95% [20]. In addition, the technique 
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provides information on atherosclerotic plaque burden and plaque composition [19]. In 
retrospective studies, calcified coronary plaques have been associated with advanced 
but stable stages of atherosclerosis [21]. On the contrary, non-calcified plaques have 
been linked to the relatively early but more unstable stages of the disease [21]. Thus 
far limited studies have addressed the risk factors associated with the presence of 
coronary atherosclerosis and its morphology in asymptomatic patients with type 2 
diabetes [22]. Due to its non-invasive nature, multi-slice CTA of the coronaries provides 
the possibility to assess atherosclerosis in asymptomatic patients with type 2 diabetes. 
Thereby, coronary atherosclerosis and its morphology can be evaluated in relation to 
both traditional risk factors and novel biomarkers, thus improving the understanding 
of pathophysiology of atherosclerosis in type 2 diabetes, as well as enabling targeted 
management strategies.
Relation of adiponectin with coronary atherosclerosis
Based on in vitro and animal studies, low adiponectin has been suggested to be 
an  important causal link between adipose tissue dysfunction and atherosclerosis 
[23-27]. Adiponectin inhibits atherosclerosis by acting as an endogenous modulator of 
endothelial function through suppressing adhesion molecules [23], by inhibiting NF-κB 
[24], an interaction with interleukin-10 against vascular inflammation [25] and reduction 
of cholesterol uptake in macrophages and their transformation into foam cells [26]. In 
addition, adiponectin reduces vascular smooth muscle cell proliferation, migration and 
apoptosis [27]. A number of genetic studies confirm and extent the evidence implicating 
anti-atherogenic effects of adiponectin [8,28,29]. For instance, administration of 
recombinant adenovirus expressing human adiponectin to apoE-deficient animals 
caused a 30% reduction in the formation of atherosclerotic plaques [28]. Furthermore, 
in a meta-analysis of 827 individuals with CAD and 1887 without CAD, the adiponectin 
gene variant with the polymorphism +276GàT was associated with a 45% decreased risk 
for CAD [29].
Nevertheless, the predictive value of plasma adiponectin for cardiovascular events has 
been variable in the general population [9-11]. In an initial 6 years follow-up study of 
18225 male participants, individuals with the highest quintile of adiponectin (24.9-56.1 
mcg/mL) compared with the lowest (2.4-10.5 mcg/mL), showed a substantial decrease 
in risk of coronary events even after correction for other cardiovascular risk factors (RR 
0.56, 95% CI 0.32-0.99) [9]. In contrast, in a prospective study and meta-analysis by Sattar 
and colleagues, comparison of men in the top adiponectin tertile with the lowest tertile, 
revealed a much more moderate association with coronary events (OR 0.84, 95% CI 0.70-
1.01) [11]. However, in cross-sectional studies, low thresholds of plasma adiponectin of 
<4.0-5.5 mg/L have been consistently associated with CAD [12,13].
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Adiponectin as a predictor of coronary atherosclerosis in type 2 diabetes
In the general population, a large variation is observed in the plasma adiponectin 
levels, which range up to 25 mcg/mL [11]. As a consequence, adiponectin levels may 
be a poor marker of coronary atherosclerosis in the general population. On the other 
hand, coherent to adipose tissue dysfunction, adiponectin levels are relatively low in 
patients with type 2 diabetes and mainly range 2-12 mcg/mL [14]. Therefore, assessment 
of adiponectin particularly in patients with type 2 diabetes is likely to yield a higher rate 
of low adiponectin levels, which predispose coronary atherosclerosis. Consequently, 
adiponectin may be a more effective marker of coronary atherosclerosis in type 2 
diabetes.
As in the general population, the pathogenesis of atherosclerosis is multi-factorial in 
type  2 diabetes. However, excessive visceral adipose tissue which prompts insulin 
resistance, may play a more pivotal role in clustering of cardiovascular risk and 
development of atherosclerosis in patients with type 2 diabetes [6]. As visceral 
adipose tissue expands, macrophages infiltrate adipose tissue resulting in adipose 
tissue dysfunction [30]. This phenomenon increases the production of adipocytokines 
involved in glucose metabolism (e.g. resistin), lipid metabolism (e.g. cholesterol ester 
transfer protein), coagulation (plasminogen activator inhibitor-1) and inflammation (e.g. 
tumor necrosis factor-α, interleukin-6, C-reactive protein) [6]. Only the production of 
the adipocytokine adiponectin decreases during this process [6]. Being produced by 
adipocytes, a low plasma adiponectin concentration is a good marker of adipose tissue 
dysfunction [31].
The results of the current study indeed confirm an association between adiponectin and 
the presence, degree and extent of coronary atherosclerosis in asymptomatic patients 
with type 2 diabetes. Of note, a plasma adiponectin of <4.5 mcg/mL was associated with 
a sensitivity of 80% for the presence of obstructive atherosclerosis in this population 
of patients. These findings confirm previous observations in patients with type 2, 
wherein adiponectin was found to be inversely associated with coronary events [15, 16]. 
In a study by Schulze et al, the predictive value of adiponectin was attenuated by HDL 
cholesterol [15]. In contrast, in the current population of asymptomatic patients with 
type 2 diabetes, low adiponectin was shown to be associated with the presence, degree 
and extent of atherosclerosis also after correction for traditional risk factors (including 
low HDL cholesterol) and hsCRP.
In line with the current study results, previous studies in asymptomatic patients with 
type 2 diabetes have revealed a high prevalence of obstructive atherosclerosis (26-34%) 
and a high proportion of non-calcified coronary plaques (41-66%) [32,33]. Prognostic 
data suggest the presence of not only obstructive atherosclerotic plaques, but also 
non-calcified coronary plaques to convey an increased risk for coronary events [34]. 
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Importantly, low adiponectin, akin to hsCRP (a marker of inflammation), was shown to 
be especially related with non-calcified atherosclerotic plaques.
Use of a biomarker, such as adiponectin, for the cardiovascular risk stratification 
of asymptomatic patients with type 2 diabetes may comprise several advantages. 
Potentially, patients at risk for CAD, could be distinguished at an early stage, prior to 
clinically manifest atherosclerosis and treated more aggressively. In addition, application 
of a biomarker may provide a more general estimation of atherosclerotic risk, opposing 
non-invasive vascular or cardiac imaging techniques which are often restricted to a 
certain aspect of vascular disease or a specific organ. On the other hand, clinical utility 
of biomarkers has often been limited by their low specificity [35]. Although several 
biomarkers (e.g. hsCRP) show a strong correlation with CAD in study populations, 
the inverse claim that elevated markers indicate a high risk has often been difficult to 
substantiate [35]. Remarkably however, in this study of asymptomatic patients with 
type 2 diabetes, low adiponectin (<4.5 mcg/mL), was not only associated with a good 
sensitivity, but also with a reasonable specificity of 71% for predicting obstructive 
coronary atherosclerosis.
study limitations
The current study was limited to the evaluation of the relation between adiponectin and 
coronary atherosclerosis in patients with type 2 diabetes, and assessment did not include 
a non-diabetic control group. As CTA is accompanied with radiation exposure, it is not 
feasible to perform a similar assessment in asymptomatic subjects free of cardiovascular 
risk. Furthermore, the prognostic value of adiponectin was not evaluated as no follow-
up data were available.
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ConClusIon
Low plasma adiponectin was independently related with the presence, degree and 
extent of coronary atherosclerosis in asymptomatic patients with type 2 diabetes. A 
predominant association was observed with the presence of non-calcified plaques. 
Assessment of plasma adiponectin conveys the potential to augment risk for CAD in 
asymptomatic patients with type 2 diabetes.
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Appendix 1. Results of CTA in asymptomatic patients with type 2 diabetes. Pie-chart on the 
top left presents the results of CTA at patient level. Pie-chart on the bottom right presents the 
distribution of plaque phenotype in patients with atherosclerotic plaques.
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Appendix 2. Relation of plasma adiponectin with coronary atherosclerosis as assessed by CTA. 
Plasma adiponectin decreased with the presence and degree of coronary atherosclerosis.
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CHAPTER 4
Differences in Atherosclerotic Plaque burden and 
Morphology between Type 1 and 2 Diabetes Mellitus 
as Assessed by Multi-slice Computed Tomography
Roxana Djaberi, Joanne D. Schuijf, Eric Boersma, Lucia J.M. Kroft, Alberto M. 
Pereira, Johannes A. Romijn, Arthur J. Scholte,  J. Wouter Jukema, Jeroen J. Bax.
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AbsTRACT
objective
It is unclear whether coronary atherosclerotic plaque burden is similar in patients 
with type 1 and type 2 diabetes. By using multi-slice CT (MSCT) the presence, degree 
and morphology of coronary artery disease (CAD) in type 1 and type 2 diabetes were 
compared.
Research design and methods
Prospectively, coronary artery calcium (CAC) scoring and MSCT coronary angiography 
were performed in 135 asymptomatic patients (65 patients with type 1 and 70 patients 
with type 2 diabetes). The presence and extent of coronary atherosclerosis as well as 
plaque phenotype were assessed and compared between groups.
Results
No difference was observed in average CAC score (217±530 vs. 174±361) nor the prevalence 
of coronary atherosclerosis (65% vs. 71%) in type 1 and type 2 diabetes. However, the 
prevalence of obstructive atherosclerosis was higher in patients with type 2 diabetes 
(n=24; 34%) as compared to type 1 diabetes (n=11; 17%) (P=0.02). Also, higher mean 
number of atherosclerotic and obstructive plaques was observed in type 2 diabetes. In 
addition, the percentage of non-calcified plaques was higher in type 2 diabetes (66%) 
versus type 1 diabetes (27%) (P<0.001), resulting in a higher plaque burden for each CAC 
score as compared to type 1 diabetic patients.
Conclusions
Although CAC scores and prevalence of coronary atherosclerosis were similar between 
patients with type 1 and type 2 diabetes, CAD was more extensive in the latter. Also, a 
relatively higher proportion of non-calcified plaques was observed in type 2 diabetes. 
These observations may be valuable in the development of targeted management 
strategies adapted to diabetes type.
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InTRoDuCTIon
Cardiovascular disease and coronary artery disease (CAD) in particular constitute a major 
cause of morbidity and mortality in patients with diabetes (1). However, management 
of this patient population remains challenging. Current European guidelines regard 
type 2 diabetes as a CAD equivalent, whereas type 1 diabetes is considered a high risk 
state only in presence of microalbuminuria (2). In contrast, US guidelines on primary 
prevention recommend stringent pharmacological therapy with lipid and blood pressure 
goals comparable to those in secondary prevention in all diabetic patients regardless 
of type (3). Notably, these guidelines are based on clinical trials in type 2 diabetes. 
However, CAD in type 1 diabetes, which has been studied less extensively, may have 
a distinct pathophysiology from type 2 diabetes. As a result, caution is indicated when 
extrapolating clinical observations obtained in type 2 diabetes to patients with type 1 
diabetes. To date, it is unclear whether asymptomatic type 1 diabetic patients equally 
benefit from the current preventive treatment strategies.
To optimize guidelines for type 1 diabetic patients, more detailed understanding of 
coronary atherosclerosis in type 1 diabetes is required. Thus far, most studies have 
evaluated the complications and risk factors associated with microvascular disease in 
this population (4). Studies of CAD have focused mainly on type 1 diabetic patients with 
kidney failure undergoing coronary angiography before kidney transplantation  (5). 
Limited information is available on the presence and morphology of CAD in 
asymptomatic patients with type 1 diabetes in daily clinical practice (6).
Multi-slice Computed Tomography (MSCT) allows evaluation of coronary artery calcium 
(CAC) score and direct assessment of coronary artery integrity. Importantly, in diabetic 
patients the diagnostic accuracy of MSCT coronary angiography for the detection of 
significant stenoses has been shown to be similar to the general population  (7). In 
addition, the technique provides information on atherosclerotic plaque burden and 
to some extent on plaque composition (8-10). Previous studies with MSCT revealed 
an increased prevalence of non-calcified coronary plaques, which have been linked to 
unstable CAD, in type 2 diabetes (11,12). However, thus far no studies have addressed 
plaque morphology in patients with type 1 diabetes. To improve understanding of 
potential differences in pathophysiology and atherosclerotic patterns as well as for 
development of more targeted management strategies, the evaluation of differences in 
plaque composition on MSCT may provide valuable information.
Therefore, the purpose of the present study was to explore and compare the extent, 
degree and morphology of coronary atherosclerosis by MSCT in asymptomatic patients 
with type 1 and type 2 diabetes recruited from a regular diabetes clinic.
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REsEARCH DEsIGn AnD METHoDs
Patients and design
A total of 135 consecutive asymptomatic patients with DM were prospectively included 
from an ongoing registry of new patients at the diabetes outpatient clinic. Diabetic 
patients were referred to the cardiology outpatient clinic for cardiovascular screening. 
Patients were stratified as having type 1 or type 2 diabetes according to the ADA 
criteria (13). Plasma levels of C-peptide and auto-antibodies to islet cells, insulin and 
glutamic-acid-decarboxylase (GAD) were determined to distinguish between primary 
insulinopenia and immune destruction of beta pancreas cells (type 1 diabetes) and 
insulin resistance (type 2 diabetes).
Asymptomatic status was confirmed using the Rose questionnaire for angina (14). A 
structured interview, physical examination and laboratory analysis were acquired 
in all patients. Cardiovascular risk factors were assessed according to the following 
criteria: 1) positive family history of CAD (CAD in first degree family members 
<55  (men) or <65 (women) years of age), 2) smoking (current smoking or smoking 
in the last 2 years), 3) hypertension (blood pressure >140/90 mmHg or treatment 
with antihypertensive medication), 4) hypercholesterolemia (total cholesterol level 
>5.0  mmol/L or use of  cholesterol lowering medication), 5) obesity (estimated by 
body mass index [BMI=Kg/m2]), 6) level of glycemic control defined by plasma HbA1c 
(mmol/L), 7) diabetic nephropathy (urine albumin/creatinine ratio ≥35 mg/mmol) and 
8) renal function (estimated by glomerular filtration rate [GFR]).
Non-invasive MSCT coronary angiography was performed in all patients as part of 
a clinical protocol. Exclusion criteria consisted of ventricular and supraventricular 
arrhythmia and contraindications for the use of iodinated contrast media.
MsCT data acquisition
Imaging was performed with a 64-slice MSCT scanner (Toshiba Medical Systems, 
Tokyo, Japan). In case of a heart rate ≥ 65 beats per minute, oral beta-blocking medication 
(metoprolol 50 mg or 100 mg) was provided 1 hour preceding the scan, if tolerated. First, 
a prospective CAC scan without contrast enhancement was performed, followed by 
MSCT coronary angiography according to protocols described previously (15).
Assessment of CAD by MsCT
CAC score
CAC score was assessed using dedicated software (Vitrea2; Vital Images, Minnetonka, 
MN). CAC was identified as a dense area in the coronary artery exceeding the threshold 
of 130 Hounsfield units. A total Agatston score was determined for each patient.
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Coronary atherosclerosis
All MSCT coronary angiograms were interpreted by two experienced observers blinded 
to the patients characteristics. Discrepancies in interpretation were immediately 
resolved by consensus. The presence of coronary atherosclerosis was evaluated by 
scrolling through axial images, followed by visual assessment of curved multiplanar 
reconstructions in at least two orthogonal planes. Coronary plaques were defined as 
structures >1 mm2 within and/or adjacent to the coronary artery lumen, which could be 
clearly distinguished from the vessel lumen and the surrounding pericardial tissue (10).
First, the presence of any atherosclerosis (≥1 plaque in the coronary tree), multi-vessel 
atherosclerosis (≥1 plaque in minimum two coronary arteries), and that of obstructive 
atherosclerosis (luminal narrowing ≥ 50%) were evaluated at the patient level, in type 1 
and type 2 diabetic patients. Thereafter, a more extensive analysis of plaque burden 
was obtained by registering the total number of atherosclerotic plaques and obstructive 
plaques for each patient (10).
In addition, plaques were classified according to phenotype: 1) non-calcified plaques 
(plaques with lower density than contrast-enhanced lumen), 2) calcified plaques (plaques 
with higher density than contrast-enhanced lumen), and 3) mixed plaques (plaques with 
components of low- and high density plaques) (8-10).
statistical Analysis
Continuous variables were expressed as means ± standard deviation and compared 
between the group of patients with type 1 and type 2 diabetes by using the two-tailed 
independent t-test. Categorical variables were expressed as numbers (percentages) or 
medians (lower-quartile, upper-quartile) and compared with a χ2-test.
Separate multivariate regression analyses with backward elimination were performed 
correcting for all baseline clinical characteristics including age, male gender, BMI, 
smoking, positive family history of CAD, hypercholesterolemia, hypertension, 
HbA1c, GFR and type of diabetes, to identify independent predictors of each coronary 
atherosclerosis variable on MSCT.
The relationship between CAC scores and extent of coronary atherosclerosis was 
compared in type 1 and type 2 diabetes. Patients were further classified according to 
CAC scores: 1) patients without coronary calcium, 2) patients with a CAC score in the 
range 1-100 and 3) patients with a CAC score >100. The mean number of atherosclerotic 
lesions was determined for each CAC score category.
Statistical analyses were performed using SPSS software (version 12.0.1, SPSS, Chicago, 
Illinois) and SAS software (version 6.12; SAS Institute, Cary, North Carolina). P <0.05 was 
considered statistically significant.
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REsulTs
Patient characteristics
A total of 135 asymptomatic diabetic patients were included in the study. Mean age 
was 48±10 years and 79 patients (59%) were male. The study population consisted of 
65 patients with type 1 and 70 patients with type 2 diabetes. Baseline characteristics 
are provided in Table 1. Importantly, age and gender distribution were comparable in 
patients with type 1 and type 2 diabetes. However, patients with type 2 diabetes had a 
significantly higher BMI and HbA1c and a shorter duration of diagnosed diabetes. Other 
baseline cardiovascular risk factors were similar in the two groups.
Assessment of CAD by MsCT
CAD at patient level
Results of CAD assessment by MSCT are illustrated in Table 2. The mean CAC score 
and prevalence of atherosclerosis were similar among patients with type 1 and type 2 
diabetes. However, the prevalence of multi-vessel atherosclerosis was higher in patients 
with type 2 (n = 41; 59%) diabetes than in type 1 (n = 19; 29%) diabetes (P = 0.001). Finally, 
obstructive stenosis was more prevalent in type 2 diabetes (n = 24; 34%) than in type 1 
diabetes (n = 11; 17%) (P = 0.02).
Plaque analysis
Quantification of the total number of atherosclerotic plaques for each patient revealed a 
significantly higher mean number of lesions in patients with type 2 diabetes (9.9 ± 11.9) 
as compared to patients with type 1 diabetes (3.4 ± 4.8) (P < 0.001) (Fig. 1A). In addition, 
the mean number of obstructive plaques was significantly higher in type 2 diabetes 
(1.7 ± 3.9) than in type 1 diabetes (0.5 ± 1.4) (P = 0.02) (Fig. 1A).
Analysis of plaque phenotype showed a higher mean number of non-calcified plaques in 
type 2 diabetes (6.5 ± 9.5) versus type 1 diabetes (1.0 ± 1.3) (P < 0.001), whereas the mean 
number of mixed- and calcified plaques was not significantly different. Accordingly, 
a higher proportion of non-calcified plaques was observed in type 2 diabetes (66%) in 
comparison with type 1 diabetes (27%) (P < 0.001) (Fig. 1B).
Relation between type of diabetes and the presence and extent of CAD
To correct for baseline characteristics, the relation between type 2 diabetes (as compared 
to type 1 diabetes) and the presence and extent of CAD was evaluated using multivariate 
regression analyses (Table 3). Although type of diabetes was not related to the presence of 
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any atherosclerosis, type 2 diabetes strongly related to the extent and degree of coronary 
atherosclerosis after correction for all other risk factors. In addition, an independent 
association was observed between the presence of type 2 diabetes and increased number 
of non-calcified coronary plaques.
Table 1. Characteristics of the study population (n=135)
Characteristic DM1 (n=65) DM2 (n=70) P value
Age (years) 46.0 (38.0-54.5) 49.5 (45.0-57.0) 0.08
Men  42 (65%) 37 (53%) 0.17
BMI (Kg/m2) 23.8 (22.2-26.6) 28.2 (24.9-33.4) <0.001
Smokers 17 (26%) 14 (20%) 0.40
Family history of CAD 30 (46%) 37 (53%) 0.44
Hypercholesterolemia 41 (63%) 50 (71%) 0.30
Hypertension 32 (49%) 43 (61%) 0.22
Duration of DM (years) 23.0 (9.5-33.0) 7.5 (2.0-13.0) <0.001
HbA1c (mmol/L) 7.6 (6.6-8.6) 8.3 (7.0-9.5) 0.04
GFR (mL/min/1.73m2) 101.6 (84.7-122.8) 98.4 (81.8-124.8) 0.88
Albuminuria* 1 (2%) 4 (6%) 0.20
Data are medians (lower quartile, upper quartile) or number of patients (%). BMI = body mass index, 
CAD = coronary artery disease, DM = diabetes mellitus. *Albuminuria was defined by a urine albumin/
creatinine ratio ≥35 mg/mmol.
Table 2. Results of MSCT coronary angiography 
DM1 DM2 P value
Patients
Coronary artery calcium scores 217 ± 530 174 ± 361 0.59
Atherosclerosis 42 (65%) 50 (71%) 0.40
Atherosclerosis Multi-vessel 19 (29%) 41 (59%) 0.001
Obstructive Atherosclerosis* 11 (17%) 2 (34%) 0.02
Plaques
No of plaques 3.4 ± 4.8 9.9 ± 11.9 <0.001
No of obstructive plaques 0.5 ± 1.4 1.7 ± 3.9 0.02
No of non-calcified plaques 1.0 ± 1.3 6.5 ± 9.5 <0.001
No of mixed plaques 0.7 ± 1.3 1.1 ± 1.9 0.25
No of calcified plaques 1.8 ± 3.6 2.2 ± 3.9 0.52
Data are mean ± standard deviation, median (lower quartile, upper quartile) or number of patients (%). 
* Obstructive Atherosclerosis defined as luminal narrowing ≥50%.
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figure
1A. Clustered columns demonstrating average number of lesions and obstructive lesions in type 1 
(DM1) and type 2 (DM2) diabetes. A significantly higher mean number of lesions and obstructive 
lesions were observed in type 2 diabetes.
1b. Bar graph illustrating plaque phenotype in type 1 and type 2 diabetes. A higher percentage of 
non-calcified plaques was observed in type 2 diabetes.
1C. Clustered bar graph illustrating the increase in number of lesions for each CAC score category 
among patients with type 1 and type 2 diabetes. Plaque burden was significantly higher in type 2 
diabetes for each CAC score category.
1D. Clustered bar graph demonstrating the increase in prevalence of obstructive atherosclerosis 
for each CAC score category among patients with type 1 and type 2 diabetes. Absence of coronary 
calcium excluded obstructive atherosclerosis in type 1 diabetes, but not in type 2 diabetes. 
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Relation between CAC scores and atherosclerosis
Comparison of the CAC score versus coronary angiography showed that the number of 
atherosclerotic lesions paralleled the increase in coronary calcium (Fig. 1C). However, for 
each CAC score category the mean number of atherosclerotic lesions was significantly 
higher in patients with type 2 diabetes (Fig. 1C).
Similarly, the prevalence of obstructive atherosclerosis increased per CAC score category 
(Fig. 1D). Importantly, absence of coronary calcium excluded the presence of obstructive 
atherosclerosis in type 1 diabetes, whereas obstructive atherosclerosis was identified 
in 3 patients with type 2 diabetes (9%). In patients with a CAC score ≤100, obstructive 
atherosclerosis was found in only 2 (4%) in type 1 diabetic patients, whereas 10 (19%) 
type 2 diabetes patients showed obstructive CAD.
ConClusIons
In the present study, no significant difference was observed in the prevalence of 
atherosclerosis in asymptomatic patients with type 1 and type 2 diabetes. However, 
in type 1 diabetes, multi-vessel disease was less prevalent and a lower atherosclerotic 
plaque burden was observed. Moreover, the number of obstructive coronary lesions was 
Table 3. Presence of type 2 diabetes (not type 1 diabetes) as a predictor of MSCT variables. Results 
of multivariate analysis in a backward regression model. Predictive value of type 2 diabetes was 
tested in a separate multi-variate regression model for each MSCT variable.
HR or ß (95% CI) P value
Patients
Coronary artery calcium score* - NS
Atherosclerosis† - NS
Atherosclerosis Multi-vessel† 4.16 (1.76-9.93) 0.001
Obstructive Atherosclerosis‡,† 4.01 (1.38-11.60) 0.01
Plaques
No of plaques* 6.82 (3.51-10.13) <0.001
No of obstructive plaques* 1.40 (1.32-2.48) 0.01
No of non-calcified plaques* 6.27 (3.60-8.94) <0.001
No of mixed plaques* - NS
No of calcified plaques* - NS
NS = Not significant.
* Results of analysis in a multivariate linear regression model.
† Results of analysis in a multivariate binary logistic regression model.
‡ Obstructive Atherosclerosis defined as luminal narrowing ≥50%.
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significantly lower in patients with type 1 diabetes. The presence of type 2 diabetes 
(as opposite to type 1 diabetes) was shown to be an independent predictor of extent 
and degree of coronary atherosclerosis on MSCT angiography. Second, for each CAC 
score category a higher atherosclerotic plaque burden was observed in type 2 diabetes. 
This observation was explained by the high proportion of non-calcified plaques in 
asymptomatic patients with type 2 diabetes compared with a high proportion of calcified 
plaques in type 1 diabetes.
Plaque burden
Most previous studies on the prevalence of coronary atherosclerosis have used 
conventional coronary angiography to examine patients with clinical suspicion of 
CAD and observed more extensive CAD in diabetic patients as compared to their non 
diabetic counterparts (16-17). Limited studies have been performed in asymptomatic 
diabetic patients. MSCT provides accurate non-invasive evaluation of the extent and 
degree of coronary atherosclerosis and may be used in patients with lower likelihood 
of CAD. Importantly, excellent sensitivity, specificity and negative predictive values 
for detection of significant stenosis have also been shown in diabetic patients (7). Thus 
far, the technique has been used in several studies to explore the presence and extent 
of CAD in patients with type 2 diabetes. Scholte et al observed a high prevalence of 
coronary atherosclerosis (80%), which predominantly involved more than 1 coronary 
artery (74%), in asymptomatic type 2 diabetic patients (12). Obstructive CAD was 
observed in 26% of patients, similar to observations in the current study. Thus far, 
no MSCT studies have reported on the presence of CAD in asymptomatic type 1 
diabetic patients. However, using magnetic resonance imaging, Kim et al previously 
evaluated CAD in asymptomatic patients with type 1 diabetes and observed a higher 
atherosclerotic plaque burden in presence of diabetic nephropathy as compared to 
normoalbuminuria  (6). In that particular study, absence of diabetic nephropathy 
excluded presence of subclinical obstructive CAD. In our current study, prevalence of 
nephropathy was low (1%) in type 1 diabetic patients, suggesting that these patients were 
at relatively low risk. Interestingly however, absence of nephropathy did not exclude 
subclinical obstructive CAD on MSCT. Nevertheless, when compared to type 2 diabetes, 
the extent of atherosclerosis was less severe with a lower prevalence of multi-vessel 
disease and a smaller number of lesions. Moreover, a smaller proportion of patients with 
type 1 diabetes had obstructive atherosclerosis. Importantly, in this study, presence of 
type 2 diabetes remained a significant predictor of the severity of atherosclerosis after 
correction for traditional cardiovascular risk factors including obesity, glycemic control 
and renal function. Accordingly, the higher atherosclerotic plaque burden in patients 
with type 2 diabetes may warrant more aggressive anti-atherosclerotic treatment. On 
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the other hand, MSCT coronary angiography excluded atherosclerosis in approximately 
30% of both type 1 and type 2 diabetic patients. This finding raises the question whether 
anti-atherosclerotic medical therapy should be initiated in all asymptomatic diabetic 
patients and to which extent. It is possible that MSCT may be used to identify or exclude 
the presence of atherosclerosis and provide a basis for individually tailored therapy.
Plaque morphology and relation with CAC
In addition to increased severity of atherosclerosis, we also observed differences in 
relative plaque composition in patients with type 2 diabetes with a higher percentage of 
non-calcified plaques. This finding is in line with a previous study in which non-calcified 
plaques comprised 41% of atherosclerotic plaques in asymptomatic patients with type 2 
diabetes (12). In retrospective studies, a higher proportion of non-calcified plaques has 
been associated with unstable CAD. Preliminary prognostic data also suggest that 
the presence of substantial non-calcified plaque indeed confers worse outcome (18). 
Accordingly, it has been suggested that these plaques represent more active stages of 
CAD and may be more prone to rupture (15,19).  Notably, the distribution of coronary 
plaque phenotype has not been previously examined in type 1 diabetes. In contrast with 
type 2 diabetes, we found a higher proportion of calcified plaques and lower proportion 
of non-calcified plaques in patients with type 1 diabetes, despite similar CAC scores. As 
a result, plaque burden was higher for each CAC score category in type 2 diabetes as 
compared to type 1 diabetes.
Assessment of CAC score has been suggested as a primary step in cardiovascular risk 
stratification and screening of asymptomatic diabetic patients (20) because the presence 
of elevated CAC scores has been associated with a higher likelihood of myocardial 
ischemia (21). However, our current observations suggest that CAC score assessment 
may be more effective in identifying CAD in patients with type 1 diabetes. Indeed, 
absence of coronary calcium accurately excluded presence of obstructive coronary 
atherosclerosis in patients with type 1 diabetes. In contrast, this relation was distorted 
in patients with type 2 diabetes with a higher prevalence of obstructive CAD in patients 
without or only minor calcium. As both the prevalence of obstructive CAD and extent of 
CAD per CAC category were higher, it appears that CAC scores may underestimate CAD 
in patients with type 2 diabetes, in line with previous comparisons with non-diabetic 
patients (22). Accordingly, strategies using CAC scores to identify diabetic patients at 
higher risk should be developed with caution and should potentially be adjusted for 
type of diabetes.
73
Atherosclerosis in type 1 and type 2 Diabetes
Djaberi.indd   73 5-8-2014   15:28:40
study limitations
Several limitations need to be acknowledged. The current analysis was restricted 
to evaluation of coronary atherosclerosis in type 1 and type 2 diabetes and the pro-
atherogenic processes involved in each form of diabetes were not investigated. In 
addition, the lack of a control group without diabetes should be acknowledged. Because 
MSCT coronary angiography involves radiation exposure it is not feasible to perform a 
similar assessment in asymptomatic subjects free of cardiovascular risk. Furthermore, 
MSCT coronary angiography requires administration of potentially nephrotoxic contrast 
media, rendering the technique unsuitable for use in asymptomatic diabetic patients 
with severe renal dysfunction. Finally, no follow-up data were available. Indeed, the 
prognostic implications of our observations should be evaluated in prospective follow-
up studies.
In summary, although CAC scores and prevalence of coronary atherosclerosis were 
similar between patients with type 1 and type 2 diabetes, CAD was more extensive 
in the latter. In addition, a relatively higher proportion of non-calcified plaques was 
observed in type 2 diabetes. These observations may be valuable in the development 
of targeted management strategies adapted to diabetes type. It is possible that MSCT 
angiography may be useful to identify or exclude the presence of atherosclerosis and 
provide a basis for individually tailored therapy.
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CHAPTER 5
Endothelial Dysfunction in Diabetic Patients with 
Abnormal Myocardial Perfusion in the absence of 
Epicardial obstructive Coronary Artery Disease
Roxana Djaberi, Jos op ’t Roodt, Joanne D. Schuijf, Ton J. Rabelink, Eelco J. de Koning, 
Alberto M. Pereira, Marcel P. Stokkel, Jan W. Smit, Jeroen J. Bax, J. Wouter Jukema.
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AbsTRACT
In patients with diabetes mellitus myocardial perfusion defects are often observed in 
absence of obstructive epicardial coronary artery disease (CAD), thereby presenting 
a diagnostic problem. We hypothesized that these perfusion abnormalities may be 
explained by endothelial dysfunction or occult coronary atherosclerosis.
Methods
Prospectively, 135 asymptomatic patients with diabetes mellitus, underwent 
cardiovascular screening by coronary artery calcium (CAC) scoring, multislice CT 
coronary angiography and myocardial perfusion imaging by SPECT. Multislice CT 
images were evaluated for the presence of obstructive epicardial CAD (≥50% luminal 
narrowing). To quantify abnormal myocardial perfusion on SPECT images, the summed 
stress score (SSS) was determined for each patient. The presence of abnormal myocardial 
perfusion was defined as a SSS of 3 or more. In addition, flow mediated dilatation 
(FMD) of the brachial artery, a marker of endothelial function, was determined using 
ultrasonography.
Results
In 35 (27%) patients, obstructive epicardial CAD was observed on multislice CT  and these 
patients were excluded from further analysis. In the remaining 95 patients, abnormal 
myocardial perfusion was observed in 30 (32%) of patients. FMD was significantly lower 
in patients with abnormal myocardial perfusion (3.6±2.4%), as compared to those with 
normal myocardial perfusion (6.4 ± 2.6%) (P < 0.001). Importantly, FMD remained a 
significant predictor of the extent of abnormal myocardial perfusion after correction 
for cardiovascular risk factors and CAC score (P < 0.001). In contrast, no association was 
observed between non-obstructive plaque burden as reflected by CAC scores and extent 
of abnormal myocardial perfusion.
Conclusion
In patients with diabetes mellitus, myocardial perfusion abnormalities in absence of 
obstructive epicardial CAD are associated with endothelial dysfunction.
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InTRoDuCTIon
Coronary artery disease (CAD) constitutes a major cause of morbidity and mortality in 
patients with diabetes mellitus (DM). In addition, due to diabetic neuropathy myocardial 
ischemia and infarction may be prevalent in the absence of typical anginal symptoms. 
Non-invasive assessment of CAD in asymptomatic diabetic patients at higher risk 
has therefore been previously suggested by the guidelines of the American Diabetes 
Association and the American Heart Association (1). Those guidelines propose testing 
for the presence of myocardial ischemia by SPECT as a possible option for early detection 
and treatment of asymptomatic obstructive CAD. If myocardial perfusion abnormalities 
are identified, coronary angiography is considered to confirm the presence of clinically 
relevant obstructive CAD possibly requiring intervention. However, previous studies 
have shown a discrepancy between the presence of myocardial perfusion defects and 
obstructive CAD in diabetic patients. Approximately, in 20-40% of diabetic patients 
myocardial perfusion defects could not be clarified by obstruction of the epicardial 
coronary arteries (2,3). Also, in the general population, a discrepancy between presence 
of myocardial perfusion defects and obstructive epicardial CAD has been observed 
(4-6). Both endothelial dysfunction and occult coronary atherosclerosis were shown 
to contribute to this condition (4-6). However, the potential mechanisms underlying 
myocardial perfusion abnormalities not attributable to obstruction of flow in the 
epicardial coronary arteries have not yet been studied in asymptomatic diabetic patients.
Ultrasonographic measurement of the flow mediated dilatation (FMD) of the brachial 
artery provides non-invasive estimation of systemic endothelial function (7). The 
observed brachial artery dilatation has been shown to be closely related to coronary 
endothelial function and vasoreactivity (8,9). The reproducibility of assessment of 
brachial artery diameter has improved with the development of the wall-track system 
(WTS) technique, rendering it suitable for cohort studies (10).
The current study was designed to prospectively evaluate the relation between myocardial 
perfusion by SPECT and endothelial function assessed by FMD in asymptomatic diabetic 
patients without epicardial obstructive CAD (as evaluated non-invasively by Multi-Slice 
Computed Tomography (MSCT) coronary angiography). In addition, the association 
between non-obstructive plaque burden as reflected by coronary artery calcium (CAC) 
scores and myocardial perfusion was studied.
MATERIAls AnD METHoDs
Patients and design
Prospectively, 130 asymptomatic diabetic patients were screened for cardiovascular 
disease.  A structured interview, physical examination and laboratory analysis were 
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acquired. Cardiovascular risk factors were assessed according to the following criteria: 
Family history of CAD was considered positive if CAD was present in any of the first 
degree family members. Hypertension was defined as a blood pressure >140/90 mmHg 
or treatment with antihypertensive medication. Hypercholesterolemia was defined as a 
total cholesterol level >5.0 mmol/L or use of lipid lowering medication.
Non-invasive MSCT, including CAC scoring and coronary angiography, and myocardial 
perfusion imaging by SPECT were performed as part of clinical work up in all patients. 
Concurrent measurement of the brachial FMD was performed in a study setting, 
approved by the institutional review committee of the Leiden University Medical 
Center, Leiden.
Primarily, patients not eligible for MSCT coronary angiography due to arrhythmia or 
contraindications for the use of iodinated contrast media were excluded.  Subsequently, 
those with obstructive epicardial CAD on MSCT angiography were excluded from 
further analyses. The relation between the presence of myocardial perfusion defects and 
FMD was thereby assessed in the remainder of patients free of obstructive epicardial 
CAD.
MsCT data acquisition
Imaging was performed with a 64-slice MSCT scanner (Toshiba Medical Systems, Tokyo, 
Japan). In patients with a heart rate ≥ 65 beats per minute, oral beta-blocking medication 
(metoprolol 50 mg or 100 mg) was provided 1 hour preceding the scan, if tolerated. 
A non-enhanced prospective electrocardiographically gated scan, triggered at 75% of 
the RR interval with 4 x 3.0 mm collimation was firstly obtained to measure the CAC 
score and to determine the start and end position of the helical scan.
Subsequently, MSCT angiography was performed using the following parameters: 
collimation 64 x 0.5 mm, tube rotation time 400, 450 or 500 ms depending on the heart 
rate, tube current 300 or 350 mA, tube voltage 120 kV. Non-ionic contrast material was 
administered in an amount of 90–100 ml in the antecubital vein, depending on the total 
scan time, and with a flow rate of 5 ml/s, followed by 50 ml of saline solution flush. 
Timing of the scan was determined by automated bolus-tracking in the aortic root. 
Data were acquired with simultaneous ECG registration during a single breath hold 
of approximately 10 seconds. Images were reconstructed in the cardiac phase showing 
least motion artifacts and transferred to a remote workstation (Vitrea 2, Vital Images, 
Minnetonka, USA) for post-processing.
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MsCT data analysis
CAC score
The CAC score was assessed with the application of dedicated software (Vitrea2, Vital 
Images, USA). CAC was defined as a dense area in the coronary artery exceeding 
the threshold of 130 Hounsfield units. For each patient the total Agatston score was 
determined.
Epicardial obstructive CAD
Two experienced observers blinded to patient characteristics interpreted all MSCT 
coronary angiograms. Discrepancies in interpretation were instantly resolved by 
consensus. Epicardial coronary arteries were examined by scrolling through axial 
images, followed by visual assessment of curved multiplanar reconstructions in at least 
two orthogonal planes. The presence of epicardial obstructive CAD (defined as luminal 
narrowing ≥ 50% in at least one vessel) was evaluated for each patient.
ECG-gated sPECT data acquisition
During a two-day stress and rest protocol, myocardial perfusion imaging was performed 
using ECG-gated SPECT with 99mTc sestamibi (99mTcMIBI). Patients were instructed to 
abstain from caffeine containing products for 24 hours, preceding the stress test. Stress 
was induced using intravenous infusion of adenosine at a rate of 140 μg/kg body weight 
per minute for 6  minutes, accompanied by simultaneous handgrip exercise. After 
completion of the third minute 99mTcMIBI (500 MBq) was injected intravenously. Blood 
pressure and a 12-lead ECG were recorded throughout the adenosine infusion. Imaging 
commenced 120 minutes after radiopharmaceutical injection using a triple-head SPECT 
gamma camera (GCA 9300/HG; Toshiba Corporation, Tokyo, Japan) equipped with 
low-energy high-resolution collimators. Images were acquired in accordance with 
American Society of Nuclear Cardiology (ASNC) guidelines, using a circular 360° orbit, 
60 projections, and 40 seconds per projection. Attenuation correction was not applied. 
Images were processed in the usual manner and short-axis, horizontal long-axis and 
vertical long-axis views were reconstructed. Patient motion was evaluated by examining 
the raw cine images.
sPECT data analysis
Short-axis slices were displayed in polar map format, adjusted for peak myocardial 
activity of 100%. Additional reconstruction yielded standard long- and short-axis 
projections perpendicular to the heart axis. All views were used for semi-quantitative 
interpretation. As proposed by the ASNC guidelines, the myocardium was divided 
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into 17 segments (11). Tracer uptake in each segment was evaluated by two observers 
in consensus, by use of a 5-point scoring system (0: normal, 1: mild, 2: moderate, 3: 
severe reduction of tracer uptake and 4: apparent absence of tracer uptake). The total 
segmental score during stress and rest was used to determine the summed stress score 
(SSS) and summed rest score (SRS) for each patient. Abnormal myocardial perfusion was 
defined as SSS ≥3. Patients with a SSS 3-7 were classified as having moderately abnormal 
myocardial perfusion and those with a SSS ≥8 as having severely abnormal myocardial 
perfusion. The location of myocardial perfusion abnormalities was classified as apical, 
anterior, inferior or lateral (11). Finally, regional wall motion on gated SPECT images 
was analyzed to differentiate between true perfusion abnormalities and attenuation 
artifacts.
flow Mediated Dilatation
The brachial artery diameter was evaluated using a Wall Track System (Scanner 200, Pie 
Medical, Maastricht, the Netherlands), which consisted of an ultrasound imager with a 
7.5-MHz linear array transducer connected to a data acquisition system and a personal 
computer. The principles of this system have been previously described in more 
detail  (12). All measurements were performed by the same experienced sonographer 
who was unaware of the clinical characteristics of the patients. On the basis of a previous 
study of 20 healthy middle-aged volunteers, the intra-observer coefficients of variation 
for FMD assessment by the same sonographer were previously determined to be 0.8% 
for the baseline diameter of the brachial artery, 2.0% for the maximal diameter, 24.2% for 
the change in diameter and 24.4% for the calculated FMD. The mean FMD in this group 
of healthy volunteers was 8.4% ± 2.1%.
In the current study, patients were asked to abstain from medication use, caffeine 
containing substances and smoking for 24 hours prior to the tests. All measurements 
were performed on fasting patients, in the morning, in a silent, temperature-controlled 
clinical research laboratory. Patients had a 15 minute rest in a comfortable supine 
position and remained in that position throughout the examination. The patients’ right 
arm was placed in extension in the elbow, with the hand in supination, thus eliminating 
longitudinal movements of the arm. The wrist and elbow were supported by cushions 
to minimize lateral movements. The heart rate was continuously monitored by a three-
lead electrocardiogram. The brachial artery was visualized distal to the elbow. Firstly, 
three diastolic measurements were averaged to provide a baseline diameter. Thereafter, 
ischemia was applied to the forearm distal to the location of the transducer by inflation 
of a blood pressure cuff for 5 minutes at a pressure of 200 mm Hg. After cuff deflation, 
ultrasonography continued for 5 minutes with measurements at 30-second intervals. 
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The widest lumen diameter was used as maximal vasodilation. FMD was expressed as 
percentage change relative to the baseline diameter.
statistical Analysis
Primarily, patients with obstructive epicardial CAD (≥50% luminal narrowing) on MSCT 
angiography were identified and excluded from all further analysis.
Continuous variables were expressed as means ± standard deviation. Categorical 
variables were expressed as number, followed by percentages in parentheses.
To investigate the relationship between FMD and myocardial perfusion, patients were 
first stratified as having either normal myocardial perfusion (SSS <3) or abnormal 
myocardial perfusion (SSS ≥3) on SPECT. Average FMD and standard deviation were 
calculated for both groups, and the independent T-test was applied to evaluate the 
difference in mean FMD.
To determine the relationship between cardiovascular risk factors and degree of 
myocardial perfusion abnormalities, a univariate linear regression analysis of baseline 
characteristics was performed to identify the potential predictors of the number of 
SSS. Thereafter, multivariate linear regression analysis with backward elimination was 
performed to identify the independent predictors of the number of SSS.
Finally, the relationship between FMD and prevalence of abnormal myocardial 
perfusion as well as between the degree non-obstructive atherosclerosis and abnormal 
myocardial perfusion were evaluated. For this purpose, patients were first categorized 
according to FMD quartiles and the prevalence of abnormal myocardial perfusion was 
determined for each FMD quartile. Subsequently, patients were stratified according 
to CAC category as having a CAC score of 0, 1-10, 11-100 or >100, and the prevalence 
of abnormal myocardial perfusion was also assessed per CAC category. Influence of 
decreasing FMD (per quartile) and that of increasing CAC scores (per category) on the 
prevalence of abnormal myocardial perfusion was investigated.
REsulTs
Patient characteristics
In the total population, MSCT coronary angiography revealed obstructive epicardial 
CAD (≥50% luminal narrowing) in 35 patients (27%) and these patients were therefore 
excluded. The patient characteristics of the remaining 95 patients (73%) included in the 
analysis, are provided in Table 1. Briefly, mean age of this population was 48 ± 12 years 
and 43 patients (46%) were male.
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baseline imaging findings
Assessment of Myocardial Perfusion by SPECT
The mean SSS was 2.0 ± 3.0 (range 0-13) in patients included in the analysis. In this 
asymptomatic diabetic population without obstructive epicardial CAD myocardial 
perfusion abnormalities (SSS ≥3) were observed in 30 patients (32%). Within this group, 
moderately abnormal myocardial perfusion (SSS 3-7) was revealed in 25 patients (83%); 
whereas 5 patients (17%) were shown to have severely abnormal myocardial perfusion 
(SSS ≥8). Furthermore, observed myocardial perfusion abnormalities were reversible 
in 14 patients (47%), partially reversible in 6 (20%) and fixed in 10 patients (33%). Of 
note, fixed myocardial perfusion abnormalities mainly comprised of light or moderate 
decrease in tracer uptake (n = 8). Only 2 patients with a fixed abnormality were shown 
Table 1. Characteristics of the study population
Age (years) 48 ± 12
Male sex 43    (46%)
Diabetes mellitus duration (years) 15 ± 13
BMI (kg/m2) 28 ± 6
HbA1c (mmol/L) 8.0 ± 1.6
Smoking 23    (25%)
Family history of CAD 42    (45%)
Hypercholesterolemia 62    (66%)
Hypertension 47    (50%)
Type 1- / Type 2 DM 45 /50
Diabetes Treatment
Diet only 5      (5%)
Oral agent 14    (15%)
Oral agent and insulin 21    (22%)
Insulin 54    (57%)
Cardiovascular medication use
Statin 41    (43%)
Aspirin 14    (15%)
Ace-inhibitor 15    (16%)
Beta-blocker 9      (9%)
Angiotensin II antagonist 12    (13%)
Calcium channel blocker 7      (7%)
Diureticum 10    (11%)
Data are averages ± standard deviation or numbers (%).
BMI = body mass index, CAD = coronary artery disease.
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to have severe decrease in tracer uptake. In total, 6 patients showed abnormal perfusion 
apically, 16 patients in the anterior wall, 15 in the inferior wall and 8 in the lateral wall of 
the myocardium. Overall, 16 patients showed a myocardial perfusion abnormality in a 
single myocardial wall, 13 patients in two walls and 1 patient in three myocardial walls.
Assessment of Endothelial function by Flow Mediated Dilatation
Mean FMD was 6.0% ± 3.0%, and ranged between 0.0% and 13.3%. The median FMD was 
calculated to be 5.4% (lower quartile 3.4%, upper quartile 7.3%).
Assessment of CAC score by MSCT
The average CAC score was 60 ± 170. Most patients (n = 53, 55%) had no coronary calcium. 
The CAC score was found to be in the range 1-10 in 12 patients (13%), 11-100 in 15 patients 
(16%) and >100 in 15 patients (16%).
Relation between fMD and abnormal myocardial perfusion
In diabetic patients with normal myocardial perfusion the mean FMD was significantly 
higher (6.4% ± 2.6%) than in patients with abnormal myocardial perfusion (3.6% ± 2.4%) 
(P <0.001) (Figure 1).
The prevalence of patients with abnormal myocardial perfusion per FMD quartile or 
CAC score category is provided in Figure 2A. Interestingly, prevalence of myocardial 
perfusion abnormalities increased gradually from 9% to 61% with decreasing FMD 
quartiles.
In contrast, no evident trend was observed between the prevalence of abnormal 
myocardial perfusion and increasing CAC score categories (Figure 2B). While 34% of 
patients without coronary calcium showed abnormal myocardial perfusion, a similar 
prevalence (40%) was observed in patients with extensive coronary calcium (CAC>100).
Predictors of the extent of abnormal myocardial perfusion
As illustrated in Table 2, FMD was the only significant predictor of the extent of abnormal 
myocardial perfusion in a univariate model (P <0.001). Importantly, after correction for 
other cardiovascular risk factors in a multivariate model with backward elimination, 
FMD remained a significant predictor of the extent of abnormal myocardial perfusion 
(P <0.001) (Table 2). HbA1c and hypercholesterolemia were also shown to be independent 
predictors of the extent of abnormal myocardial perfusion.
DIsCussIon
The current prospective study revealed that 32% of asymptomatic patients with DM 
had abnormal myocardial perfusion despite the absence of obstructive epicardial CAD. 
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figure 1. FMD in diabetic patients with normal and abnormal myocardial perfusion. Mean FMD 
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figure 2. Percentage of patients with abnormal myocardial perfusion per FMD quartile or CAC 
score category. Prevalence of abnormal myocardial perfusion increased with decreasing FMD 
(Panel A.), whereas no clear trend was observed among increasing CAC score categories (Panel B.).
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Assessment of the brachial FMD showed less vasoreactivity in these patients as compared 
to those with normal myocardial perfusion. Importantly, after correction for risk factors 
as well as CAC scores, endothelial function remained a significant predictor of abnormal 
myocardial perfusion. Further analysis showed the prevalence of myocardial perfusion 
abnormalities to increase per decreasing FMD quartile, whereas no such trend was 
observed for occult atherosclerotic plaque burden as determined by CAC scoring.
Myocardial perfusion by sPECT
In the general population of patients with known or suspected CAD, myocardial 
perfusion imaging (MPI) by SPECT has been shown to successfully identify obstructive 
CAD and predict future coronary events (13,14). The prognostic value of myocardial 
Table 2. Predictors of the extent of abnormal myocardial perfusion (SSS) in patients without 
obstructive epicardial CAD.
univariate Analysis Multivariate Analysis
Exp ß (95% CI) P Value Exp ß (95% CI) P Value
FMD (%) 0.61   (0.48-0.78) <0.001 0.58  (0.43-0.75) <0.001
CAC score 1.00   (0.99-1.00) 0.22 - -
Age (years) 1.01   (0.98-1.06) 0.45 - -
Male sex 1.57  (0.66-3.75) 0.31 - -
Diabetes Mellitus duration (years) 0.98   (0.95-1.01) 0.33 - -
BMI (kg/m2) 1.02  (0.95-1.09) 0.59 - -
HbA1c (mmol/L) 0.76  (0.55-1.04) 0.09 0.50  (0.31-0.82) 0.01
Smoking 0.91   (0.33-2.53) 0.86 - -
Family history of CAD 0.93  (0.39-2.21) 0.86 0.36  (0.11-1.19) 0.09
Hypercholesterolemia 1.65   (0.64-4.29) 0.30 4.04  (1.07-15.24) 0.04
Hypertension 1.22   (0.51-2.90) 0.66 - -
Type 1 DM 0.16  (-0.90-1.22) 0.77 - -
Treatmnet with only diet 1.57  (-0.78-3.91) 0.19 - -
Treatmnet with oral agents -0.41 (-1.51-0.68) 0.45 - -
Treatmnet with insulin 0.15  (-1.18-1.47) 0.83 - -
Statin use 0.36  (-0.71-1.43) 0.50 - -
Aspirin use 0.79  (-0.70-2.27) 0.30 - -
Ace-inhibitor use -0.14 (-1.59-1.31) 0.85 - -
Beta-blocker use 0.15  (-1.76-2.05) 0.88 - -
Angiotensin II antagonist use -0.99 (-2.57-0.58) 0.21 - -
Calcium channel blocker use 0.95  (-1.06-2.97) 0.35 - -
Diureticum use 0.16  (-1.52-1.85) 0.85 - -
CI = confidence interval, ß = beta coefficient, FMD = flow mediated dilatation, CAC = coronary artery 
calcium, BMI = body mass index, CAD = coronary artery disease.
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perfusion has also been confirmed in diabetic patients with suspected CAD, as well as in 
asymptomatic diabetic patients (15-17). Based on these observations in combination with 
the non-invasive nature of MPI by SPECT, the ADA/AHA has proposed this technique 
as a potential screening tool for identification of asymptomatic diabetic patients with 
obstructive CAD (1). However, previous studies in diabetic patients imply that a significant 
proportion of observed perfusion abnormalities are not attributable to obstruction of 
blood flow in the epicardial coronary arteries (2,3). In the general population, a similar 
discrepancy has been observed regarding presentation with anginal symptoms and 
manifested ischemia in absence of obstructive epicardial CAD (4-6). Mechanisms 
underlying myocardial perfusion abnormalities in that particular group of patients have 
been studied extensively and revealed the presence of diffuse coronary atherosclerosis 
and endothelial dysfunction as potential causal factors (4-6). However, little is known 
about the contribution of these parameters to the occurrence of myocardial perfusion 
defects in asymptomatic patients with DM. Therefore, in the current study we examined 
the influence of endothelial dysfunction and non-obstructive atherosclerotic plaque 
burden on myocardial perfusion in asymptomatic diabetic patients without epicardial 
obstructive CAD.
Assessment of endothelial function by fMD
Assessment of systemic endothelial function by FMD has been shown to be closely 
related to coronary vasoreactivity (8,9). To date, measurement of brachial FMD is 
accepted as the most validated and reproducible non-invasive technique for assessment 
of endothelial function (7). Inter-observer reproducibility of the baseline and maximum 
post-ischemia brachial artery are satisfactory with diameter variations of approximately 
4%, and have improved with the introduction of semi-automated wall track systems 
(10,18). In contrast, the intra-observer reproducibility is limited by within subject 
variability and surrounding factors, as vasoreactivity fluctuates through the day and is 
further influenced by stress, temperature, diet and glucose levels (10). Therefore, FMD 
appears to be less applicable for individual serial testing. However, a panel of experts 
has recognized the test as appropriate for cohort studies, providing that patient and 
surrounding factors are standardized (19). FMD ranges from approximately 20% in 
young adults to 0% in patients with established CAD (20). In diabetic patients, mean 
FMD values tend to be lower as well (range 0-12%) (20). In DM, endothelial dysfunction 
is suspected to be induced by hyperglycemia (sorbitol-, hexosamin-, protein kinase C-, 
and advanced glycation end product-pathways) and insulin resistance, which result in 
mitochondrial superoxide overproduction. As a consequence, nitric oxide availability is 
negatively affected, leading to endothelial dysfunction (21,22).
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Relationship with myocardial perfusion
In the current study, FMD of the brachial artery was further decreased in diabetic 
patients with abnormal myocardial perfusion. Several studies have described an 
association between endothelial dysfunction and the occurrence of myocardial ischemia 
due to impaired endothelium-dependent coronary vasodilation during stress (23). It is 
therefore presumable that in the current study insufficient vasomotor response in the 
coronary microvasculature due to endothelial dysfunction may indeed have resulted 
in relative hypoperfusion during stress (reflected by reversible perfusion abnormalities 
on SPECT) in the absence of obstructive epicardial CAD (23). However, endothelial 
dysfunction has also been shown to affect resting myocardial perfusion (24). Accordingly, 
hypoperfusion of the microvasculature during rest may occur. Interestingly, in our study 
the majority of fixed perfusion abnormalities comprised of a mild decrease in tracer 
uptake, which has been linked to hypoperfused but viable myocardial tissue rather than 
scar (25). Nevertheless, impaired coronary endothelial function has also been suggested 
as a cause of myocardial infarction in patients with minimally obstructive disease, 
possibly through prolonged vasoconstriction (26). Therefore, it is possible that the fixed 
abnormalities comprising of severely decreased tracer uptake, which we observed in 
2 patients, may indeed reflect loss of viable myocardium. Finally, the possibility remains 
that some of the fixed perfusion abnormalities were due to attenuation. However, in the 
current study, regional wall motion on gated SPECT images was analyzed for optimal 
differentiation between true perfusion abnormalities and attenuation artifacts.
Importantly, FMD was shown to be an independent predictor of the extent of abnormal 
perfusion, even after correction for occult coronary atherosclerosis by means of CAC 
scores. Accordingly, it appears that in the absence of epicardial obstructive CAD, 
endothelial dysfunction may have a greater impact on myocardial perfusion than the 
extent of diffuse atherosclerosis. Further investigations are needed to confirm these 
observations.
Potential clinical implications
The direct cardiovascular prognostic consequence of endothelial dysfunction in 
diabetic patients remains to be determined. In previous studies of non-diabetic patients, 
impaired endothelial function has been shown to predict cardiovascular events (27). 
In addition, Bugiardini and colleagues have shown reduced coronary vasoreactivity 
in angiographically normal coronaries to be a predecessor of overt atherosclerosis on 
angiography after a long term follow-up of 10 years (28). Therefore, dysfunction of the 
endothelium seems to occur in early stages of vascular disease, and may be reversible. 
Accordingly, cholesterol lowering therapy has shown to improve endothelium 
dependent vasomotion in patients with hypercholesterolemia, as well as myocardial 
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perfusion in a non-diabetic cohort of patients with previous evidence of myocardial 
perfusion defects on SPECT (29,30). In line with these observations, inducible ischemia 
was shown to resolve in 79% of asymptomatic diabetic patients who had abnormal 
myocardial perfusion at baseline in the DIAD study (31). This recovery was associated 
with intensification of treatment with statins, aspirin and ACE inhibitors.
Thus, in the current study abnormal myocardial perfusion not attributable to obstructive 
CAD was related with impaired endothelial function. As this condition is most likely 
to be an early stage of vascular disease amendable by treatment, intensification of anti-
atherogenic therapy seems to be indicated in asymptomatic diabetic patients with 
perfusion abnormalities even in absence of obstructive epicardial CAD.
Furthermore, considering that in DM abnormal myocardial perfusion is often 
observed in the absence of epicardial obstructive CAD, the question emerges whether 
this test should not be accompanied by a non-invasive anatomical test such as MSCT 
coronary angiography. Indeed, referral of all asymptomatic diabetic patients with 
abnormal myocardial perfusion for invasive coronary angiography should be avoided 
considering that many patients will not have obstructive epicardial stenosis amendable 
for revascularization. Accordingly, combined non-invasive imaging of myocardial 
perfusion imaging by SPECT and coronary anatomy with MSCT may allow a more 
comprehensive and accurate assessment of CAD and facilitate further management. 
However, routine combination of these two non-invasive imaging modalities carries 
the disadvantage of increased costs and radiation exposure. Possibly, MSCT coronary 
angiography could be of most incremental value in asymptomatic diabetic patients with 
abnormal myocardial perfusion, to differentiate between obstructive epicardial CAD 
and endothelial dysfunction as a causal factor.
study limitations
Firstly, the size of the study population was limited. In addition, it must be 
acknowledged that brachial FMD is a measure of systemic endothelial function, and 
not a direct measure of coronary endothelial function. However, previous studies 
have shown a good correlation between brachial FMD and direct invasive measures 
of coronary endothelial function (13,14). Furthermore, the radiation burden associated 
with combined MSCT (64-slice MSCT approximately 9-15 mSv) and SPECT myocardial 
perfusion imaging (99mTcMIBI approximately 7 mSv per scan) is a limitation (32,33). 
However, the radiation dose of MSCT has been decreased significantly with the use 
of dedicated dose reduction MSCT acquisition techniques that have recently become 
available (34,35). Finally, no follow-up data were available and whether our observations 
have prognostic implications should be evaluated in prospective follow-up studies.
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ConClusIon
In asymptomatic diabetic patients with no obstructive epicardial CAD, abnormal 
myocardial perfusion is common and is strongly associated with impaired endothelial 
function. In view of the likely reversible nature of endothelial dysfunction and the 
cardiovascular prognostic value of abnormal myocardial perfusion in asymptomatic 
diabetic patients, it is presumable that asymptomatic diabetic patients with abnormal 
myocardial perfusion will benefit from intensified pharmacological treatment even in 
the absence of obstructive epicardial CAD.
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AbsTRACT
Cardiovascular disease is the major cause of mortality in type 2 diabetes mellitus. The 
criteria for the selection of those asymptomatic patients with type 2 diabetes who should 
undergo cardiac screening and the therapeutic consequences of screening remain 
controversial.
Non-invasive techniques as markers of atherosclerosis and myocardial ischaemia may 
aid risk stratification and the implementation of tailored therapy for the patient with 
type 2 diabetes. In the present article we review the literature on the implementation 
of non-invasive vascular tools and cardiac imaging techniques in this patient group. 
The value of these techniques as endpoints in clinical trials and as risk estimators in 
asymptomatic diabetic patients is discussed.
Carotid intima–media thickness, arterial stiffness and flow-mediated dilation are 
abnormal long before the onset of type 2 diabetes. These vascular tools are therefore 
most likely to be useful for the identification of ‘at risk’ patients during the early stages 
of atherosclerotic disease. The additional value of these tools in risk stratification and 
tailored therapy in type 2 diabetes remains to be proven.
Cardiac imaging techniques are more justified in individuals with a strong clinical 
suspicion of advanced coronary heart disease (CHD). Asymptomatic myocardial 
ischaemia can be detected by stress echocardiography and myocardial perfusion 
imaging. The more recently developed non-invasive multi-slice computed tomography 
angiography is recommended for exclusion of CHD, and can therefore be used to screen 
asymptomatic patients with type 2 diabetes, but has the associated disadvantages of 
high radiation exposure and costs. Therefore, we propose an algorithm for the screening 
of asymptomatic diabetic patients, the first step of which consists of coronary artery 
calcium score assessment and exercise ECG.
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InTRoDuCTIon
Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes 
mellitus [1]. Current guidelines on the treatment of dyslipidaemia and hypertension in 
diabetes recommend rigorous primary prevention, with target lipid and blood pressure 
levels similar to those used for secondary prevention in non-diabetic patients [2]. To date, 
there is much debate as to whether all diabetic patients will benefit from this strategy 
and whether risk stratification should be attempted.
Non-invasive imaging techniques as markers of atherosclerosis and myocardial 
ischaemia may help risk stratification and the implementation of tailored therapy for 
the individual patient. However, many of these tools have not been validated in diabetic 
individuals. In this article we will review the reproducibility and predictive value of the 
following surrogate markers of atherosclerosis: intima–media thickness (IMT), arterial 
stiffness and flow-mediated dilation (FMD). We will discuss the diagnostic accuracy 
and predictive value of imaging techniques used for direct anatomic assessment of 
coronary atherosclerosis (coronary artery calcium [CAC] scores and multi-slice computed 
tomography [MSCT] angiography) and functional tests that detect myocardial ischaemia 
(ambulatory ECG, exercise ECG, stress echocardiography (SE) and nuclear myocardial 
perfusion imaging (MPI) by single photon emission computed tomography (SPECT). 
Finally, the value of these non-invasive techniques as endpoints in clinical trials and as 
risk estimators in diabetic patients will be discussed. We will concentrate on methods of 
risk stratification and the implementation of non invasive techniques in patients with type 
2 diabetes, as the value of these techniques has scarcely been studied in type 1 diabetes.
suRRoGATE MARkERs of ATHERosClERosIs
Carotid intima media thickness
Since its introduction in the early 1990s, IMT, especially carotid IMT (CIMT), has 
increasingly been used as a surrogate marker of atherosclerotic disease. IMT can be 
assessed non-invasively using B-mode ultrasound. Two approaches are used: (1) multiple 
measurements of CIMT in the near and far walls of the three main segments of the 
carotid arteries (common carotid, bifurcation and internal carotid); and (2) automated 
computerised measurement of CIMT, restricted to the far wall of the distal common 
carotid artery. Computerised measurement of CIMT is superior in terms of precision 
and reproducibility, with an approximately 3% difference between two successive 
measurements [3].  As a result, common CIMT has become a valid tool for large-scale 
multicentre studies. However, the common carotid artery is less likely to have intrusive 
plaque than the bifurcation and internal segments of the carotid arteries.
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CIMT correlates with prevalent CVD and with risk factors for CVD [4]. In prospective 
studies, CIMT has proven to be a consistent and independent predictor for coronary 
events and stroke in the general population [5-6].
CIMT in type 2 diabetes Mean common CIMT in middle-aged individuals is reported 
to range from 0.71–0.98 mm in diabetic patients vs 0.66–0.85 mm in controls [7-9]. In 
diabetic individuals without a history of myocardial infarction CIMT is similar to that 
in non-diabetic individuals with a history of myocardial infarction [9]. Progression 
of maximal CIMT in the Insulin Resistance Atherosclerosis Study was twice as high 
in persons with diabetes vs controls [10], but other studies report lower rates [11]. In 
type 2 diabetes, prevalent CVD is associated with higher CIMT [9]. In two prospective 
studies, baseline CIMT was shown to be an independent predictor of cardiovascular 
events [12-13]. However, when Folsom and colleagues analysed CIMT in a large cohort 
that included 1500 diabetic participants, they found that CIMT has predictive value for 
future coronary events only in combination with several other novel risk factors [14].
CIMT measurements show good reproducibility. CIMT is increased in type 2 
diabetic patients with CVD and is an independent predictor of coronary events. 
However, the magnitude of its predictive value when added to other risk factors 
is questionable.
Arterial stiffness
Whereas IMT is a marker of structural vessel wall properties, arterial stiffness reflects 
functional wall properties. Stiffness can be measured in many ways, including 
distensibility, pulse wave velocity (PWV) and augmentation index (AIx). Distensibility, 
defined as the change in arterial lumen diameter during the cardiac cycle, can be 
evaluated by ultrasound imaging using wall-tracking systems based on Doppler shift or 
using B- or M-mode. The change in arterial diameter during the cardiac cycle varies by 
about 5-6% in middle-aged individuals [15]. PWV is the speed with which the arterial 
pressure wave progresses through the arterial tree, and this increases with increasing 
vascular stiffness. The PWV can be determined either by placing a probe on two sites and 
recording the waveform simultaneously, or by recording the waveforms independently 
and comparing the time delay at both sites with a simultaneously measured QRS 
complex. PWV gradually increases with age, from about 4 m/s in the third decade to 
10 m/s in the ninth decade. The AIx, which is the augmentation of aortal pressure as 
a percentage of pulse pressure, has also emerged as a parameter for arterial stiffness 
(Fig.  1) [16-17]. Studies report excellent reproducibility of PWV, with a coefficient of 
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variation (CV) of approximately 3.2%, which is lower than that for distensibility indices 
(CV 5.3%) or AIx (CV 10.1%) [17-19].
In cross-sectional studies, arterial stiffness is strongly associated with age and classical 
risk factors for CVD [15, 20-21], and it has been reported to be related to angiographic 
coronary atherosclerosis [17]. In a cohort of men aged >70 years, baseline arterial 
distensibility predicted cardiovascular mortality during a 2 year follow-up, but added 
little to clinical risk estimation [22]. However, in a Danish population study, aortic PWV 
predicted a composite of cardiovascular events outcome above and beyond traditional 
risk factors [23].
figure 1. The pulse pressure wave form. (a) The incident wave generated by the left ventricle (in 
the ascending aorta). (b) Waves reflected back from the peripheral vascular bed (ascending aorta). 
(c) The resultant wave in the ascending aorta, which is a combination of (a) and (b). AIx is the 
measure of additional pressure to which the left ventricle is subjected as a result of wave reflection 
and is calculated as: AIx = (a/[b+a]) × 100
Review of Non-invasive Cardiovascular Tools in type 2 Diabetes
105
Djaberi.indd   105 5-8-2014   15:28:42
Arterial stiffness in type 2 diabetes  Diabetic patients have increased arterial stiffness [17, 24]. 
Compromised carotid distensibility and PWV have been demonstrated even before the 
onset of diabetes, in patients with impaired glucose tolerance. Healthy offspring of type 
2 diabetic patients have a higher PWV than matched controls [17, 25]. Arterial stiffness in 
diabetes is related to prevalent CVD [16] and has shown to be an independent predictor 
of CHD [26].
Baseline distensibility did not predict mortality in 140 individuals with impaired glucose 
tolerance during a follow-up period of 6.6 years [18]. Conversely, PWV does seem to have 
a reasonable predictive value for mortality in patients with impaired glucose tolerance 
and type 2 diabetes [24].
The reproducibility of PWV is superior to that of AIx and distensibility. Therefore, 
PWV is the most accepted method for estimating vascular stiffness. Vascular 
stiffness is increased in type 2 diabetic patients with CVD and has been shown to 
predict cardiovascular mortality.
Flow mediated dilation
FMD of the brachial artery is a non-invasive technique for measuring endothelial 
function. FMD is measured with B-mode ultrasound or a wall-track system. The brachial 
artery is visualised in the elbow, and by inflating a cuff (mostly distal to the elbow) 
for 4 min, hypoxia is created. After deflation, reactive hyperaemia induces shear stress, 
thereby stimulating NO synthesis, resulting in NO-dependent dilation [27]. FMD is thus 
defined as the percentage change in the diameter of the brachial artery after hypoxia, 
estimated to be 5–10% in healthy individuals. The observed brachial artery dilatation 
has shown to be closely related to coronary vasoreactivity [28].
FMD fluctuates during the day and is influenced by the temperature, stress, diet, glucose 
levels and the menstrual cycle [29]. Within-subject variability of FMD is therefore often 
poor, with coefficients of variation ranging from 14-50% [29-30]. In spite of the biological 
variation, there is good intra- and interobserver reproducibility for measurements 
of baseline and maximum post-ischaemia diameter in the brachial artery (diameter 
variations of approximately 4%) [30].
FMD ranges from about 10% in young adults to 0% in patients with established coronary 
heart disease (CHD), and it has proven to be predictive for the presence of CHD [31] 
and for future coronary events in high-risk populations [32]. High sensitivity and high 
negative predictive values were calculated using cut-off points of 8.1-10% [32]. FMD has 
not been independently associated with coronary events in patients at lower risk [33].
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FMD in type 2 diabetes Type 2 diabetes is associated with endothelial dysfunction. 
The underlying mechanisms are suspected to be related to hyperglycaemia (sorbitol, 
hexosamine, protein kinase C, and AGE pathways) and insulin resistance, which results 
in mitochondrial superoxide overproduction, and thus decreased NO availability [34-
35]. Clustering of risk factors such as dyslipidaemia, hypertension and obesity in the 
metabolic syndrome play an additional role. Insulin-mediated vasodilatation is at least 
in part NO-dependent, thus explaining how insulin resistance may cause endothelial 
dysfunction.
The predictive value of endothelial dysfunction in epicardial coronary arteries of 
diabetic patients has been established for long-term coronary events [36]. However, to 
our knowledge, no studies to date have evaluated the relationship between FMD and 
prediction of coronary events in diabetes.
FMD is a marker of endothelial function. It should only be assessed under 
strictly constant external and physical circumstances, so that reproducibility is 
optimised. The potential of FMD for the identification of type 2 diabetic patients 
at risk for CVD is as yet unknown.
DIRECT AnAToMIC AssEssMEnT of CoRonARy ATHERosClERosIs
Coronary artery calcium scores
Anatomical and intravascular studies have illustrated that the presence of coronary 
calcium is indicative of coronary atherosclerosis [37]. Coronary calcification can be 
detected non-invasively by electron beam CT (EBCT), and more recently by MSCT. 
Agatston et al. developed a coronary calcium scoring algorithm, based on calcification 
volume and density, that is now widely used in clinical practice [38]. The extent of 
coronary calcium increases with age, and is, on average, higher in men than in women 
[39-40].
CAC scores in type 2 diabetes  Diabetic patients without manifest CVD have a higher 
CAC score than non-diabetic individuals, independent of classical risk factors [41-43]. 
In addition, CAC scores show significantly more progression over time in patients with 
diabetes than in non-diabetic patients [44].
In a study by Raggi et al. [45], 10,377 patients (903 with diabetes) were followed for a 
period of 5.0 ± 3.5 years after CAC imaging. Mortality increased with increasing baseline 
CAC levels for both diabetic and non-diabetic individuals. However, despite similar CAC 
scores, there was a greater increase in mortality in diabetic than non-diabetic patients 
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for every increase in CAC score [45]. The predictive value of CAC scores in diabetes 
has been questioned by Qu et al. [46], who found no significant relationship between 
coronary events and CAC scores during a 6 year follow-up of 269 diabetic patients [46].
CAC score is associated with prevalent CVD in diabetes. However, CAC scores 
may underestimate the risk for CVD in type 2 diabetic patients.
Multislice CT coronary angiography
Application of MSCT scanners for non-invasive coronary angiography has developed 
rapidly during the recent years. Employment of 16 and 64 slice systems have demonstrated 
a sensitivity ranging from 83–99% and a specificity of between 93% and 98% [47-51]. 
Several studies have demonstrated that CT angiography has a high negative predictive 
value of 99% on average [47-51]. Therefore, the technique is currently most suited to 
exclude CHD.
Besides visualisation of the coronary artery lumen (Fig. 2), CT angiography allows 
the identification of non-stenotic atherosclerosis and the various types of plaques. In 
addition, chronic myocardial infarction and left ventricular ejection fraction can be 
assessed. Non-stenotic atherosclerosis may prove to be a predictor of coronary events; 
however, this remains to be determined in prospective long-term clinical studies. 
Plaques can be classified as non-calcified, mixed or calcified. Initial comparisons have 
shown that calcification may represent the duration of atherosclerosis, whereas non-
calcified and mixed lesions are more frequently observed in patients with an acute 
coronary syndrome [52].
MSCT is subject to a number of limitations, including exposure to a relatively high dose 
of radiation, currently in the range of 9-12 mSv [47,51], lower accuracy in the presence 
of severe calcification and movement artefacts, and limited application possibilities 
in case of irregular heart rate [49-51]. Taking the radiation exposure and the high 
negative predictive value of MSCT angiography into consideration, this technique is 
recommended for excluding CHD in patients of intermediate risk.
MSCT coronary angiography in type 2 diabetes  MSCT angiography has demonstrated a 
higher percentage of non-calcified and calcified plaques and a relatively lower percentage 
of mixed plaques in diabetes [53], which can be explained by the rapid progression 
of atherosclerosis. Schuijf et al., have reported a sensitivity and specificity of 95% for 
detection of stenosis. Inclusion of uninterpretable segments reduced sensitivity and 
specificity to 81% and 82%, respectively [54]. In an evaluation of the diagnostic accuracy 
of 16 slice MSCT angiography, there were no statistically significant differences between 
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the diabetic and non-diabetic individuals in the study population [55]. Importantly, 
negative predictive value of MSCT angiography in diabetes was found to be 98% and 
100% on segmental and patient basis, respectively [55].
The prevalence of CHD has been assessed by MSCT angiography in 70 asymptomatic 
patients with type 2 diabetes. The majority of the patients (80%) had atherosclerosis 
(obstructive CHD [luminal narrowing ≥50%] in 26%, non-obstructive CHD in 54% of 
figure 2. An asymptomatic patient with type 2 diabetes was screened for CAD using MSCT 
angiography. (a) The occluded right coronary artery (RCA) is easily visible using the three-
dimensional volume rendering technique, which provides an overview of coronary anatomy. 
Arrows indicate occlusion. (b) Multiplanar reconstruction of the RCA gives a more precise 
overview of abnormalities. (c), (d) Multiplanar reconstruction of the left anterior descending (LAD) 
and left circumflex (LCx) coronary arteries
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patients) [56]. Thus, results on the use of non-invasive MSCT angiography for CHD 
screening and as a prognostic indicator in the diabetic population appear promising, 
but further studies in larger population groups are needed.
MSCT angiography has good sensitivity, specificity and negative predictive value 
for identification of CHD in diabetic patients. However, assessment of CHD by 
MSCT in asymptomatic type 2 diabetic patients should be limited to patients 
at high risk, because of exposure to high radiation and contrast as well as cost 
factors.
funCTIonAl TEsTs In AssEssMEnT of CoRonARy ARTERy DIsEAsE
Functional tests detect myocardial ischemia which is the physiologic consequence 
of coronary obstruction. These include: ambulatory ECG, exercise ECG, stress 
echocardiography and nuclear myocardial perfusion imaging.
Ambulatory ECG
It has been postulated that periods of silent myocardial ischaemia (SMI), which can 
be detected with ambulatory ECG, precede a first coronary event. Ambulatory ECG 
monitoring can be performed with a three-channel recording system for a continuous 
period of 48 h. Transient myocardial ischaemia is defined as the presence of episodes 
showing >0.1 mV horizontal or downsloping ST-segment depression. The sensitivity of 
ambulatory ECG for detecting CHD is poor, ranging from 19–62% [57-59]. Compared 
with coronary angiography, the specificity of ambulatory ECG ranged between 54% and 
92% [57-60]. Frequent episodes of transient ischaemia detected by ambulatory ECG have 
shown to be a marker for an increased coronary event rate in asymptomatic middle-
aged men and in patients with known CHD [61].
Ambulatory ECG in type 2 diabetes The prevalence of SMI in diabetes as assessed by 
ambulatory ECG varies between 35% and 58% [62-64]. Although the prevalence of 
SMI determined by this method is expected to be higher in diabetic than non-diabetic 
individuals, findings have been inconsistent. Comparison of diabetic and non-diabetic 
patients in the Asymptomatic Cardiac Ischemia Pilot (ACIP) study, illustrated lower rates 
of asymptomatic ischaemia in diabetes, despite more extensive and diffuse coronary 
disease in the non-diabetic group [65]. A study comparing exercise ECG with ambulatory 
ECG for detection of SMI in diabetes reported that ambulatory ECG identified ischaemia 
only in diabetic patients with three-vessel disease, whereas exercise ECG also revealed 
ischemia in one- and two-vessel disease [66]. In one study, patients with previously 
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detected silent ischaemia had a higher incidence of new coronary events (87%) than 
those with no silent ischaemia (51%) during a 40 month follow-up period [63]. Further 
studies are needed to validate the prognostic value of SMI detected by ambulatory ECG.
The diagnostic value of ambulatory ECG for CHD is poor. The predictive value of 
ischaemia detected by ambulatory ECG in type 2 diabetic patients has not been 
extensively studied.
Exercise ECG
The exercise ECG is considered positive for myocardial ischaemia if horizontal 
downsloping or upsloping ST-segment depression of ≥0.1 mV occurs at least 0.08 s 
after the J point. In a pooled meta-analysis of 24,074 patients who had undergone 
both an exercise ECG and conventional coronary angiography, mean sensitivity and 
specificity were calculated to be 68% and 77%, respectively, for the diagnosis of CHD 
by exercise ECG [67]. Sensitivity was higher in three-vessel disease [67]. In addition to 
myocardial ischaemia, the exercise ECG provides information on exercise capacity and 
haemodynamic response, which both have prognostic value [68].
The prognostic significance of exercise-induced myocardial ischaemia has been 
evaluated in prospective studies [69-70]. In a population-based study, an average follow-
up period of 10 years was completed in 1,769 asymptomatic men who had undergone an 
exercise ECG [69]. The risks of acute coronary events and cardiac death were increased 
1.7-fold and 3.5-fold, respectively, in men with SMI compared with men without SMI, 
after adjusting for conventional factors.
Exercise ECG in type 2 diabetes mellitus  The use of an exercise ECG for diagnosing 
myocardial ischaemia specifically in the setting of diabetes has not been assessed in large 
studies. In an evaluation of the correlation between the ECG exercise test and coronary 
angiography for the identification of significant coronary artery stenosis in 59 diabetic 
patients, the sensitivity and specificity were 75% and 77%, respectively [71]. The mean 
positive predictive value of the exercise ECG for predicting angiographic coronary 
disease varies between 70% and 90% [72-73]. However, the test is often inconclusive or 
unfeasible in diabetic patients (approximately 32%) because exercise capability may be 
impaired by peripheral vascular or neuropathic disease [72]. Furthermore, the specificity 
of this method is lower for detecting significant coronary artery disease in diabetes 
because of the presence of microvascular disease.
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Abnormal ECG stress tests have shown to be independent predictors of coronary events 
[74-75]. A 38 month follow-up of 262 asymptomatic diabetic patients who had undergone 
a maximal ECG stress test showed a good negative predictive value (97%) for major 
cardiac endpoints [74]. Gerson et al. [75] showed that the exercise ECG successfully 
identified all diabetic patients who developed clinical CHD within 50 months, but 
provided little prognostic information after the first 50 months, suggesting the need for 
serial testing.
Exercise ECG has moderate sensitivity and specificity for detection of CHD. 
During intermediate follow-up exercise ECG has shown to have a good predictive 
value of CE. Application of exercise ECG as a screening tool in type 2 diabetes is 
limited as the test is often inconclusive.
Stress echocardiography
SE is a well-established functional technique for assessing CHD that can be used to 
demonstrate inducible wall motion abnormalities in the general population. Exercise or a 
pharmacological form of stress can be used. In the case for the former, echocardiography 
is performed shortly after exercise. This method provides additional information on 
exercise capacity, symptoms and haemodynamic response, which are beneficial prognostic 
factors. A potential hindrance may be the rapid resolution of ischaemia after exercise, 
and therefore normalisation of any wall motion abnormality prior to echocardiography. 
Pharmacologically induced stress echocardiography is preferred in those with a limited 
exercise capacity. An additional advantage is that images are obtained during stress. 
In a meta-analysis of 10,817 patients in which dobutamine was compared with stress 
testing with adenosine or dipyridamole, dobutamine echocardiography had the highest 
combination of sensitivity (80%) and specificity (84%) for the diagnosis of coronary 
disease [76]. The accuracy of the method is dependent on the degree of stenosis, the 
amount of myocardium at risk and the degree of induced wall motion abnormality [77]. 
False-negative results are more likely with submaximal exercise (in the case of exercise-
induced stress), single-vessel disease and moderate stenosis (50–70%) [78].
The presence of ischaemia on SE and the number of ischaemic segments predict the 
likelihood of coronary events during long-term follow-up among members of the 
general population with known or suspected CHD [79-80]. However, in a 10 year 
follow-up of 1,832 asymptomatic patients who underwent SE, exercise testing and a 
resting echocardiogram, SE did not offer additional prognostic information in terms of 
identifying patients at a higher risk of coronary events [81].
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SE in type 2 diabetes The diagnostic accuracy of SE for significant CHD in diabetes has 
been verified in two studies. In one study in which 55 diabetic patients underwent 
dobutamine SE and invasive angiography, the sensitivity and specificity of SE were 81% 
and 85%, respectively [82]. Another study that compared SE with coronary angiography 
in diabetic patients (n=52) reported a similar sensitivity (82%) but a much lower specificity 
(54%) [83].
In a prospective study, SE plus an exercise ECG were used to screen 71 diabetic patients 
with unknown asymptomatic cardiac disease and two or more cardiovascular risk 
factors [84]. Those who obtained an abnormal result in one test underwent coronary 
angiography, and if necessary, revascularisation. Compared with patients randomised 
to the control arm (n=70), coronary events were significantly reduced in the screening 
arm during follow-up [84]. The preclinical diagnosis of CHD by SE may therefore be 
effective. However, more studies are needed to determine the prognostic role of SE in 
screening for cardiac disease in asymptomatic diabetic patients.
The sensitivity and specificity of SE for diagnosing extensive CHD are satisfactory. 
However, the predictive value of a positive test in type 2 diabetes needs to be 
further analysed.
SPECT myocardial perfusion imaging
The majority of studies on ischaemia have used SPECT MPI. This imaging modality 
reveals the presence and extent of perfusion defects. Images are taken following exposure 
to stress (exercise of pharmacological) and at rest, allowing the identification of fixed 
and reversible defects (Fig. 3). The dimensions of the left ventricle and ejection fraction 
can also be determined. An analysis of the diagnostic accuracy of pharmacologically 
induced stress MPI in a pooled meta-analysis of 10,817 patients with angiographic data 
reported a mean sensitivity and specificity of 88% and 77%, respectively [85].
Perfusion defects are significant predictors of coronary events in patients with known 
or suspected CHD [86]. However, over a follow-up period of 4.6 years the presence of 
perfusion defects did not independently predict coronary events in a purely asymptomatic 
group of volunteers [87]. Normal MPI results have shown a low coronary event rate 
(1%) over a 5 year follow-up period [88]. Significant predictors of future coronary events 
after pharmacologically induced stress MPI include large defects, defects in multiple 
coronary artery territory suggestive of multi-vessel disease, major irreversible defects, 
left ventricular dilatation and decreased resting left ventricular ejection fraction [86].
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Nuclear SPECT MPI in type 2 diabetes  To our knowledge, the diagnostic accuracy of MPI in 
diabetes has only been studied by Kang et al. [89], who performed MPI and conventional 
coronary angiography n 138 diabetic patients. Mean sensitivity and specificity were 86% 
and 56%, respectively, for ≥50% coronary stenosis, and 90% and 50% for ≥70% coronary 
stenosis [89].
In asymptomatic diabetic patients, the rate of SMI diagnosed by stress MPI ranges from 
17–59% (Table 1) [90-95]. In general, a higher percentage of perfusion defects has been 
detected in retrospective studies [90-91]. In the Detection of Ischemia in Asymptomatic 
Diabetics (DIAD) study, which included 1,123 participants, the occurrence of perfusion 
defects was not significantly associated with the traditional risk factors for CVD [92].
During an intermediate follow-up period, persistent and reversible perfusion defects 
have been shown to be predictors of coronary events in asymptomatic diabetic patients 
[93-95]. Rajagopalan et al. [90], categorised diabetic patients, according to SPECT imaging 
figure 3. Myocardial perfusion imaging was carried out in the patient described in Fig. 2, in 
whom coronary abnormalities had been observed on MSCT angiography. (a) A perfusion defect 
was observed in the posterolateral segment (indicated by the arrows) during stress, which did not 
exist during rest (b), indicating ischaemia. (c) Partial ischaemia was observed during stress, shown 
by an increase in the size of the defect in the inferior segment (indicated by the arrow) compared 
with the rest scan (d)
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Table 1. Comparison of studies which have used single-photon emission-computed tomography 
myocardial perfusion imaging to detect silent ischemia in diabetic patients
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scans, as being at high, intermediate or low risk. The annual mortality rate was 5.9%, 
5.0% and 3.6%, respectively, with a significant difference in mortality (p<0.001) between 
the three groups [90]. The long-term prognostic value of MPI in asymptomatic diabetic 
patients needs to be further analysed. It is speculated that concurrent abnormalities of 
perfusion imaging scans in diabetic patients with normal coronary angiograms may 
be caused by microangiopathy or endothelial dysfunction, and therefore represent an 
increased likelihood of future coronary events [96].
MPI shows good sensitivity but poor specificity (possibly because of microvascular 
disease) for diagnosing CHD in diabetes. Intermediate follow-up has shown a 
good predictive value of MPI for coronary events in type 2 diabetes.
ConClusIon
CIMT, arterial stiffness and perhaps FMD are abnormal long before the onset of diabetes. 
Therefore these measurements are the most likely to be useful for the identification 
of at risk patients during the early stages of atherosclerotic disease, when functional 
wall properties are still reversible. However, further studies are necessary to evaluate 
whether these tools provide any additional prognostic value when used in combination 
with clinical risk scores (Table 2) before they can be implemented on large scale in 
clinical practice.
In individuals with a strong clinical suspicion of advanced CHD, cardiac imaging 
techniques are more warranted. When functional techniques are compared, ambulatory 
ECG and exercise ECG are less sensitive and specific than functional cardiac imaging 
tests for the detection of ischaemia in type 2 diabetes. Head-to-head comparison has 
revealed that SPECT MPI has a higher sensitivity than SE for the detection of multi-
vessel and single-vessel CHD [97]. Furthermore, the predictive value of SPECT MPI in 
the diabetic population has been studied more extensively than that of SE (Table 2). CAC 
scoring and the more recently developed MSCT non-invasive coronary angiography 
allow quantification of atherosclerotic burden. CAC scores have been shown to 
predict coronary events [56]. MSCT coronary angiography has good sensitivity for the 
identification of prevalent CHD and can therefore enable more widespread screening in 
combination with CAC scores in diabetes, but its use is limited by radiation exposure 
and costs.
We propose an algorithm for the screening of asymptomatic diabetic patients (Fig. 4). 
A selection strategy using a CAC score >100 AU has been shown to be an effective way 
of identifying patients with moderate to large perfusion defects [98]. Nevertheless, 
recent observations have shown that low CAC scores do not exclude CHD in diabetes 
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[56]. Based on this, the initial step of our algorithm involves the combined use of CAC 
assessment and exercise ECG to maximise sensitivity for the detection of CHD. MPI or 
MSCT coronary angiography seem to be justified for individuals with a CAC score >100 
or a positive exercise ECG. Conventional coronary angiography can then be considered 
in the presence of ischaemia according to stress MPI or obstructive atherosclerosis 
illustrated by MSCT angiography. Prospective studies may be conducted to evaluate the 
effectiveness of such a screening approach.
The criteria for the selection of those asymptomatic patients with type 2 diabetes 
who should undergo non-invasive cardiac screening for risk stratification remain 
controversial. The ‘two or more risk factors’ criterion for screening, as suggested by the 
1998 American Diabetes Association guidelines, failed to accurately identify a large 
number of patients with ischaemia in the DIAD study [92]. Future studies may prove 
non-invasive vascular tools such as measurement of CIMT, PWV and FMD to be more 
effective for the identification of patients at risk who should be screened for CHD (Fig. 4).
THE fuTuRE
In type 2 diabetic patients, plaque development is not only accelerated but also distinct, 
exhibiting more lipid-rich atheroma, macrophage infiltration and a higher thrombogenic 
potential compared with development in non-diabetic individuals [99]. This implies 
that screening tools such as magnetic resonance angiography, which enable assessment 
of plaque composition and may reflect the real culprit, i.e. plaque vulnerability, could 
emerge as more potent risk predictors in diabetes. However, the application of magnetic 
resonance angiography as a screening tool is not feasible in the near future because of 
the high costs and complex methodology involved.
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CHAPTER 7
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AbsTRACT
Identification of asymptomatic patients with diabetes mellitus (DM) at increased risk 
for coronary artery disease (CAD) remains a challenge. Carotid intima media thickness 
(CIMT) has been proposed as a surrogate marker for CAD but only limited data are 
available. The purpose of the study was to evaluate the potential of CIMT for prediction 
of CAD in asymptomatic patients with DM. Prospectively, CIMT of the left and right 
common carotid artery was assessed by B-mode ultrasound in 150 asymptomatic 
diabetic patients (age 50±13 years, male 83). In addition, non-invasive multi-slice 
computed tomography (MSCT) coronary angiography was performed to relate CIMT to 
the presence and severity of CAD. For this purpose, patients were classified as having 1)
no atherosclerosis, 2)non-obstructive atherosclerosis or 3)obstructive stenosis with ≥50% 
luminal diameter narrowing. Mean CIMT increased significantly from 0.58±0.08 mm 
in patients with normal coronary arteries (n=59, 39%) to 0.67±0.12 mm in patients with 
non-obstructive atherosclerosis (n=54, 36%). Highest mean CIMT (0.75±0.12 mm) was 
observed in patients with obstructive stenosis (n=36, 25%, P<0.01). ROC curve analysis 
yielded a sensitivity and specificity of respectively 85% and 72% with a CIMT cut-off 
value of 0.67 mm, for predicting obstructive coronary atherosclerosis. Multivariate 
analysis of baseline risk factors showed CIMT to be an independent predictor of any- 
and obstructive atherosclerosis (P<0.01). In conclusion, significant relation was shown 
between CIMT and the presence and severity of CAD in asymptomatic patients with 
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InTRoDuCTIon
Presence of diabetes mellitus (DM) confers a substantially increased risk of coronary 
artery disease (CAD).1 Moreover, in patients with DM, CAD often progresses without 
evident symptoms (silent ischemia). Therefore, current guidelines recommend stringent 
primary prevention with lipid and blood pressure goals similar to secondary prevention, 
in all patients with DM.2 Nevertheless, within the asymptomatic diabetic population, 
some patients may be at relatively low risk and require limited medical therapy and 
risk modification, while others at elevated risk may benefit from more extensive cardiac 
evaluation and intensive medical therapy. Accordingly, a clear need exists for more 
individualized risk stratification. However, at present no consensus exists on the most 
appropriate approach for the identification of diabetic patients who may benefit from 
further non-invasive assessment of CAD. Possibly, initial assessment of cardiovascular 
risk may be performed by means of carotid intima media thickness (CIMT), which serves 
as a non-invasive marker of subclinical atherosclerosis.3 Although this technique has 
been extensively studied in the general population 4-8, less data are available concerning 
its relation with CAD in asymptomatic patients with diabetes.3,9 The current study was 
designed to prospectively evaluate the relation between CIMT and the presence and 
extent of CAD as assessed non-invasively by Multi-Slice Computed Tomography (MSCT) 
in asymptomatic diabetic patients, and thereby explore the potential role of CIMT as a 
tool for identification of diabetic individuals at higher risk for cardiovascular disease.
METHoDs
One hundred fifty asymptomatic patients with DM were prospectively included and 
clinically referred for cardiovascular screening. Cardiovascular risk factors were 
derived through a structured interview, physical examination and laboratory analysis. 
Hypertension was defined as a blood pressure >140/90 mmHg or treatment with 
antihypertensive medication. Hypercholesterolemia was defined as a total cholesterol 
level >5.0 mmol/L or use of lipid lowering medication. All patients underwent assessment 
of the CIMT and non-invasive MSCT coronary angiography as part of their clinical 
evaluation. Exclusion criteria consisted of ventricular and supraventricular arrhythmia 
and contraindications for the use of iodinated contrast media.
Imaging was performed with a 64-slice MSCT scanner (Aquilion64, Toshiba Medical 
Systems, Japan). If necessary and tolerated, oral beta-blockers (metoprolol 50  mg or 
100 mg) were provided 1 hour preceding the scan to achieve a heart rate <65 beats per 
minute. Initially, a non-enhanced prospective electrocardiographically gated scan, 
triggered at 75% of the R-R interval with 4 x 3.0 mm collimation was obtained to measure 
coronary artery calcium (CAC) score and determine the start and end position of the 
helical scan.
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Thereafter, MSCT angiography was performed using the following parameters: 
collimation 64 x 0.5 mm, tube rotation time 400, 450 or 500 ms depending on the heart 
rate, tube current 300 or 350 mA, tube voltage 120 kV. Non-ionic contrast material 
was administered in the antecubital vein at a flow rate of 5 ml/L and the amount of 
90–105 ml (depending on the total scan time), followed by 50 ml of saline solution flush. 
Automated bolus-tracking in the aortic root was used for the timing of the scan. Images 
were acquired with simultaneous ECG registration during a single breath hold of 
approximately 10 seconds. Segmental reconstruction algorithm was applied to generate 
a single image from the data of one, two or three consecutive heartbeats. Images were 
reconstructed in the cardiac phase showing least motion artifacts. In general, the end-
diastolic phase was used. However, additional reconstructions were made throughout 
the entire cardiac cycle if necessary to improve image quality. Subsequently, the images 
were transferred to a remote workstation (Vitrea 2, Vital Images, Minnetonka, USA) for 
post-processing.
All data were evaluated with a remote workstation using dedicated software (Vitrea2, 
Vital Images, Minnetonka, USA). In each patient, coronary calcium was identified as a 
dense area in the coronary artery exceeding the threshold of 130 Hounsfield units. The 
total Agatston score was determined for each patient. Patients with a CAC score >100 
were classified as having increased CAC.
MSCT coronary angiography images were interpreted by two experienced observers 
blinded to the patient characteristics. Discrepancies in interpretation were resolved by 
consensus. The presence of coronary atherosclerosis was visually evaluated on axial 
images and curved multiplanar reconstructions in at least two orthogonal planes. 
Obstructive coronary atherosclerosis was defined as the presence of luminal narrowing 
≥ 50%.
Carotid arteries were evaluated using high resolution B-mode ultrasound with a 
10-MHz linear transducer (Art.Lab Esaote Picus, Genova, Italy). The ultrasound device was 
connected to an acquisition modem with an automatic boundary detection system (Art.
Lab Esaote Picus, Genova, Italy). The CIMT was thereby quantified semi-automatically. 
All measurements were performed by the same two trained ultrasonographers who 
were blinded to all clinical information.
With the patient in supine position, measurements of the CIMT were performed 
throughout 10 mm segments across the far wall of the left and right common carotid 
artery (CCA), at a point most proximal to the carotid bifurcation. The probe was moved to 
obtain measurements of the CCA at four angles on the right (180º, 150º, 120º and 90º) and 
at four angles on the left (180º, 210º, 240º and 270º). For each measured segment the mean 
and maximum CIMT value was acquired automatically throughout the 10 mm vessel 
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length. Finally, the average of the mean CIMT values of all segments was calculated to 
determine mean CIMT per patient.
Of note, all measurements complied with the consensus recommendations that were 
recently proposed to standardize CIMT methodology and to restrict variations in 
definition of CIMT (mean or maximum IMT), location of measurements and the 
technique used (manual or semi-automatic edge detecting systems).10-12
Continuous variables were expressed as means ± standard deviation. Categorical 
variables were expressed as numbers (percentages). Firstly, the relationship between 
CAC score and CIMT was analyzed. For this purpose the study population was divided 
into patients with a CAC score 0-100 and those with an elevated CAC score study defined 
as a CAC score >100. Average CIMT and standard deviation were calculated in each 
group. The independent T-test was used to assess the difference in mean CIMT between 
the 2 groups. To evaluate the relation between coronary atherosclerosis and CIMT, 
the study population was categorized according to the results of the MSCT coronary 
angiography. MSCT coronary angiograms were stratified as normal in absence of 
atherosclerosis. In presence of coronary atherosclerosis, the examinations were further 
sub-classified as non-obstructive (defined as coronary narrowing <50%) or obstructive 
atherosclerosis (defined as coronary narrowing ≥50%). Average CIMT and standard 
deviation were calculated for all three groups, and the independent T-test was applied 
to evaluate the difference in mean CIMT. Using ROC curve analysis cut-off values were 
chosen for mean CIMT. Subsequently, sensitivity and specificity values were calculated 
for predicting: 1) CAC score >100, 2) presence of any coronary atherosclerosis and 3) 
presence of obstructive coronary atherosclerosis. To determine the relationship between 
cardiovascular risk factors and coronary atherosclerosis, a univariate analysis of 
baseline clinical characteristics was performed to identify the potential predictors of any 
coronary atherosclerosis on MSCT coronary angiography. Thereafter, risk factors with a 
P value <0.05 were included in a multiple regression analysis to identify the independent 
predictors of any coronary atherosclerosis. A similar procedure was repeated to identify 
the predictors of obstructive coronary atherosclerosis on MSCT coronary angiography. 
Finally, the incremental value of CIMT over other clinical predictors of obstructive 
coronary atherosclerosis was assessed by calculating the global chi-square test. 
Statistical analyses were performed using SPSS software (version 12.0.1, Inc., Chicago, 
Illinois). P values <0.05 were considered statistically significant.
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REsulTs
The baseline characteristics of the study population are provided in Table1.
Mean CAC score was 211 ± 448 in the total population. In 102 patients (68%) CAC was 
absent or ≤100, while 48 patients (32%) had a CAC score >100. MSCT coronary angiography 
showed normal coronaries in 59 patients (39%). Coronary atherosclerosis was present in 91 
patients (61%). Within this group, 54 patients (36% of total population) had non-obstructive 
atherosclerosis defined as luminal narrowing <50%, and 37 patients (25% of total 
population) were observed with obstructive atherosclerosis (luminal narrowing ≥50%).
CIMT ranged from 0.43 to 1.01 mm, with an average of 0.65 ± 0.12 mm. Mean CIMT was 
higher in patients with a CAC score >100 (0.74 ± 0.13 mm) as compared to those with a CAC 
score in the range 0-100 (0.61 ± 0.10 mm) (P <0.001) (Figure 1A). Using ROC curve analysis 
a cut-off value of 0.65 mm was identified for CIMT. This cut-off value yielded a sensitivity 
and a specificity of respectively 72% and 70% for predicting a CAC score >100 (Figure 1B).
After stratification according to MSCT angiography results, lowest mean CIMT was 
observed in patients with normal coronaries (0.58 ± 0.08 mm). Mean CIMT increased to 
an average of 0.67 ± 0.12 mm in patients with non-obstructive coronary atherosclerosis 
(P <0.001) and further to an average of 0.75 ± 0.12 mm in patients stratified as having 
obstructive coronary atherosclerosis (P = 0.002) (Figure 2A). ROC curve analysis 
resulted in a sensitivity and specificity of 76% and 71% with a cut-off value of 0.62 mm 
for predicting any coronary atherosclerosis (Figure 2B). Similarly, ROC curve analysis 
resulted in a sensitivity and specificity of 85% and 72% with a cut-off value of 0.67 mm 
for predicting obstructive coronary atherosclerosis (Figure 2C).
Results of the univariate – and multivariate regression analysis of the baseline 
characteristics for prediction of any coronary atherosclerosis and obstructive coronary 
atherosclerosis are provided in Table 2. CIMT, DM duration and family history of CAD 
were identified as independent predictors of any coronary atherosclerosis. Likewise, 
age, plasma HbA1c and CIMT were identified as independent predictors of obstructive 
coronary atherosclerosis. Importantly, calculation of global chi-square showed significant 
incremental value of CIMT values above age and plasma HbA1c in the prediction of 
obstructive coronary atherosclerosis (Figure 3).
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Table 1. Characteristics of the study population (n = 150)
Variable
Age (years) 50 ± 13
Men 83 (55%)




Diabetes Mellitus duration (years) 14 ± 13
Glycosylated hemoglobin A1c (mmol/L) 8.1 ± 1.7
Data are averages ± standard deviation or number of patients (%).
* Total cholesterol level > 5.0 mmol/L or use of cholesterol-lowering medication.
† Blood pressure > 140 mmHg or treatment with antihypertensive medication.
P < 0.001
0.61 ± 0.10 0.74 ± 0.13
N = 48N = 102
0-100 >100

































0.43 0.52 0.57 0.64 0.71 0.78 0.99
0.65
Mean Carotid Intima Media Thickness (mm)
1B. Prediction of Coronary Artery Calcium Score >100
figure 1. Relation between CIMT and CAC scores.  (A) Mean CIMT was significantly higher in 
patients with a CAC score >100. (B) Receiver operating characteristics curve analysis yielded a 
sensitivity and specificity of 72% and 70% with a CIMT cut-off value of 0.65 mm for prediction of 
a CAC score >100.
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0.62
Mean Carotid Intima Media Thickness (mm)
2B. Prediction of Coronary Atherosclerosis
Sensitivity Specicity









Mean Carotid Intima Media Thickness (mm)
2C. Prediction of Obstructive Atherosclerosis
figure 2. Relation between CIMT and coronary atherosclerosis. (A) Mean CIMT increased 
significantly with degree of coronary atherosclerosis. Receiver operating characteristics curve 
curve analysis yielded (B) a sensitivity and specificity of 76% and 71% with a CIMT cut-off value 
of 0.62 mm for prediction of any coronary atherosclerosis, and (C) a sensitivity and specificity 
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DIsCussIon
In this asymptomatic population recruited from a diabetes clinic, a significant relation 
was observed between CIMT and the presence of atherosclerosis determined by CAC 
and MSCT coronary angiography. CIMT increased with elevated CAC scores as well as 
with the degree of coronary atherosclerosis on MSCT coronary angiography. In addition, 
ROC curve analysis of the CIMT relation with variables of atherosclerosis on MSCT 
resulted in reasonable sensitivity values for prediction of CAD. Good sensitivity was 
observed for detection of obstructive CAD in particular. Furthermore, after correction 
for traditional risk factors CIMT was found to be an independent predictor of any- and 
obstructive coronary atherosclerosis.
DM is considered a CAD equivalent and currently rigorous primary prevention is 
recommended by AHA/ADA in all diabetic patients.2 However, whether all diabetic 
patients equally benefit from this treatment strategy remains uncertain. A risk 
stratification algorithm allowing exclusion of patients at lower risk from further 
evaluation and intensive treatment would improve cost-effectiveness, but remains 
a challenge. Thus far, various strategies have been recommended for individual risk 
stratification within the diabetic population. Primarily, the AHA/ADA 1998 guidelines 
suggested more aggressive medical treatment and assessment of CAD only in presence 
3.
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figure 3. Incremental value of CIMT over significant clinical predictors of obstructive coronary 
atherosclerosis. Addition of CIMT value, to age and HbA1c, resulted in a significant increase of 
global chi-square from 37.7 to 49.5 (P <0.001).
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of two additional risk factors.13 However, the Detection of Ischemia in Asymptomatic 
Diabetics (DIAD) study based on 1123 asymptomatic diabetic patients showed the 
number of cardiovascular risk factors to be a poor predictor of hemodynamically 
relevant CAD.14 Moreover, that particular study revealed that a selection strategy based 
on a minimum of two additional risk factors underestimates the presence of CAD in a 
large proportion of patients, as 41% of patients with myocardial ischemia would not have 
been identified. The clinical utility of more refined risk prediction models may also be 
limited as the Framingham score has been shown to underestimate event rates in DM as 
compared to the non diabetic population.15 The SCORE and DECODE models incorporate 
DM in a categorical fashion and have been criticized of inadequate risk estimation 
due to negligence of glycemic level.15 Prospective evaluation of the diabetes specific 
UKPDS score in an asymptomatic diabetic population suggested less underestimation 
of coronary events as compared to the Framingham score.16 Nevertheless, also the 
UKPDS score showed a poor relation between actual and predicted coronary events on 
an individual basis. It is assumable that direct estimation of atherosclerosis as can be 
obtained with CIMT may provide more accurate risk stratification.
Before CIMT can be advocated as a potential cardiovascular screening tool in diabetic 
patients asymptomatic for CAD, it is necessary to evaluate the association between CIMT 
measurement and the presence and extent of CAD in this population. Previous histological 
analyses have illustrated a strong agreement between the ultrasonographic estimation 
and actual IMT values.17 Evaluation of IMT provides a direct measure of the presence 
of atherosclerosis, which is a systemic disease.17 In the general population, association 
of CIMT with the presence of current CAD, as well as its significant predictive value 
for cardiac events have been shown.4-8 In diabetic patients, the relation between CIMT 
and CAD has been assessed in sub-analyses of the ARIC and the IRAS investigations to 
reveal higher mean CIMT in patients with established CAD.18,19 However, the association 
between CIMT and CAD has not been examined in asymptomatic patients with DM. In 
the current study, therefore, we evaluated in asymptomatic diabetic patients the relation 
between CIMT and CAD, as assessed by MSCT, a technique which not only allows 
assessment of CAC but also provides information on coronary integrity and degree of 
coronary atherosclerosis.20 We observed a strong relation between CIMT and CAC scores 
as well as with the degree of coronary atherosclerosis. Importantly, CIMT was shown 
to be an independent predictor of coronary atherosclerosis in asymptomatic diabetic 
patients after correction for baseline risk factors. Furthermore, CIMT showed good 
sensitivity for the prediction of obstructive CAD, and was revealed to have incremental 
value over clinical risk factors in the prediction of obstructive CAD.
Based on these findings, CIMT appears to be a useful tool to identify asymptomatic 
diabetic patients at higher risk for CAD. Two previous prognostic studies in asymptomatic 
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diabetic patients, which showed CIMT to be predictive of future cardiovascular events, 
further support this concept.21,22 Although direct assessment of coronary atherosclerosis 
by means of CAC or MSCT coronary angiography may provide more detailed information 
and allow more accurate risk stratification 23, these techniques involve radiation and 
higher costs. In contrast, ultrasonographic measurement of CIMT offers the advantage 
of being truly non-invasive, inexpensive and radiation-free. Accordingly, CIMT may be 
particularly useful in asymptomatic diabetic patients as an initial step to select patients 
requiring more aggressive medical therapy and further cardiovascular evaluation.
Several limitations must be acknowledged. The prognostic value of CIMT was not 
evaluated as no follow-up data were available. Furthermore, the current analysis was 
restricted to the evaluation of the relation between CIMT and CAD in diabetic patients, 
and assessment did not include a non-diabetic control group. As MSCT coronary 
angiography is accompanied with radiation exposure, it is not feasible to perform a 
similar assessment in asymptomatic subjects free of cardiovascular risk.
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CHAPTER 8
Increased Carotid Intima Media Thickness as a 
Predictor of the Presence and Extent of Abnormal 
Myocardial Perfusion in Type 2 Diabetes
Roxana Djaberi, Joanne D. Schuijf, J. Wouter Jukema, Ton J. Rabelink, 
Marcel P. Stokkel, Jan W. Smit, Eelco J. de Koning, Jeroen J. Bax.
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AbsTRACT
objECTIvE
Identification of asymptomatic patients with type 2 diabetes at increased risk for coronary 
artery disease remains a challenge. We evaluated the potential of carotid intima media 
thickness (CIMT) for prediction of abnormal myocardial perfusion in this population.
REsEARCH DEsIGn AnD METHoDs
CIMT and SPECT myocardial perfusion imaging were assessed in 98 asymptomatic 
patients with type 2 diabetes. An increased CIMT was defined as ≥75th percentile of 
reference values.
REsulTs
Increased CIMT was an independent predictor of the extent of abnormal perfusion 
(P <0.001). In patients with increased CIMT as compared to patients with normal CIMT, 
abnormal perfusion (75% vs. 9%) and severely abnormal perfusion (28% vs. 3%) were 
observed more frequently.
ConClusIons
Increased CIMT was significantly related to the presence and extent of abnormal 
myocardial perfusion. Assessment of CIMT may be useful to identify asymptomatic 
patients with type 2 diabetes at higher risk for coronary artery disease.
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InTRoDuCTIon
Identification of asymptomatic patients with type 2 diabetes at increased risk for 
coronary artery disease (CAD) remains a challenge. In the current study, we evaluated 
the potential of carotid intima media thickness (CIMT) to identify asymptomatic patients 
with type 2 diabetes at higher risk for abnormal myocardial perfusion.
REsEARCH DEsIGn AnD METHoDs
Prospectively, 98 consecutive asymptomatic patients with type 2 diabetes (1), were 
recruited from a routine outpatient diabetes clinic, and referred for cardiovascular risk-
stratification. Asymptomatic status was confirmed using the Rose questionnaire (2). All 
patients underwent myocardial perfusion imaging by SPECT and CIMT assessment.
sPECT data acquisition and data analysis
Myocardial perfusion imaging was performed using ECG-gated SPECT with 
99mTc-sestamibi, during pharmacological stress and rest, according to protocols described 
previously (3).
Using a 17-segment model tracer uptake in each segment was evaluated by two 
observers in consensus, by use of a 5-point scoring system (4). The total segmental score 
during stress was used to determine the extent of abnormal perfusion as reflected by 
the summed stress score (SSS). Abnormal perfusion was defined as SSS ≥3, and severely 
abnormal perfusion as SSS ≥8.
CIMT measurement and data analysis
CIMT was assessed using high resolution B-mode ultrasound with a 10-MHz linear 
transducer, with an automatic boundary detection system (Art.Lab-Esaote-Picus, 
Genova, Italy). Measurements were performed by an experienced sonographer blinded 
to clinical information (5). Mean CIMT was assessed throughout 10-mm segments, at 
four angles, across the far wall of the right and left common carotid artery (CCA). The 
average of the mean CIMT values of the 4 segments was calculated to determine the 
mean right and left CIMT per patient.
CIMT values ≥75th percentile (per age and gender category) are defined as increased, 
indicating elevated cardiovascular risk (5). In the current study, the mean CIMT was 
compared with reference values from the Multi-Ethnic Study of Atherosclerosis (5). 
Patients were thereby stratified as having normal CIMT (CIMT <75th percentile), or 
increased CIMT (CIMT ≥75th percentile in at least one CCA).
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statistical analysis
First, average SSS and standard deviations were calculated in patients with normal or 
increased CIMT. The independent T-test was used to assess the difference in mean SSS 
between the two groups.
Thereafter, univariate analysis of baseline characteristics including age, positive 
family history of CAD, smoking, hypertension, hypercholesterolemia, body mass 
index, nephropathy (urine albumin/creatinine ≥3.5 mg/mmol), fasting glucose, 
glycated-hemoglobin  (by chromatography) (6), retinopathy, peripheral arterial disease 
and increased CIMT, was performed to identify potential predictors of the extent of 
abnormal perfusion (SSS). Subsequently, risk factors with a P value <0.05 were included 
in a linear multiple regression model to identify independent predictors of SSS.
Finally, the prevalence of abnormal perfusion (SSS≥3) and severely abnormal perfusion 
(SSS≥8) was compared between patients with normal and increased CIMT.
REsulTs
Briefly, the mean age of the study population was 54 ± 11 years with the majority of 
patients being male (n = 50, 51%).
Mean SSS was 3.1 ± 4.2 in the total population. Overall, 34 patients (35%) showed abnormal 
perfusion (SSS ≥3), including severely abnormal perfusion (SSS ≥8) in 14 patients (14%).
Average CIMT was 0.68 ± 0.12 mm. Comparison with reference values revealed normal 
CIMT in 60 patients (61%), while in the remaining 38 patients (39%) an increased CIMT 
value was observed in at least one CCA.
CIMT versus extent of abnormal perfusion
The mean SSS increased significantly from 1.2±2.1 in patients with normal CIMT, 
to 5.6±4.6 in patients with increased CIMT (P<0.001).
Age, smoking, hypertension, nephropathy and increased CIMT, were identified as 
potential predictors of SSS on SPECT, in a univariate regression model. Importantly, after 
adjustment for age, smoking, hypertension and nephropathy in a multivariate model, 
increased CIMT remained a significant predictor of SSS (P <0.001) (ß = 4.41 [95% CI 3.05-
5.76]).
CIMT versus prevalence of abnormal perfusion
Abnormal perfusion was present in 9% of patients with normal CIMT versus 75% of 
patients with increased CIMT (Figure 1A). Notably, prevalence of severely abnormal 
perfusion increased from 3% in patients with normal CIMT to 28% in those with 
increased CIMT (Figure 1B).
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ConClusIons
The prognostic value of SPECT imaging has been confirmed in diabetic patients (7). 
In particular, a favorable cardiovascular prognosis has been described in patients with 
normal myocardial perfusion, whereas significantly higher adverse event rates were 
observed in patients with severely abnormal perfusion (8). SPECT has therefore been 
proposed as a screening tool for identification of asymptomatic diabetic patients with 
obstructive CAD (9). However, considering the high global prevalence of type 2 diabetes, 
a broad screening strategy of all asymptomatic patients using SPECT perfusion imaging 
does not appear feasible or cost-effective (10). AHA/ADA therefore initially suggested 
more aggressive medical treatment and assessment of CAD only in the presence of two 
additional risk factors (9). Nonetheless, baseline analysis of SPECT data in the DIAD 
study demonstrated that a selection strategy based on a minimum of two additional 
risk factors underestimates the presence of abnormal perfusion in a large proportion 
of patients (41%)(11). Accordingly, the key question remains how asymptomatic diabetic 
patients with severe CAD should be identified from the general diabetic population.
Assessment of CIMT has been previously proposed for this purpose (12). Moreover, the 
truly non-invasive, inexpensive and radiation-free nature of CIMT may represent an 
important advantage over other suggested screening techniques such as coronary calcium 





































figure 1. Relation between CIMT and myocardial perfusion imaging. Prevalence of abnormal 
perfusion (Figure 1A), and severely abnormal perfusion (Figure 1B), was higher in patients with 
increased CIMT.
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scoring (5). However, the relation of CIMT with CAD has not been fully established in 
asymptomatic diabetic patients. In the current study, increased CIMT was shown to 
be a strong predictor of the extent of abnormal perfusion and improved identification 
of patients with severely abnormal perfusion (28%). Normal CIMT values on the other 
hand were associated with a low risk for abnormal perfusion. Importantly, only few 
asymptomatic diabetic patients with normal CIMT values had severely abnormal 
perfusion (3%). However, it must be acknowledged that a non-diabetic control group was 
not available for comparison. Also, patients were referred from a diabetes clinic and may 
thus represent a more high-risk group than the general asymptomatic population with 
diabetes. Nevertheless our findings suggest that initial risk-stratification using CIMT 
may allow selective referral of asymptomatic patients with type 2 diabetes requiring 
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CHAPTER 9
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AbsTRACT
Purpose
Vascular stiffness may potentially be used as a screening tool to identify asymptomatic 
patients with diabetes with abnormal myocardial perfusion. The purpose of this study 
was therefore to determine the association between vascular stiffness measured with 
pulse wave velocity (PWV) and augmentation index (AIx), and abnormal myocardial 
perfusion imaging (MPI) in asymptomatic patients with diabetes.
Methods
Prospectively, 160 asymptomatic patients with diabetes (mean age 51  yrs, male 87) 
underwent MPI with adenosine stress. Summed stress score (SSS) was determined 
per patient according to a 17 segment and 5 point score. Abnormal MPI (SSS ≥3) was 
sub-classified as moderate (SSS 3-7) or severe (SSS ≥8) MPI defects. Using applanation 
tonometry, the carotid-femoral PWV and the radial AIx corrected to 75 beats per minute 
were determined non-invasively.
Results
MPI was abnormal in 61 patients (38%), with severe MPI defects in 22 patients (14%). 
Mean PWV increased with deteriorating MPI from 8.4 ± 2.2 m/s in normal MPI to 9.0 ± 
2.2 m/s in moderate MPI defects (P = 0.11), and to 11.1 ± 2.5 m/s in severe MPI defects (P 
< 0.01). Likewise, mean AIx increased from 18.4 ± 13.4% to 19.4 ± 10.7% (P = 0.66) and to 
25.4 ± 9.0% (P = 0.03). After adjustment for age and other risk factors, PWV remained a 
significant predictor of severe MPI defects (P = 0.01, OR 1.50, 95% CI 1.11-2.00), whereas 
AIx was no longer significant (P = 0.20).
Conclusions
Vascular stiffness measured by PWV is associated with severe MPI  defects in 
asymptomatic patients with diabetes.
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InTRoDuCTIon
It is considered that the global prevalence of diabetes will approximately double in the 
next two decades [1]. Diabetes is associated with a marked increase in the incidence of 
cardiovascular morbidity and mortality, mainly attributable to coronary artery disease 
(CAD). Moreover, the presence and progression of CAD in diabetic patients is often 
asymptomatic, leading to more extensive disease at the time of diagnosis [2]. Since a 
delayed diagnosis of CAD considerably worsens the prognosis, early recognition of 
CAD could lead to more effectively targeted intervention and reduce morbidity and 
mortality in this population. Myocardial perfusion imaging (MPI) with SPECT is most 
commonly applied to identify patients with CAD and can accurately identify patients 
at increased cardiovascular risk [2-4]. However, based on recent data, a wide ranged 
routine MPI screening strategy of all asymptomatic patients with diabetes appears to 
be ineffective [5]. Accordingly, a selective “prescreening” strategy using an initial test 
for the identification of patients with a higher likelihood of abnormal MPI followed by 
referral of only these patients to MPI may be preferred. Non-invasive assessment of 
vascular stiffness could represent a promising tool for this purpose. In several studies, a 
relation between vascular stiffness and cardiovascular disease has been observed [6-8]. 
Assessment of the vascular stiffness, by means of pulse wave velocity (PWV) or pulse 
wave analysis (PWA) for augmentation index (AIx), may therefore have the potential 
to serve as a marker of abnormal MPI. Although PWV and AIx have been extensively 
studied in the general population [9-13], less data are available concerning their relation 
with CAD in asymptomatic patients with diabetes.
The aim of the current study was to prospectively assess the relation between the non-
invasive measures of vascular stiffness (PWV and AIx) with the presence and extent of 




Prospectively, 160 consecutive asymptomatic patients with diabetes were recruited from 
a routine outpatient clinic. Patients were referred to the cardiology outpatient clinic 
for risk assessment and cardiovascular screening. Anginal symptoms were ruled out 
using a self-completed questionnaire for encountered chest pain [14]. The American 
Diabetes association (ADA) criteria were used to identify diabetes and for further 
stratification in type 1 or 2 diabetes [15]. Patients were considered as having type 1 
diabetes if laboratory analysis demonstrated auto-antibodies to islet cells, insulin and 
glutamic acid decarboxylase or low levels of plasma c-peptide. Otherwise, patients were 
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considered to have type 2 diabetes. Medical history and demographics were obtained. 
All patients underwent physical examination, and blood and urine laboratory testing. 
MPI was performed as part of clinical work-up to determine presence and extent of 
myocardial perfusion defects. Additional measurements of PWV and AIx were used to 
assess vascular stiffness.
Cardiovascular risk factors
Cardiovascular risk factors were defined according to the following criteria: positive 
family history for CAD (presence of CAD in first degree family members male <55 years 
and / or female <65 years), smoking (current smoking or smoking in the last 2 years), 
hypertension (blood pressure >140/90 mmHg or treatment with antihypertensive 
medication), body mass index (kg/m²), hypercholesterolemia (total cholesterol level 
>5.0 mmol/L or use of cholesterol lowering medication), and micro-albuminuria (urine 
albumin/creatinine ratio ≥3.5 mg/mmol) [2]. Plasma hemoglobin A1c was determined as 
a measure of glycemic control.
sPECT myocardial perfusion imaging
SPECT data acquisition
ECG-gated adenosine technetium-99m sestamibi (Tc99m MIBI) SPECT MPI was 
performed using a 2-day protocol, comprising of stress imaging on the first day and 
a rest scan on the second day [16]. Anti-hypertensive treatment with beta-adrenergic 
blocking agents or calcium antagonists was stopped and patients were instructed to 
abstain from caffeine containing products 24 hours prior to the stress test. Vasodilator 
stress was induced by intravenous infusion of adenosine 140 µg/kg/min for 6 min, 
with simultaneous handgrip exercise. Tc99m MIBI (500MBq) was injected intravenously 
after the third minute. Blood pressure and a 12-lead ECG were recorded throughout the 
adenosine infusion.
Images were acquired 2 hours after radiopharmaceutical injection using a triple head 
SPECT gamma camera (GCA 9300/HG; Toshiba Corporation, Tokyo, Japan) with low-
energy, high-resolution collimators. Image acquisition was performed, using a circular 
360˚ orbit, 60 projections, and 40 seconds per projection, in compliance with the American 
Society of Nuclear Cardiology (ASNC) imaging guidelines. Images were processed to 
obtain the short-axis, vertical long-axis, and horizontal long-axis sections, as well as 
polar map formats, normalized to maximal myocardial activity [16]. Patient motion was 
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SPECT data analysis
For semi-quantitative visual interpretation the myocardium was divided into 17 segments 
according to ASNC guidelines [16]. Tracer uptake in each segment was evaluated 
in consensus by two expert observers, blinded to patient’s clinical characteristics 
and test results, using a 5-point scoring system ranging from 0 (normal uptake) to 4 
(absent uptake). The summed stress score (SSS) was determined by the total sum of 
the 17 segmental scores of the stress images. MPI was considered normal if SSS <3. In 
case of abnormal MPI, a SSS 3-7 was considered to represent moderate MPI defects, and 
a SSS ≥8 to represent severe MPI defects [17]. Finally, regional wall motion on gated 
SPECT images was evaluated to allow differentiation between true MPI abnormalities 
and diaphragmatic or breast attenuation artifacts.
Assessment of vascular stiffness
Measurements were derived and analyzed non-invasively by applanation tonometry 
using a Sphygmocor system (SphygmoCor, Atcor Medical, Sydney, Australia). All 
measurements were performed in the morning in a quiet, temperature controlled 
clinical research laboratory by a specially trained technologist, blinded to patient’s 
clinical characteristics and test results. Patients were instructed to abstain from their 
morning medication and remain fasting until after the test. Assessment of PWV and 
PWA commenced following a 10 minute rest in supine position, after a state of constant 
heart rate and blood pressure was reached.
Pulse wave velocity
The pulse waves were recorded at the common carotid artery and the femoral artery by 
sequential tonometry with simultaneous electrocardiographic gating. Pulse transit time 
was determined as the average of 10 consecutive beats. The distance between the two sites 
was measured. Aortic PWV (m/s) was defined as the distance between the 2 recording 
sites traveled by the pulse wave, divided by transit time. Using system software, aortic 
PWV was determined semi-automatically. The validation and reproducibility of this 
semi-automatic method have been previously published [18]. Measurements were 
performed three times in each patient and averaged to obtain the mean aortic PWV.
Pulse wave analysis
The peripheral pressure waveforms were recorded from the radial artery at the wrist, 
with a hand-held high fidelity tonometer (Millar Instruments, Houston, TX, USA) and 
calibrated by peripheral blood pressures of the brachial artery [7,19]. The corresponding 
central aortic pressure waveform was generated by a validated generalized transfer 
function. The central aortic pressure waveform was analyzed to identify the first shoulder 
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of the pressure wave representing the incident wave attributable to left ventricular 
ejection. The merging point of the incident and the reflected wave (the inflection point) 
was then identified on the generated aortic pressure waveform. The absolute augmented 
pressure was the maximum systolic pressure minus pressure at the inflection point. 
Subsequently, the AIx was defined as the absolute augmented pressure divided by the 
pulse pressure and expressed as a percentage [7,8].
Finally, the AIx was normalized for the heart rate of 75 bpm (AIx@75). For each patient, 
3 consecutive waveform recordings were averaged to obtain the mean AIx@75, which 
was used for statistical analysis.
statistical analysis
Continuous variables were expressed as means ± standard deviation and categorical 
variables as numbers (percentages). Firstly, associations of PWV and AIx@75 with 
baseline clinical risk factors were assessed using the Pearson’s correlation coefficient 
(r) or the Spearman’s rank correlation coefficient (rs) in case of dichotomous variables. 
Secondly, differences in the mean PWV and AIx@75 for each group of MPI results were 
evaluated with the independent T-test. Thereafter, with univariate logistic regression 
analysis potential predictors of severe MPI defects were identified. Subsequently, 
all potential predictors were analyzed in a multivariate logistic regression model 
to identify the independent predictors of severe MPI defects. Additionally, patients 
were categorized according to PWV quartiles and for each quartile the prevalence of 
severe MPI defects was obtained. Subsequently, global chi square analysis was used 
to determine the incremental predictive value of PWV over baseline characteristics. 
Thereafter, using receiver operating characteristic (ROC) curve analysis two cut-off 
values were chosen for PWV; one cut-off value for the detection of severe MPI defects 
with optimal sensitivity and specificity and another cut-off value for the exclusion of 
severe MPI defects with optimal sensitivity and negative predictive value. All statistical 
analyses were performed using SPSS software (version 16.0, Inc., Chicago, Illinois). 
P-values <0.05 were considered statistically significant.
REsulTs
Patient characteristics
The study population comprised of 160 asymptomatic diabetic patients. Baseline 
characteristics are provided in Table 1.
Chapter 9
160
Djaberi.indd   160 5-8-2014   15:28:48
sPECT myocardial perfusion imaging
The overall mean SSS was 3.1 ± 4.1 (range 0-21). Abnormal MPI (SSS ≥3) was observed 
in 60 patients (38%), including moderate MPI defects (SSS 3-7) in 38 patients (24%) and 
severe MPI defects (SSS ≥8) in 22 patients (14%).
vascular stiffness
Pulse wave velocity
The overall mean PWV was 8.9 ± 2.4 m/s. PWV was associated with age (r = 0.62, 
P <0.01), type 2 diabetes (rs  = 0.23, P <0.01), diabetes duration (r = 0.30, P <0.01), body 
mass index (r = 0.22, P <0.01), hypertension (rs  = 0.43, P <0.01), and micro-albuminuria 
(r = 0.29, P <0.01).
Table 1 Baseline characteristics of the study population, n =160
Clinical factors Mean ± st dev. or number (%)
Age 51 ± 12
Men 87 (54%)
Type 2 diabetes 91 (57%)
Diabetes duration (years) 15 ± 13
Insulin use 125 (78%)
Family history of CADa 75 (47%)
Smoking 42 (26%)
Body mass index (kg/m²) 28 ± 6
HbA1c (mmol/l)b 8.2 ± 1.7
Hypertension 92 (58%)
Use of antihypertensive medication 76 (48%)
ACE-inhibitor usec 43 (27%)
Beta-blocker use 19 (12%)
Systolic blood pressure (mmHg) 133 ± 16
Diastolic blood pressure (mmHg) 80 ± 9
Hypercholesterolemia 107 (67%)
Cholesterol lowering medication 73 (46%)
Total cholesterol (mmol/l) 4.8 ± 1.1
Micro-albuminuria 39 (24%)
Aspirin use 31 (19%)
aCAD = coronary artery disease
bHbA1c = plasma hemoglobin A1c
cACE = angiotensin converting enzyme
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As shown in Figure 1a, mean PWV increased only slightly from 8.4 ± 2.2 m/s in patients 
with normal MPI to 9.0 ± 2.2 m/s in patients with moderate MPI defects (P  =  0.11). 
However, the mean PWV was significantly higher in patients with severe MPI defects 
(11.1 ± 2.5 m/s, P <0.01).
Association between pulse wave analysis with myocardial perfusion
The mean AIx was 21.1 ± 12.3% in the total population. Normalization for a heart rate 
of 75 beats per minute resulted in an overall mean AIx@75 of 19.6 ± 12.4%. A significant 
association was observed between AIx@75 and the following risk factors: age 
(r = 0.47, P <0.01), male gender (rs = -0.43, P <0.01), type 2 diabetes (rs = 0.30, P <0.01), 
hypercholesterolemia (rs = 0.17, P <0.03), and micro-albuminuria (r = 0.26, P <0.01).
After stratification of mean AIx@75 according to SPECT MPI results, a trend similar 
to that of PWV was observed. Likewise, mean AIx@75 was slightly higher in patients 
with moderate MPI defects than in those with normal MPI (19.4 ± 10.7% and 18.4 
± 13.4% respectively, P = 0.66), and was significantly higher in patients with severe 
MPI (25.4 ± 9.0%, P = 0.03;  Figure 1b).
figure 1 Relation between parameters of vascular stiffness and the extent of MPI defects as 
assessed  by SPECT MPI. a Mean aortic PWV was increased in patients with abnormal MPI. 
The most  substantial increase in PWV was observed in patients with severe MPI defects. 
b  The relationship between mean AIx@75 and MPI shows a similar trend. Abbreviations: 
MPI = myocardial perfusion imaging and @ 75 = corrected for heart rate to 75 bpm.
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Table 2 Predictors of severe MPI defects (SSS ≥8) on SPECT
Clinical characteristic Exp β (95% CI) P-value Exp β (95% CI) P-value
Age 1.09 (1.04-1.14) <0.01 1.06 (0.98-1.14) 0.16
Male gender 3.30 (1.15-9.45) 0.03 6.35 (1.47-27.41) 0.01
Type 2 diabetes 1.47 (0.55-3.90) 0.44
Diabetes duration (years) 1.02 (0.99-1.06) 0.15
Family history of CADa 1.16 (0.47-2.85) 0.75
Smoking 3.80 (1.48-9.77) 0.01 5.74 (1.35-24.46) 0.02
Body mass index (kg/m²) 0.99 (0.91-1.07) 0.77
HbA1c (mmol/l)b 1.28 (1.00-1.65) 0.05 1.52 (1.03-2.25) 0.03
Hypertension 1.98 (0.73-5.41) 0.18
Hypercholesterolemia 1.65 (0.57-4.79) 0.36
Micro-albuminuria 3.86 (1.52-9.81) 0.01 1.05 (0.26-4.27) 0.95
PWVc 1.49 (1.22-1.81) <0.01 1.49 (1.11-2.00) 0.01
AIx@75d 1.06 (1.01-1.11) 0.02 1.05 (0.97-1.14) 0.20
MPI = myocardial perfusion imaging
aCAD = coronary artery disease
bHbA1c = plasma hemoglobin A1c
cPWV = Pulse wave velocity (in m/s)
dAIx@75 = Augmentation index (%) normalized for the heart rate of 75 bpm.
figure 2 Prevalence of patients with severe MPI defects per PWV quartile. The prevalence of 
severe MPI defects increased with increasing PWV. Of note, the prevalence of severe MPI 
defects chiefly increased in the third and fourth PWV quartile. Abbreviations: MPI = myocardial 
perfusion imaging.
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Predictors of severe myocardial perfusion defects
As illustrated in Table 2, age, gender, smoking, HbA1c, micro-albuminuria, and both 
PWV and AIx@75 were identified as potential predictors of severe MPI defects in a 
univariate logistic regression model. Of note, after adjustment for age, gender, smoking, 
HbA1c, and micro-albuminuria, the PWV remained a significant predictor of severe MPI 
defects (P = 0.01), whereas the AIx@75 was no longer significant.
As demonstrated in Figure 2, the prevalence of severe MPI defects gradually increased 
per PWV quartile. Importantly, in none of the patients in the lowest PWV quartile severe 
MPI defects were present. Also, only a relatively small proportion of patients (5%) in the 
second PWV quartile had severe MPI defects. In contrast, the prevalence of severe MPI 
defects increased to 20% in the third PWV quartile, while reaching 30% in the fourth 
quartile. Moreover, the addition of PWV to a model with baseline clinical risk factors 
age, gender, and smoking for the prediction of severe MPI defects showed significant 
incremental value of PWV (Figure 3).
ROC curve analysis for the detection of severe MPI defects showed highest sensitivity 
and specificity (77% and 75% respectively) with a PWV cut-off value of 9.8 m/s. An 
optimal sensitivity of 91% with an associated negative predictive value of 98% for the 
exclusion of severe MPI defects was found using a cut-off value of 9.2 m/s for PWV 
(Figure 4).
DIsCussIon
In the present study of asymptomatic patients with diabetes, vascular stiffness as 
assessed by PWV and AIx was increased in the presence of severe MPI defects. PWV was 
figure 3 Incremental predictive value of PWV for the detection severe MPI defects as shown by an 
increase in global chi square. Addition of PWV to a model with baseline clinical risk factors age, 
gender, and smoking provided a significant incremental predictive value.
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independently associated with severe MPI defects, whereas AIx lost significance after 
correction for other cardiovascular risk factors and PWV. Addition of PWV to a model 
of baseline clinical risk factors showed significant incremental value for the prediction 
of severe MPI defects. Furthermore, ROC curve analysis revealed a moderate to good 
sensitivity of 77% and a specificity of 75% for the detection of severe MPI defects, with a 
PWV cut-off value of 9.8 m/s. Conversely, changing the cut-off value to 9.2 m/s resulted 
in a high sensitivity of 91% and negative predictive value of 98% for the exclusion of 
severe MPI defects. Accordingly, the current results indicate that non-invasive evaluation 
of vascular stiffness may be a practical tool to prescreen asymptomatic patients with 
diabetes for the differentiation in a higher and lower likelihood of abnormal MPI.
vascular stiffness and relationship to CAD
In the general population the relation between vascular stiffness and the presence of CAD 
has been confirmed in a considerable number of studies. Vascular stiffness measured as 
PWV or AIx is not only directly associated with the presence and severity of CAD on 
invasive coronary imaging [10], but also has incremental prognostic value for predicting 
cardiovascular events [9,11-13]. A recent meta-analysis (15877 subjects, 17 studies, average 
figure 4 Detection of severe MPI defects on SPECT by PWV. a ROC curve analysis for the detection 
of severe MPI defects yielded an optimal sensitivity and specificity of 77% and 75% with a PWV 
cut-off value of 9.8 m/s. b In contrast, optimization for the exclusion of severe MPI defects resulted 
in a cut-off value of 9.2 m/s with a sensitivity of 91% and corresponding negative predictive value 
of 98%. ROC = receiver operating characteristics.
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follow-up of 7.7 years) showed that the risk of cardiovascular events increased a two-fold 
in patients with increased PWV [22]. Moreover, the predictive ability of PWV was shown 
to be even higher in patients with elevated baseline cardiovascular risk, supporting a 
role for PWV in high-risk populations such as patients with diabetes.
A few studies have specifically evaluated vascular stiffness in patients with diabetes. 
Cruickshank et al. evaluated the prognostic value of PWV for all-cause and cardiovascular 
mortality in 397 patients with diabetes with or without CAD. During a mean follow-up 
of 10.7 years, aortic PWV was an independent predictor for all-cause and cardiovascular 
mortality [23]. Additionally, Hatsuda et al. found in 595 patients with diabetes that PWV 
was significantly increased in 70 patients with established CAD [24]. Finally, Fukui et 
al. investigated 208 consecutive patients with type 2 diabetes and reported that AIx 
was significantly higher in 47 patients with previously confirmed CAD [21]. These 
observations indicate that markers of vascular stiffness may indeed be associated with 
CAD in patients with diabetes.
However, to our knowledge this is the first study in which PWV and AIx were applied 
in asymptomatic patients with diabetes to prospectively identify the presence of CAD 
defined by the presence of (severe) MPI defects. Although both PWV and AIx were 
increased in patients with severe MPI defects, only PWV was shown to be an independent 
predictor of severe MPI defects. These observations are in agreement with the previous 
literature as also in the general population more discrepant results have been reported 
using AIx as compared to PWV [25,26].
Possibly, the more variable results with AIx may be explained by underlying 
methodological differences. Carotid-femoral PWV is a direct measure of vascular 
stiffness as determined by the intrinsic stress/strain relationship of the arterial wall 
and mean arterial pressure. Therefore PWV is considered as the ‘gold-standard’ [6-8]. In 
contrast, AIx is an indirect measurement, derived from peripherally recorded pressure 
waveforms. Using a generalized transfer function the corresponding central arterial 
waveform is generated from which AIx is determined. Therefore, AIx is influenced by 
multiple factors such as PWV, heart rate, diastolic blood pressure, peripheral circulation, 
and endothelial function [7,8]. Furthermore, its discriminatory value may be less in 
the elderly [25,26], whereas also the use of the generalized transfer function may be 
inappropriate in certain populations [25-28]. In fact, Hope et al. recently evaluated the 
validity of this method found in patients with diabetes and revealed that estimation of 
central pressures was prone to substantially greater error in this population [27]. Similar 
differences in accuracy have also been reported in relation to gender, indicating that 
AIx  might be a less representative marker of vascular stiffness as compared to PWV 
[25,26]. Conceivably, the weaker association between AIx and CAD as compared to PWV 
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may therefore be explained by the fact that our study was performed in patients with 
diabetes while also including a high percentage of female patients.
Clinical implications and perspectives
At present, screening of asymptomatic patients with diabetes for CAD remains 
controversial. Thus far, the majority of available data are based on CAD detection using 
SPECT MPI [3,4]. In the present study, the prevalence of abnormal MPI was 38%. In 
contrast, the recent DIAD trial demonstrated a much lower rate of abnormal MPI with 
only few patients having severe MPI defects [5,29]. To a large extent, this discrepancy 
may be explained by differences in baseline characteristics of the enrolled patients. 
Importantly, cardiac event rates were low in the DIAD study and not significantly 
reduced by a MPI based screening strategy. Nevertheless, in the small group of patients 
with abnormal MPI, a stepwise increase in event rates was observed with increasing 
MPI abnormality. Of note, hard event rates were 2% in patients with normal scans 
but increased to 12% in patients with at least moderately abnormal MPI scans. In 
contrast to the general asymptomatic diabetic population, these high risk patients may 
benefit from screening, as also suggested by the bypass angioplasty revascularization 
investigation BARI 2 diabetes trial [30,31]. In this trial no survival benefit was shown 
in patients undergoing early coronary revascularization as compared to intensive 
medical treatment. However, among high risk patients selected for coronary artery 
bypass grafting, prompt revascularization reduced major cardiovascular events as 
compared with medical therapy. Accordingly, these observations indicate that while 
routine screening for abnormal MPI may not be effective in asymptomatic patients with 
diabetes, selective screening strategies are warranted to identify the small but high risk 
subgroup within this population. In this regard, our current study may provide valuable 
data for the design of such strategies. Assessment of vascular stiffness by means of 
PWV was shown to accurately identify patients with a high-risk for severe MPI defects. 
Accordingly, further screening in patients with elevated PWV may be recommended. 
On the other hand, when using a slightly lower cut-off value, PWV was also shown 
to have a high negative predictive value, indicating that PWV can accurately rule out 
severe MPI defects. Therefore, further evaluation in patients with a negative PWV study 
may be safely omitted. Due to its low costs and non-invasive nature, PWV may represent 
a practical first-line tool to differentiate patients with a higher and lower likelihood of 
having abnormal MPI in this regard.
A number of limitations must be acknowledged in the current study. Some of the 
observed MPI defects may be attributed to artifact attenuation. However, regional wall 
motion on gated SPECT images was analyzed for optimal differentiation between true 
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MPI defects and attenuation artifacts. Evidently, larger prospective studies are needed to 
demonstrate the effectiveness of this strategy in terms of costs and outcome.
ConClusIon
Vascular stiffness as non-invasively assessed by PWV is related with severely abnormal 
myocardial perfusion in asymptomatic patients with diabetes. Accordingly, PWV could 
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AbsTRACT
Aim
Patients with type 1 diabetes are often only considered at high risk for myocardial 
ischemia in the presence of micro-albuminuria. However, limited data are available on 
the prevalence and predictors of myocardial ischemia in this population and possibly 
more refinement is needed. We evaluated the presence and extent of myocardial ischemia, 
as well as the predictive value of micro-albuminuria and coronary artery calcium (CAC) 
scores, in asymptomatic patients with type 1 diabetes.
Methods
Prospectively, clinical characteristics and CAC scores were obtained in 83 asymptomatic 
patients with type 1 diabetes. Myocardial ischemia was evaluated by determining the 
presence and extent of myocardial perfusion defects on SPECT myocardial perfusion 
imaging. The relation between clinical characteristics, including micro-albuminuric 
status, and CAC scores, with the extent of myocardial perfusion defects was analyzed.
Results
Myocardial ischemia was observed in 34 patients (41%) with 12 patients (14%) having 
severe perfusion defects. Significant predictors of extent of perfusion defects were 
age, micro-albuminuria and a CAC score >100. Nevertheless, severe perfusion defects 
were observed in 7 patients (9%) without micro-albuminuria, whereas a CAC score 
<100 excluded severe perfusion defects. Additionally, CAC scoring was shown to have 
incremental value for predicting severe perfusion defects over age and the presence of 
micro-albuminuria (P = 0.01).
Conclusions
In asymptomatic patients with type 1 diabetes, myocardial ischemia was observed 
in a substantial number of patients. Predictors of the extent of ischemia were micro-
albuminuria and a CAC score >100. However, CAC score assessment was superior to 
micro-albuminuria in exclusion of severe myocardial perfusion defects.
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InTRoDuCTIon
Cardiovascular disease is the major cause of mortality not only in type 2 – but also in type 
1 diabetes (1,2). Compared with the general population, coronary artery disease (CAD) as 
reflected by the presence of myocardial ischemia, occurs in patients with type 1 diabetes 
earlier in life (3). To suppress the premature progression of atherosclerosis, AHA/ADA 
guidelines for primary prevention advise stringent pharmacological therapy including 
statin therapy and anti-hypertensive medication in all diabetic patients regardless of 
the type of diabetes (4). However, based on previous observations indicating that excess 
cardiovascular mortality in type 1 diabetes predominantly occurs in patients with 
nephropathy, European guidelines consider patients with type 1 diabetes only as being 
at high risk for myocardial ischemia in presence of micro-albuminuria (5). Nonetheless, 
uncertainty exists regarding the degree to which renal disease influences the presence 
and extent of myocardial ischemia in type 1 diabetes. Furthermore, recent studies suggest 
persistent risk of myocardial ischemia in type 1 diabetes despite adjustment for micro-
albuminuria (6). As a result, the effectiveness of micro-albuminuric status as a selection 
strategy to identify type 1 diabetic patients at high risk for myocardial ischemia is 
questioned and additional markers may be needed. To improve identification of patients 
at risk for myocardial ischemia, the use of direct markers of coronary atherosclerosis, 
such as coronary artery calcium (CAC) scoring has been evaluated in patients with type 
2 diabetes (7-9). However, thus far only limited data are available on both the prevalence 
of myocardial ischemia and potential clinical markers to predict myocardial ischemia in 
type 1 diabetes (10,11). In order to optimize guidelines for management of asymptomatic 
type 1 diabetic patients more data are required.
The purpose of the present study was therefore to explore the prevalence and extent of 
abnormal myocardial perfusion (as a marker of myocardial ischemia) as assessed by 
SPECT in asymptomatic patients with type 1 diabetes. In addition, the value of clinical 
factors including micro-albuminuric status as well as CAC scoring for predicting the 
presence and extent of abnormal myocardial perfusion was evaluated.
METHoDs
Patients and design
Eighty-three consecutive asymptomatic patients with type 1 diabetes were prospectively 
recruited from a routine diabetes clinic, and referred to the cardiology outpatient 
clinic for cardiovascular screening. Asymptomatic status was confirmed using the 
self-administered Rose questionnaire for angina (12). Baseline clinical demographics 
were acquired through a structured interview, physical examination and laboratory 
analysis. For this purpose, cardiovascular risk factors were assessed in compliance 
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with the following criteria: 1. positive family history of CAD (defined as presence of 
CAD in first degree family members at <55 years in men and <65 years in women), 
2. smoking (defined as current smoking or smoking in the last 2 years), 3. body mass 
index (BMI) (kg/m2), 4. level of glycemic control represented by glycated-haemoglobin 
A1c (HbA1c) (mmol/L), 5. hypertension (defined as a blood pressure >140/90 mmHg or 
treatment with antihypertensive medication), 6. hypercholesterolemia (defined as a total 
cholesterol level >5.0 mmol/L or use of cholesterol lowering medication) and  7. micro-
albuminuria (defined as urine albumin/creatinine ratio ≥3.5 mg/mmol).
All patients underwent assessment of CAC scores by means of Multi-Slice Computed 
Tomography (MSCT) and myocardial perfusion imaging by SPECT as part of their 
clinical evaluation.
Coronary artery calcium score – data acquisition
CAC scoring was performed with a 64-slice MSCT scanner (Aquilion64, Toshiba Medical 
Systems, Tokyo, Japan). If necessary and tolerated, oral beta-blockers (metoprolol 50 mg 
or 100 mg) were provided 1 hour preceding the scan to achieve a heart rate <65 beats 
per minute. Thereafter, a non-enhanced prospective electrocardiographically gated 
scan, triggered at 75% of the R-R interval with 4 x 3.0 mm collimation was obtained to 
measure CAC score.
Coronary artery calcium score - data analysis
Data were evaluated with a remote workstation using dedicated software (Vitrea2, Vital 
Images, Minnetonka, USA). In each patient, coronary calcium was identified as a dense 
area in the coronary artery exceeding the threshold of 130 Hounsfield units. The total 
Agatston score was determined for each patient. Patients with a CAC score >100 were 
classified as having increased CAC (13).
ECG-gated sPECT - data acquisition
During a two-day stress and rest protocol, myocardial perfusion imaging to detect 
myocardial ischemia was performed using ECG-gated SPECT with 99mTc sestamibi 
(99mTcMIBI)(8). Patients were instructed to abstain from caffeine containing products for 
24 hours, preceding the stress test. Stress was induced using intravenous infusion of 
adenosine at a rate of 140 μg/kg body weight per minute for 6 minutes, accompanied 
by simultaneous handgrip exercise. After completion of the third minute 99mTcMIBI 
(500  MBq) was injected intravenously. Blood pressure and a 12-lead ECG were 
recorded throughout the adenosine infusion. Imaging commenced 120 minutes after 
radiopharmaceutical injection using a triple-head SPECT gamma camera (GCA 9300/
HG; Toshiba Corporation, Tokyo, Japan) equipped with low-energy high-resolution 
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collimators. Image acquisition was performed in accordance with American Society of 
Nuclear Cardiology (ASNC) guidelines, using a circular 360° orbit, 60 projections, and 40 
seconds per projection. Attenuation correction was not applied. Images were processed 
in the usual manner and short-axis, horizontal long-axis and vertical long-axis views 
were reconstructed. Patient motion was evaluated by examining the raw cine images.
ECG-gated sPECT - data analysis
Short-axis slices were displayed in polar map format, adjusted for peak myocardial 
activity of 100%. Additional reconstruction yielded standard long- and short-axis 
projections perpendicular to the heart axis. All views were used for semi-quantitative 
interpretation. As proposed by the ASNC guidelines, the myocardium was divided 
into 17 segments (14). Tracer uptake in each segment was evaluated by two observers 
in consensus, by use of a 5-point scoring system (0: normal, 1: mild, 2: moderate, 
3: severe reduction of tracer uptake and 4: apparent absence of tracer uptake). The total 
segmental score during stress and rest was used to determine the summed stress score 
(SSS) and summed rest score (SRS) for each patient. Presence of a myocardial perfusion 
defect was defined as SSS≥3, and severe myocardial perfusion defects were defined as 
SSS≥8 (corresponding with approximately ≥10% of myocardium) (15,16). Furthermore, 
regional wall motion on gated SPECT images was analyzed to differentiate between true 
perfusion abnormalities and attenuation artifacts (14).
In addition, data were evaluated for other abnormalities indicative of myocardial 
ischemia (14). Ischemic ECG changes were defined as a down-sloping or depression of 
the ST-segments greater than 1 mm following the J-point in two or more leads during 
stress. Left ventricular ejection fraction (LVEF) at rest and during stress was derived from 
the end-diastolic volume (EDV) and end-systolic volume (ESV). Patients with a LVEF 
<45% in rest were stratified as having left ventricular dysfunction. Furthermore, SPECT 
images revealing increased radiotracer lung-uptake or transient ischemic dilation (TID) 
(defined as a stress- and rest short axis volume ratio larger than 1.21) were also classified 
as abnormal.
Finally, the overall SPECT myocardial perfusion imaging study result was considered 
abnormal in presence of any of the following abnormalities: 1) abnormal myocardial 
perfusion (SSS ≥3), 2) ischemic ECG changes, 3) left ventricular dysfunction, 4) increased 
lung-uptake, 5) TID (14).
statistical Analysis
Continuous variables were expressed as means ± standard deviation. Categorical 
variables were expressed as numbers (percentages).
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First, the prevalence of 1. an abnormal SPECT myocardial perfusion imaging study, 
2. myocardial perfusion defects and 3. severe myocardial perfusion defects were 
determined.
Second, univariate linear regression analysis of baseline clinical characteristics was 
performed to identify potential predictors of the extent of myocardial perfusion defects 
represented by SSS. Thereafter, clinical characteristics with a P value <0.05 were included 
in a linear multiple regression model to identify independent predictors of SSS. In a next 
step, the relation between the presence of micro-albuminuria and a CAC score >100 with 
abnormal myocardial perfusion was further studied. To this end, the distribution of 
patients with 1. an abnormal SPECT myocardial perfusion imaging study, 2. myocardial 
perfusion defects and 3. severe myocardial perfusion defects, was first compared 
according to presence of micro-albuminuria. The analysis was then repeated according 
to the presence of a CAC score >100.
Finally, the incremental value of micro-albuminuria and presence of a CAC score >100 
over other observed clinical predictors of severe myocardial perfusion defects (namely 
age) was assessed by calculating the global chi-square test.
Statistical analyses were performed using SPSS software (version 16.0.1, Inc., Chicago, 
Illinois). P values <0.05 were considered statistically significant.
REsulTs
Patient characteristics
In total, 83 consecutive asymptomatic patients with type 1 diabetes were referred to 
the cardiology outpatient clinic and included in the analysis. The baseline clinical 
demographics of the study population are provided in Table 1. Briefly, mean age was 
48 ± 12 years and the majority of the patients were male (63%). The mean duration of 
diabetes was 23 ± 12 years. At the time of referral to the cardiology outpatient clinic, 
37% of the patients received statin therapy, 19% were treated with aspirin and 27% of the 
patients were treated with ACE-inhibitors.
Coronary artery calcium scoring
Overall, the CAC score ranged from 0 to 2773 with a mean CAC score of 214 ± 510. In 
total, 57 patients (69%) had a CAC score in the range 0-100, whereas an increased CAC 
score (>100) was observing in 26 patients (31%).
sPECT Myocardial perfusion imaging
Mean SSS was 3.1 ± 4.2 in the total population. Overall, 34 patients (41%) had an abnormal 
SPECT myocardial perfusion study reflecting the presence of myocardial ischemia. 
Chapter 10
178
Djaberi.indd   178 5-8-2014   15:28:49
Herein, 27 patients (33%) had myocardial perfusion defects (SSS ≥3), including reversible 
defects in 11 patients (41%), partially reversible defects in 9 patients (33%) and fixed 
defects in 7 patients (26%). Importantly, in 12 patients (14%), severe myocardial perfusion 
defects (SSS ≥8) were observed.
Additionally, SPECT data analysis revealed other abnormalities indicative of myocardial 
ischemia in 7 patients (8%) with normal myocardial perfusion: 2 patients (2%) had 
ischemic ECG changes during adenosine stress, another 2 patients (2%) were diagnosed 
with left ventricular dysfunction, and 3 patients (4%) were shown to have TID.
Predictors of the extent of myocardial perfusion defects
Using univariate linear regression analysis, age, presence of micro-albuminuria and 
a CAC score >100 were identified as significant predictors of the extent of myocardial 
perfusion defects represented by SSS (Table 2). Analysis of these risk factors in a 
multivariate linear regression model revealed micro-albuminuria and CAC score >100 
to be independent predictors of the extent of myocardial perfusion defects on SPECT 
(Table 2).
Relation of micro-albuminuria with myocardial perfusion
As illustrated in Figure 1, the prevalence of an abnormal SPECT myocardial perfusion 
imaging study was significantly higher in patients with micro-albuminuria (77%) as 
compared to those without micro-albuminuria (34%) (P = 0.004). Similarly, the prevalence 
Table 1. Characteristics of the study population
Age (years) 48  ± 12
Male sex 52 (63%)
Diabetes duration (years) 23  ± 13
Family history of CAD 35 (42%)
Smoking 24 (29%)
BMI (kg/m2) 25  ± 4
HbA1c (mmol/L) 7.9 ± 1.5
Hypercholesterolemia 51 (61%)
Hypertension 43 (52%)
Cardiovascular medication use at the time of referral
      Statin 31 (37%)
      Aspirin 16 (19%)
      ACE-inhibitor 22 (27%)
Data are averages ± standard deviation or numbers (%).
BMI = body mass index, CAD = coronary artery disease.
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of myocardial perfusion defects was higher in presence of micro-albuminuria (69%) than 
in its absence (26%) (P = 0.002). Finally, also severe myocardial perfusion defects were 
more often observed in the presence of micro-albuminuria (P <0.001). However, severe 
perfusion defects were still noted in 9% of patients without micro-albuminuria.
Relation of coronary artery calcium scores with myocardial perfusion
Relation of CAC scores with SPECT data are provided in Figure 2. The presence of an 
increased CAC score (>100) as compared to a CAC score 0-100 was associated with a 
higher prevalence of abnormal SPECT myocardial perfusion imaging studies (63% vs 
30%) (P = 0.005) and a higher prevalence of myocardial perfusion defects (59% vs 20%) 
(P <0.001). Importantly, severe myocardial perfusion defects were absent in patients with 
a CAC score 0-100. In contrast, almost half (44%) of patients with an increased CAC score 
(>100) showed severe myocardial perfusion defects (P <0.001).
Incremental value of micro-albuminuria and CAC score in the prediction of severe 
myocardial perfusion defects
The incremental value for prediction of severe myocardial perfusion defects was 
analyzed for micro-albuminuria and an increased CAC score (>100) over age (the only 
other clinical risk factor predictive of the extent of myocardial perfusion defects). For 
this purpose global chi-square scores were calculated and are presented in Figure 3. The 
































































































figure 1. Bar graphs illustrating the relation between micro-albuminuria and SPECT myocardial 
perfusion imaging. Patients with micro-albuminuria were shown to have a higher prevalence of 
abnormal SPECT myocardial perfusion imaging studies (panel A), myocardial perfusion defects 
(panel B) and severe myocardial perfusion defects (panel C). However, the absence of micro-
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in the prediction of severe myocardial perfusion defects. Importantly the addition of 
CAC scores provided further information, incremental over the combination of age and 
micro-albuminuric status (P = 0.01).
Table 2. Predictors of the extent of myocardial perfusion defects (SSS)
univariate Analysis Multivariate Analysis
Exp ß (95% CI) P Value Exp ß (95% CI) P Value
Age (years) 0.10  (0.02-0.18) 0.01 0.01 (-0.07-0.09) 0.77
Male sex 0.68  (-1.22-2.57) 0.48 - -
Diabetes duration (years) 0.03  (-0.04-0.09) 0.48 - -
BMI (kg/m2) 0.11  (-0.12-0.35) 0.34 - -
HbA1c (mmol/L) 0.08  (-0.55-0.70) 0.81 - -
Smoking 1.56  (-0.46-3.58) 0.13 - -
Family history of CAD -1.22 (-3.06-0.63) 0.19 - -
Hypercholesterolemia 0.98  (-0.90-2.86) 0.30 - -
Hypertension 1.26  (-0.59-3.10) 0.18 - -
Micro-albuminuria 5.04  (2.77-7.32) <0.001 3.19 (0.84-5.54) 0.008
Statin use -0.21 (-2.12-1.69) 0.83 - -
Aspirin use 1.15  (-1.17-3.47) 0.33 - -
ACE-inhibitor use 1.49  (-0.57-3.55) 0.15 - -
CAC score >100 4.51  (2.79-6.23) <0.001 3.30 (1.17-5.43) 0.003
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figure 2. Bar graphs illustrating the relation between CAC score and SPECT myocardial perfusion 
imaging. As compared to patients with a low CAC score (0-100), patients with a CAC score >100, 
were shown to have a higher prevalence of abnormal SPECT myocardial perfusion imaging 
studies (panel A), myocardial perfusion defects (panel B) and severe myocardial perfusion defects 
(panel C). A CAC score 0-100 successfully excluded the presence of severe myocardial perfusion 
defects (panel C).
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DIsCussIon
In the current study of asymptomatic patients with type 1 diabetes, an abnormal SPECT 
myocardial perfusion imaging study reflecting myocardial ischemia was obtained 
in 41% of patients. Moreover, severe myocardial perfusion defects were detected in a 
considerable number of patients (14%). The presence of micro-albuminuria, which 
is currently proposed as a criterion for stringent pharmacological therapy in type 1 
diabetes by the European prevention guidelines, was indeed associated with the extent 
of myocardial perfusion defects. In particular, 77% of patients with micro-albuminuria 
had an abnormal myocardial perfusion imaging study while severe myocardial perfusion 
defects were observed in 46% of patients with micro-albuminuria. However, the absence 
of micro-albuminuria could not exclude severe myocardial perfusion defects. Almost 
10% of patients without micro-albuminuria still had severe myocardial perfusion 
defects, indicating the need for additional clinical markers to determine cardiovascular 
risk more precisely. In this regard, CAC scoring was demonstrated to have incremental 
value for the prediction of severe myocardial perfusion defects. Importantly, a low CAC 
score (0-100) was shown to successfully rule out severe myocardial perfusion defects on 
SPECT in all patients.
Age



























figure 3. Bar graph illustrating the incremental value of micro-albuminuria and a CAC score 
>100 in predicting severe myocardial perfusion defects. The addition of micro-albuminuric status 
provided incremental information over age. Furthermore, the addition of CAC score >100 resulted 
in further incremental information over age and micro-albuminuric status.
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Myocardial perfusion imaging by sPECT
In the general population of patients with known or established CAD, SPECT myocardial 
perfusion imaging has been shown to accurately identify the presence of myocardial 
ischemia (as a marker of CAD) and predict future cardiac events (17). Similarly, the 
prognostic value of SPECT has been confirmed in studies of heterogeneous populations 
of type 1 and type 2 diabetic patients with known or established CAD (17). In particular, 
severe ischemia involving a large proportion of the left ventricular myocardium has been 
associated with occurrence of adverse cardiac events (18). The prevalence, extent and 
clinical predictors of myocardial ischemia have been evaluated in relatively large cohorts 
of asymptomatic patients with type 2 diabetes (7-9). However, limited data are available 
on the prevalence and extent of silent myocardial ischemia in type 1 diabetes (10,11). In 
a small population of patients with type 1 diabetes scheduled for islet transplantation, 
SPECT imaging revealed myocardial perfusion defects in only a minority of patients 
(9%), although a substantially higher prevalence of obstructive coronary stenoses (43%) 
was observed during conventional coronary angiography (11). Possibly, differences in 
study design and definitions of an abnormal myocardial perfusion study account for the 
discrepancies in observed results and limit direct comparison between the studies. In 
the current study, abnormal myocardial perfusion was defined and quantified according 
to guidelines proposed by the ASNC (14). Using this approach, we observed a high 
prevalence of abnormal SPECT myocardial perfusion imaging studies (41%). Notably, 
severe myocardial perfusion defects were identified in 14% of patients, underlining 
the notion that patients with type 1 diabetes may be at higher risk as compared to the 
general population (1,2).
Current guidelines for primary prevention and risk stratification in type 1 diabetes
The high risk of mortality from CAD in type 1 diabetes has been recognized in the Diabetes 
UK Cohort study (19). As compared to the general population, cardiovascular mortality 
was increased by a 6 fold in type 1 diabetic men and a 15 fold in women, emphasizing 
the need to identify and treat CAD in this cohort. To reduce the progression and clinical 
impact of CAD, the AHA/ADA guidelines for primary prevention therefore recommend 
pharmacological treatment of cardiovascular risk factors in all asymptomatic patients 
with type 1 diabetes (4). In contrast, European guidelines consider type 1 diabetic patients 
to be at higher risk only in presence of micro-albuminuria (5). This recommendation is 
based on previous studies which identified diabetic nephropathy as a main predictor 
of cardiovascular prognosis in patients with type 1 diabetes (20-23). Indeed, a strong 
relation has been shown between nephropathy in type 1 diabetic patients and the extent 
of coronary and aortic atherosclerosis as assessed by magnetic resonance imaging (24). 
Increasing evidence suggests that these two complications of type 1 diabetes, share risk 
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factors such as hyperglycaemia and consequent endothelial dysfunction, and therefore 
develop among similar path-lines (25-27). The results of the current study also support 
the importance of micro-albuminuria as a risk factor, as its presence was significantly 
related with the extent of myocardial ischemia. However, myocardial perfusion defects, 
as well as severe myocardial perfusion defects were observed even in absence of 
micro-albuminuria. Thus, use of micro-albuminuria as the sole criterion for further 
risk stratification of asymptomatic patients with type 1 diabetes may underestimate 
preclinical myocardial ischemia and result in insufficient treatment. Possibly, additional 
clinical markers may be needed to identify patients with type 1 diabetes that are at 
elevated risk for myocardial ischemia.
Risk stratification using coronary artery calcium scoring
CAC scoring is a well-established, non-invasive technique to identify coronary 
atherosclerotic plaque burden, both in the general population (28) and in patients with 
diabetes (29). Furthermore, Anand and colleagues have previously described the potential 
of CAC scoring in the prediction of silent myocardial ischemia in type 2 diabetic patients 
(30). Hence, evaluation of the CAC score has been suggested as a primary step in risk 
stratification of patients with type 2 diabetes (31). Interestingly, recent data suggest that 
CAC scores may be even more accurate in the identification of coronary atherosclerosis 
in patients with type 1 diabetes as compared to type 2 diabetes (32,33). In line with 
these observations, the current study of asymptomatic patients with type 1 diabetes 
showed that the presence of an increased CAC score (>100) was a significant predictor 
of the extent of myocardial perfusion defects. Of note, in patients with limited coronary 
calcium (CAC score 0-100), the prevalence of abnormal myocardial perfusion was low. 
Furthermore, the presence of a severe myocardial perfusion defect could be reliably 
ruled out based on the absence of increased CAC. In addition, CAC scores were shown 
to provide incremental value over age and micro-albuminuric status in the prediction 
of severe myocardial perfusion defects. While patients with micro-albuminuria are 
considered to be at high risk, CAC scores may be of particular value in patients without 
micro-albuminuria. In these patients, knowledge of the extent of CAC may allow more 
accurate separation of patients at either low or high risk of myocardial ischemia.
Importantly, prospective studies in preferably larger cohorts should address the 
prognostic implications of our observations.
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ConClusIon
In asymptomatic patients with type 1 diabetes, abnormal myocardial perfusion imaging 
studies, including the presence of severe myocardial perfusion defects, were observed 
in a substantial number of patients. The presence of micro-albuminuria and increased 
CAC scores (>100) were shown to be independent predictors of the extent of myocardial 
perfusion defects. However, CAC score assessment was superior to micro-albuminuric 
status in the exclusion of severe myocardial perfusion defects.
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CHAPTER 11
Comparative Performance of Risk stratification Tools 
for Predicting functionally Relevant Coronary Artery 
Disease in Asymptomatic Type 2 Diabetes
Roxana Djaberi, Joanne D. Schuijf, Ton J. Rabelink, Eelco J. de Koning, Alberto 
M. Pereira, Albert de Roos, Jan W. Smit, Jeroen J. Bax, J. Wouter Jukema.
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AbsTRACT
objective
Early identification of asymptomatic diabetic patients with coronary artery disease (CAD) 
has the potential to improve prognosis. For this purpose, selective screening algorithms 
that allow accurate identification of patients with a higher likelihood of functionally 
relevant CAD are needed.  Several risk stratification tools have been suggested but no 
direct comparative data are available. The purpose of the present study was therefore 
to evaluate the comparative performance of Framingham risk score (FRS) and surrogate 
markers of CAD (carotid intima media thickness (CIMT), pulse wave velocity (PWV) 
and coronary artery calcium (CAC) scores) to identify functionally relevant coronary 
artery disease (CAD) in asymptomatic patients with type 2 diabetes.
Research design and methods
In 99 consecutive asymptomatic patients with type 2 diabetes, the FRS, CIMT, PWV and 
CAC were obtained. Patients were screened for the presence of functionally relevant CAD 
defined by the concurrent presence of significant coronary stenosis on CT angiography 
and abnormal myocardial perfusion on SPECT. The association between the FRS (low, 
intermediate, high), CIMT (≥75th percentile), PWV (quartiles) and CAC scoring (0, 1-100, 
101-400, >400) with the presence of functionally relevant CAD was assessed.
Results
Functionally relevant CAD was observed in 24% of patients. FRS did not increase the 
AUC for predicting functionally relevant CAD (AUC 0.61, P = 0.18). In contrast, the AUC 
increased significantly for PWV (AUC 0.68, P = 0.03), CIMT (AUC 0.81, P <0.001) and CAC 
scoring (AUC 0.84, P <0.001). An excellent sensitivity and negative predictive value were 
observed with increased CIMT (83% and 95%) and a CAC score >100 (85% and 97%) for 
predicting functionally relevant CAD.
Conclusions
As compared to FRS and PWV, CIMT and CAC scoring were superior in predicting 
the presence of functionally relevant CAD. Accordingly, CIMT and CAC scoring may 
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InTRoDuCTIon
Type 2 diabetes presents a constellation of risk factors caused by insulin resistance 
resulting in elevated coronary artery disease (CAD) risk (1). Despite optimal medical 
treatment of cardiovascular risk factors, CAD related mortality remains high in this 
patient population (1). However, early identification of high-risk patients with extensive 
CAD that may benefit from aggressive intervention may improve outcome (2). The 
ADA/AHA have therefore previously recommended non-invasive screening for CAD 
by cardiac imaging techniques, in the presence of ≥ two additional cardiovascular 
risk factors (3). Nevertheless, this selection strategy was shown to be ineffective in the 
DIAD study, wherein 41% of asymptomatic diabetic patients with abnormal myocardial 
perfusion did not have ≥ two risk factors (4). Also, a wide ranged routine screening 
strategy of all diabetic patients by non-invasive cardiac imaging on the other hand 
was shown to be ineffective due to the low overall prevalence of abnormal myocardial 
perfusion in this trial (5). Possibly, a selective screening strategy, allowing identification 
of patients with a high likelihood of significant epicardial coronary stenosis resulting 
in abnormal myocardial perfusion ( functionally relevant CAD) would be preferred and 
could improve clinical management (2). Indeed, knowledge of functionally relevant 
CAD has important implications for risk stratification and can guide clinical decision 
making regarding the need for revascularization (2,6).
Several risk stratification tools have been proposed as potential first-line screening 
methods in patients with type 2 diabetes (7-11). These approaches include assessment of 
the Framingham risk score (FRS) (7) or non-invasive surrogate markers as carotid intima 
media thickness (CIMT) (8-9), aortic pulse wave velocity (PWV) (10) and coronary artery 
calcium (CAC) scoring (9,11-12). However, the value of these approaches to identify 
functionally relevant CAD has not been extensively investigated in type 2 diabetic patients. 
In addition, direct comparisons are lacking.
The current study was therefore designed to prospectively evaluate the comparative 
performance of FRS, CIMT, PWV and CAC scoring to identify functionally relevant CAD 
(defined by the concurrent presence of significant coronary stenosis on CT angiography 
(CTA) and abnormal myocardial perfusion on SPECT) in asymptomatic patients with 
type 2 diabetes.
REsEARCH DEsIGn AnD METHoDs
Patients and study design
Prospectively, 99 consecutive asymptomatic patients with type 2 diabetes were screened 
for the presence of cardiovascular disease. All patients underwent a comprehensive 
evaluation, which included a structured interview, physical examination, blood serum 
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and urine laboratory testing to assess cardiovascular risk factors and determine FRS. 
CIMT, PWV and CAC scoring were obtained as surrogate markers of CAD. To directly 
determine the presence of functionally relevant CAD, combined anatomical and 
functional cardiac assessment was performed non-invasively using CTA and SPECT 
myocardial perfusion imaging.
Cardiovascular risk factors and fRs
Cardiovascular risk factors were assessed according to the following criteria: positive 
family history of CAD (presence of CAD in first degree family members male <55 years 
and/or female <65 years), smoking (current smoking or smoking in the last 2 years), 
body mass index (kg/m²), hypertension (blood pressure >140/90 mmHg or treatment 
with antihypertensive medication), hypercholesterolemia (total cholesterol level 
>5.0 mmol/L or use of cholesterol lowering medication), plasma hemoglobin A1c and 
micro-albuminuria (urine albumin/creatinine ratio ≥3.5 mg/mmol).
The FRS adjusted for diabetes was calculated in all patients (7). Accordingly, patients 
were stratified as having a low (<10%), intermediate (10-20%) or high (>20%) 10-year risk 
for CAD.
non-invasive measurement of surrogate markers of CAD and data analysis
PWV and CIMT were assessed by an experienced sonographer blinded to clinical 
information. Measurements were performed in fasting patients who had abstained from 
their morning medication, in a quiet, temperature controlled clinical research laboratory.
PWV was determined using applanation tonometry (SphygmoCor, Atcor Medical, 
Sydney, Australia). Measurements started when a state of constant heart rate and blood 
pressure was reached after a 10 minute rest in supine position. The pulse waves were 
recorded at the common carotid artery and the femoral artery by sequential tonometry 
with simultaneous electrocardiographic gating. Pulse transit time was determined as 
the average of 10 consecutive beats. The distance between the two sites was measured. 
PWV (in m/s) was defined as the distance between the 2 recording sites traveled by 
the pulse wave, divided by transit time. Using system software, PWV was determined 
semi-automatically (13). Measurements were performed three times in each patient and 
averaged to obtain the mean PWV. Thereafter, patients were stratified according to mean 
PWV quartiles.
CIMT was assessed using high resolution B-mode ultrasound with a 10-MHz linear 
transducer, with an automatic boundary detection system (Art.Lab-Esaote-Picus, 
Genova, Italy). Mean CIMT was assessed throughout 10-mm segments, at four angles, 
across the far wall of the right and left common carotid artery. The average of the 
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mean CIMT values of the 4 segments was calculated to determine the mean right and 
left CIMT per patient. The obtained mean CIMT was compared to reference values 
from the MESA study (14). Patients were thereby stratified as having normal CIMT 
(CIMT <75th percentile), or increased CIMT (CIMT ≥75th percentile in at least one common 
carotid artery).
CAC scoring was performed with a 64-row CT scanner (Aquilion64, Toshiba Medical 
Systems, Japan), according to standard clinical protocols (15). The total Agatston score 
was determined for each patient. Patients were stratified according to the CAC score 
ranges of 0, 1-100, 101-400, and >400.
Assessment of functionally relevant CAD
CTA data acquisition and analysis
CTA was performed in the same session as CAC scoring, according to protocols 
described previously (15). CTA images were interpreted by two experienced observers. 
Discrepancies in interpretation were resolved by consensus. The presence of significant 
coronary stenosis, defined as the presence of luminal narrowing ≥50%, was visually 
evaluated on axial images and curved multiplanar reconstructions in at least two 
orthogonal planes.
SPECT data acquisition and analysis
Myocardial perfusion imaging was performed using ECG-gated SPECT with 
99mTc  sestamibi, after pharmacological stress, according to standard clinical protocols 
(16).
Short-axis slices were displayed in polar map format, adjusted for peak myocardial 
activity of 100%. Additional reconstruction yielded standard long- and short-axis 
projections perpendicular to the heart axis. All views were used for semi-quantitative 
interpretation. The myocardium was divided into 17 segments, and tracer uptake in each 
segment was evaluated by two observers in consensus using a 5-point scoring system 
(0:normal, 1:mild, 2:moderate, 3:severe reduction of tracer uptake and 4:apparent absence 
of tracer uptake) (17). The total segmental score during stress was used to determine 
the summed stress score (SSS) for each patient. The presence of abnormal myocardial 
perfusion was defined as SSS ≥3. Regional wall motion on gated SPECT images was 
analyzed to differentiate between true perfusion abnormalities and diaphragmatic or 
breast attenuation artifacts. Obvious or probable attenuation artifacts were interpreted 
as normal.
Comparing Non-invasive Tools for Detection of Coronary Artery Disease
195
Djaberi.indd   195 5-8-2014   15:28:51
Finally, the presence of functionally relevant CAD was defined by the concurrent 
presence of significant coronary stenosis on CTA as well as abnormal myocardial 
perfusion.
statistical analysis
Continuous variables were expressed as mean ± standard deviation. Categorical 
variables were expressed as numbers (percentages).
First, patients were stratified according to the FRS category (low, intermediate and high).
The prevalence of functionally relevant CAD was examined across the FRS risk score 
categories.
Thereafter, the potential of the FRS, PWV, CIMT, and CAC scoring for predicting the 
presence of functionally relevant CAD in asymptomatic patients with type 2 diabetes 
was compared. For this purpose, using C-statistics, the area under ROC curve (AUC) 
was calculated for FRS, PWV, CIMT, and CAC scoring. Finally, diagnostic accuracy was 
determined for the markers with the highest AUC. Statistical analyses were performed 




The study population comprised of 99 asymptomatic patients with type 2 diabetes. 
Baseline patient characteristics are provided in Table 1. At the time of referral, 
hypercholesterolemia was identified in 71% of the patients. Cholesterol lowering 
medication was used by 51% of the patients. The mean total cholesterol was 
4.8  ±  1.2  mmol/L, the LDL-cholesterol 3.0 ± 1.1 mmol/L and the HDL-cholesterol 
1.3 ± 0.4 mmol/L. Overall, 66% of the patients had hypertension, of which 51 patients 
(52% of total population) used anti-hypertensive medication. The mean systolic blood 
pressure was 134 ± 16 mmHg, and the mean diastolic pressure was calculated to be 
82 ± 8 mmHg.
fRs assessment and surrogate markers of CAD
FRS: Calculation of the FRS for the 10-year risk of CAD in the study population resulted 
in classification of 42 patients (42%) at low risk, 37 (37%) at intermediate risk and 20 (21%) 
at high risk.
PWV: The average PWV was calculated to be 9.0 ± 2.0 m/s in the total population. The 
interquartile ranges were defined as <7.7 m/s, 7.7-9.3 m/s, 9.4-10.6 m/s and >10.6 m/s.
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CIMT: Mean CIMT was 0.68 ± 0.13 mm. Comparison with reference values revealed an 
increased CIMT value (≥75th percentile) in 38 patients (39%).
CAC scoring: Average CAC score was 203 ± 381 in the total population. CAC was absent in 
45 patients (45%). The CAC score ranged 1-100 in 23 patients (23%), 101-400 in 13 patients 
(14%) and >400 in 18 (18%) of the asymptomatic patients with diabetes.
Presence of functionally relevant CAD
The presence of CAD was excluded on CTA in 64 patients (65%). In the remaining 
35 patients (35%) significant coronary stenosis defined as luminal narrowing of ≥50% 
was observed. Using SPECT abnormal myocardial perfusion (SSS ≥3) was revealed in 
34 patients (35%). Finally, in the total population of asymptomatic patients with diabetes, 
23 patients (24%) were shown to have significant coronary stenosis on CTA accompanied 
by abnormal myocardial perfusion and were thus classified as having functionally 
relevant CAD.
Relation of fRs and the surrogate markers with functionally relevant CAD
The distribution of asymptomatic patients with diabetes with functionally relevant CAD 
according to the FRS category is provided in Figure 1. The proportion of patients with 
functionally relevant CAD increased gradually per risk level with the highest percentage 
observed in patients classified at high risk. Nevertheless, functionally relevant CAD was 
also observed in 13% of patients classified at low risk.
Table 1. Characteristics of the study population (n = 99)
Age (years) 54 ± 11
Men 51 (51%)
Diabetes duration (years) 9 ± 7
Smokers 22 (22%)
Family history of CAD 48 (49%)
BMI (kg/m2) 30 ± 7 
Hypercholesterolemia 70 (71%)
Hypertension 65 (66%)
HbA1c (mmol/L) 8.4 ± 1.9
Micro-albuminuria 30 (30%)
FRS distribution
low risk 42 (42%)
intermediate risk 37 (37%)
high risk 20 (21%)
Data are averages ± standard deviation or number of patients (%). CAD: coronary artery disease; FRS: 
Framingham risk score.
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Framingham risk score categories
figure 1. Distribution of asymptomatic patients with type 2 diabetes with functionally relevant 
CAD according to the Framingham risk score category. The proportion of patients with functionally 
relevant CAD increased gradually per risk level. However, functionally relevant CAD was present 
in still 13% of patients stratified as having low risk.
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Parameter AUC 95% CI P-value
FRS (per category: low, intermediate, high) 0.61 (0.45 -0.77) 0.18
PWV (per quartile) 0.68 (0.56 -0.80) 0.03
Increased CIMT (left or right) 0.81 (0.69 -0.93) <0.001
CAC score (per range: 0, 1 - 100, 101 - 400, >400) 0.84 (0.73 -0.95) <0.001
figure 2. ROC curves and corresponding C-statistics data for FRS, PWV, CIMT and CAC scoring 
to identify functionally relevant CAD in asymptomatic patients with type 2 diabetes. PWV, CIMT 
and CAC scoring significantly increased the AUC. Notably, the highest AUC was observed for 
CIMT and CAC scoring.
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The data for C-statistics for the AUC and the corresponding ROC curves for the FRS, 
PWV, CIMT and CAC for predicting the presence of functionally relevant CAD are 
provided in Figure 2. FRS did not significantly increase the AUC (AUC 0.61, P = 0.18). 
However, a significant increase in AUC was observed for all surrogate markers of CAD. 
Although significant, the increase in AUC was limited using PWV (AUC 0.68, P = 0.03). 
Of note, the AUC was high for CIMT (AUC 0.81, P <0.001). Similarly, a good AUC was 
obtained for CAC scoring (AUC 0.84, P <0.001).
Further ROC curve analysis for CIMT resulted in a sensitivity of 87%, specificity of 76%, 
negative predictive value of 95% and a positive predictive value of 48% for predicting the 
presence of functionally relevant CAD. Similarly, a CAC score >100 yielded a sensitivity 
of 85%, specificity of 83%, negative predictive value of 97% and a positive predictive 
value of 46% for predicting the presence of functionally relevant CAD. Using a higher 
threshold for CAC (score >400), a lower sensitivity of 60% and a specificity of 81%, with 
a negative predictive value of 93% and a positive predictive value of 63% were found.
ConClusIons
In asymptomatic patients with type 2 diabetes, functionally relevant CAD was observed 
in 24% of patients. When evaluating the relation between increasing FRS and the presence 
of functionally relevant CAD, a gradual increase was observed from low to high risk. 
However, functionally relevant CAD was still observed in a substantial number of 
asymptomatic patients stratified as having low risk (13%). Moreover, FRS did not increase 
the AUC for predicting functionally relevant CAD. In contrast, a better performance 
in the prediction of the presence of functionally relevant CAD was observed for the 
surrogate markers of CAD. Particularly, a good AUC was observed for CIMT (AUC 0.81) 
and CAC scoring (AUC 0.84). In continuation of these findings, excellent sensitivities and 
negative predictive values were observed using CIMT (83% and 95%) and a CAC score 
>100 (85% and 97%) for predicting functionally relevant CAD in asymptomatic patients 
with type 2 diabetes.
Risk stratification in asymptomatic patients with type 2 diabetes
To improve prognosis, screening of asymptomatic patients with type 2 diabetes for 
CAD has been proposed to facilitate early identification and patient-tailored treatment. 
A variety of first-line risk stratification methods have been proposed as an initial step for 
selective screening of asymptomatic patients with type 2 diabetes (2,3, 6-12). The aim of 
these algorithms is to identify within the asymptomatic diabetic population a subgroup 




Djaberi.indd   200 5-8-2014   15:28:51
Refined risk calculators, especially the FRS, have been well validated for CAD 
risk assessment in the general population (18). However, the general FRS equation 
incorporates diabetes as a categorical variable and is shown to underestimate the risk of 
CAD events in diabetic populations (18). In the current study, the modified FRS equation 
by Wilson et al was applied to predict the presence of functionally relevant CAD in 
patients with type 2 diabetes (7). While a significant relation between FRS and the 
prevalence of functionally relevant CAD was observed, still a non-negligible  portion 
(13%) of patients at low risk were shown to have functionally relevant CAD. Possibly, 
surrogate markers, as estimates of atherosclerosis, may present a more suitable approach 
to identify CAD as compared to risk engines.
For this purpose, several tools are available that may provide a practical first-line 
approach for selective screening. PWV, a marker of vascular stiffness, has been shown 
to increase with the presence and severity of CAD both in the general population and 
in patients with type 2 diabetes (10, 19). More information is available on CIMT, which 
has been shown to be a consistent predictor of CAD in large prospective epidemiological 
studies (20). Also in type 2 diabetes, the relation between CIMT and CAD has been 
confirmed in sub-analyses of the ARIC and the IRAS investigations (21-22). Finally, 
extensive data have been obtained with CAC, supporting its potential use in selective 
screening algorithms (23). Comparative data however, are scarce and predominantly 
lacking in patients with diabetes.
In line with previous investigations, PWV was shown to improve prediction of 
functionally relevant CAD as compared to risk stratification based on FRS. As expected 
however, AUC to predict functionally relevant CAD was lower for PWV as compared 
to the more direct measures of atherosclerosis provided by CIMT and CAC. Aortic 
stiffness is regulated by numerous factors and in turn contributes to atherosclerosis and 
reduced myocardial perfusion by several separate mechanisms (24). Therefore, PWV 
should preferably be considered as a marker of total cardiovascular risk rather than 
specifically of atherosclerotic changes alone. More accurate prediction of functionally 
relevant CAD may be achieved through direct visualization of atherosclerosis. Indeed, 
in the current study, CIMT (AUC 0.81) and CAC scoring (AUC 0.84) were superior to 
PWV (AUC 0.68) for the identification of functionally relevant CAD. In a next step, 
diagnostic accuracy for increased CIMT and CAC were explored. Using a CIMT value 
≥75th percentile to define increased CIMT, as recommended by the Society for Vascular 
Medicine consensus (14), a good sensitivity of 87% and high negative predictive value 
of 95% to identify functionally relevant CAD were obtained. Similarly, a CAC score 
>100 yielded a sensitivity of 85% with a corresponding negative predictive value of 97%. 
Interestingly, changing the cut-off value to define increased CAC from 100 to 400, which 
is commonly used in the general population, resulted in lower accuracy. This is in fact 
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in line with previous literature, suggesting that in the presence of diabetes, lower CAC 
thresholds should be used (23,25-27).
In addition to diagnostic performance however, also other criteria, such as safety, 
reproducibility, costs and practicality, should be taken into account when determining 
the most appropriate first-line screening tool. While PWV may have the advantage of 
lowest costs as well as simplicity, disadvantages include lower accuracy and to a lesser 
extent, lower reproducibility (28). For both CIMT and CAC, accuracy and reproducibility 
are higher, while still being relatively straightforward techniques. For CAC however, 
costs are highest while also the associated radiation dose remains a limitation (29). On 
the other hand, CAC may have the advantage of highest accuracy as well as strong 
prognostic value for future cardiovascular events (23). Further investigations should 
address these issues into more detail, while also providing comparative prognostic data.
In summary, the surrogate markers of CAD, including PWV, CIMT and CAC scoring, 
but not FRS, were shown to be significantly associated with the presence of functionally 
relevant CAD in asymptomatic patients with type 2 diabetes. An increased CIMT 
measurement and a CAC score of >100 were revealed superior in predicting the presence 
of functionally relevant CAD with good sensitivity and high negative predictive value. 
Accordingly, CIMT assessment and CAC scoring convey the most potential to identify 
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CHAPTER 12
non-Invasive Assessment of Microcirculation by sidestream Dark 
field Imaging as a Marker of Coronary Artery Disease in Diabetes
Roxana Djaberi, Joanne D. Schuijf, Eelco J. de Koning, D. Champa 
Wijewickrama, Alberto M. Pereira, Johannes W. Smit, Lucia J. Kroft, 
Albert de Roos, Jeroen J. Bax, Ton J. Rabelink, J. Wouter Jukema.
Diab Vasc Dis Res. 2013;10:123-34
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AbsTRACT
Purpose
In diabetes, generalized microvascular disease and coronary artery disease (CAD) 
are likely to occur in parallel. We used sidestream-dark-field (SDF) handheld imaging 
device to determine the relation between the labial microcirculation parameters and 
CAD in asymptomatic patients with diabetes.
Methods
SDF imaging was validated for assessment of labial capillary density and tortuosity. 
Thereafter, mean labial capillary density and tortuosity were evaluated and compared 
in non-diabetic controls, and in asymptomatic patients with type 1- and type 2 diabetes. 
In diabetic patients, mean capillary density and tortuosity were compared according to 
the presence of CAD.
Results
Both type 1- and type 2 diabetes were associated with increased capillary density and 
tortuosity. In diabetes, mean capillary density was an independent predictor of elevated 
CAC (P = 0.03) and obstructive CAD on CT-angiography (P = 0.01). Using a cut-off mean 
capillary density of 24.9 (per 0.63 mm2) the negative predictive value was 84% and 89% for 
elevated CAC and obstructive CAD. Likewise, capillary tortuosity was an independent 
predictor of increased CAC (P = 0.01) and obstructive CAD (P = 0.04).
Conclusion
Assessment of labial microcirculation parameters using SDF imaging is feasible and 
conveys the potential to estimate vascular morbidity in patients with diabetes, at bedside.
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InTRoDuCTIon
Cardiovascular disease, especially coronary artery disease (CAD), is a predominant 
cause of morbidity and mortality in diabetes.1 As a result, recent research has aimed to 
determine additional risk factors and markers, to distinguish high risk diabetic patients.2,3 
Likewise, the presence of microvascular co-morbidities, in form of nephropathy, 
retinopathy and neuropathy, has been previously associated with an increased risk of 
CAD as well as its worse prognosis in diabetes.4-7 Generalized microvascular disease 
and CAD may occur in parallel due to common pathogenic mechanisms initiated by 
hyperglycaemia.8 However, microvascular disease has also been suggested to contribute 
to CAD directly through angiogenesis of microvessels in the atherosclerotic plaque.9 As 
a consequence, a measure to quantify and qualify microvascular disease in diabetes 
may convey the potential to predict vascular morbidity and CAD more accurately than 
the traditional risk factors.
The orthogonal polarization spectral (OPS) and the more novel sidestream dark field (SDF) 
handheld imaging device allow direct visualization of blood in the microcirculation.10,11 
Thereby, the microcirculatory network of arterioles and capillaries can be investigated 
non-invasively. In particular, the technique is suitable for the study of easily accessible 
tissues with a superficial microcirculatory network of the skin and mucous membranes. 
Accordingly, OPS and SDF imaging have been applied to assess the characteristics of the 
microcirculation and monitor its alterations in the nail fold as well as in sublingual and 
labial tissue of patients with heart failure, rheumatic diseases and sepsis.12,13 However, 
to our knowledge no previous studies have been performed in patients with diabetes.
In the current study we first sought to validate the assessment of labial microcirculation 
parameters, comprising of capillary density and tortuosity, using the SDF imaging 
device. Secondly, the labial capillary density and tortuosity were compared in non-
diabetic controls and patients with diabetes. Finally, the relation between labial capillary 
density and tortuosity with CAD was evaluated in the sub-population of patients with 
diabetes.
METHoDs
study design and population
One hundred and thirty-one consecutive asymptomatic patients with diabetes were 
referred to the cardiology outpatient clinic for cardiovascular screening. The American 
Diabetes Association criteria were used to define diabetes and for further stratification 
in type 1 or 2.14 Patients were considered as having type 1 diabetes if laboratory analysis 
demonstrated auto-antibodies to islet cells, insulin and glutamic acid decarboxylase. 
Otherwise, patients were considered to have type 2 diabetes. Further cardiovascular risk 
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factors were assessed according to the following criteria: positive family history of CAD 
(defined as presence of CAD in first degree family members younger than 55 (men) or 
65 (women) years of age), smoking (defined as current smoking or smoking in the last 
2 years), hypertension (defined as a blood pressure >140/90 mmHg or treatment with 
antihypertensive medication), hypercholesterolemia (defined as a total cholesterol level 
>5.0 mmol/L or use of cholesterol lowering medication), degree of obesity (estimated by 
body mass index [BMI = Kg/m2]), level of glycemic control defined by plasma glycated-
haemoglobin (mmol/L) and presence of micro-albuminuria (defined by a urine albumin/
creatinine ratio ≥3.5 mg/mmol). Second, non-invasive multi-slice CT (MSCT), including 
coronary artery calcium (CAC) scoring and coronary angiography, were performed as 
part of clinical work up. Also, all patients underwent non-invasive assessment of the 
labial microcirculation using SDF imaging, to determine capillary density and tortuosity. 
The latter was performed in a study setting, performed according to the Declaration of 
Helsinki and approved by the institutional review committee of the Leiden University 
Medical Centre, Leiden. All patients gave written informed consent.
In addition, as part of the study setting, 50 asymptomatic healthy individuals comprising 
the non-diabetic control group, underwent a similar non-invasive assessment of the labial 
microcirculation using SDF. The healthy individuals comprising this control group had 
no history of diabetes or cardiovascular disease and were not known with related risk 
factors (hypertension, hypercholesterolemia, smoking or micro-albuminuria).
validation study of the microcirculation parameters as assessed by sDf
The intra- and interobserver variability of the labial capillary density and structure was 
determined in the non-diabetic control group (n = 50). For this sub-population, SDF 
imaging of the four inner lip quadrants was performed by two experienced observers. 
SDF imaging was performed twice by each observer, on two different occasions. 
Each observer independently performed processing of own recordings followed by 
assessment of the capillary density and tortuosity.
Assessment of labial microcirculation
Data acquisition by Side-stream Dark Field imaging
Imaging of the capillaries was performed with SDF imaging with a handheld MicroScan 
Video Microscope (MicroVision Medical, Amsterdam, Netherlands). The SDF device 
was fitted with a sterile disposable 5x magnification lens. Video output was visualized 
on a monitor and connected to a computer via a signal converter (Canopus, ADVC110).
Measurements were performed by two trained physicians blinded to clinical data. All 
subjects (patients with diabetes and non-diabetic controls) were instructed to refrain 
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from caffeine containing substances 2 h prior to the evaluation. Subjects were in supine 
position, in a temperature controlled room with a temperature of approximately 22ºC. 
The tip of the SDF probe was placed on the inner lip. To prevent microcirculatory 
perfusion disturbance due to application of pressure on the imaging area, the probe was 
first placed on the labial tissue and then retracted to an extent which minimized contact 
but enabled visualization of the capillary bed. Illumination intensity and depth of focus 
were modulated to fine-tune image quality.
Continuous digital image recordings (duration 1 minute) were captured in four quadrants 
of the inner lip: upper right quadrant, upper left quadrant, lower right quadrant and 
lower left quadrant. Per quadrant, digital image recordings were saved on a hard drive 
as DV-AVI files to enable off-line analysis.
Assessment of microcirculation
For further assessment of capillary density and structure, 3 frozen microcirculatory 
imaging areas were selected from the digital image recordings for each quadrant. 
Microcirculatory imaging areas were selected to meet the following criteria: 1) 
representative capillary density and structure for the studied quadrant, 2) longitudinal 
axis view with full-length capillaries enabling structural as well as quantitative 
assessment of the capillaries, 3) clear, well-focused view of the capillaries. Each 
microcirculatory imaging area visualized by SDF corresponded with a tissue area of 
0.63 mm2 (0.9 mm x 0.7 mm) (Figure 1).
Capillary density
To determine capillary density, the number of capillaries was counted manually on 
each selected microcirculatory imaging area, on the monitor. All vessels identified as 
capillaries were included. Partially visible capillaries were included if the observer was 
certain that the vessel was a capillary due to its morphology. Capillary density was 
defined as the number of counted capillaries per microcirculatory image area (capillaries 
per 0.63 mm2) (Figure 1). Finally, capillary density of the 12 microcirculatory imaging 
areas (3 microcirculatory imaging areas per quadrant) were averaged to obtain the mean 
capillary density per subject.
Capillary tortuosity
To assess the capillary tortuosity score, the number of twists per capillary in the 
majority of capillaries was evaluated, on each selected microcirculatory imaging area. 
The number of twists was stratified as 0: no twists (or pinhead capillaries) to 4: 4 or more 
twists (Figure 1). Subsequently, the overall tortuosity score per subject was determined 
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by selecting the most frequent tortuosity score in the 12 studied microcirculatory 
imaging areas.
Assessment of coronary artery disease by MsCT in patients with diabetes
MSCT data acquisition
Imaging was performed with a 64-slice MSCT scanner (Aquilion64, Toshiba Medical 







B. Capillary tortuosity dened as capillary twists inmajority of capillaries




figure 1. Visualization of the labial micro-vasculature by SDF. Capillaries are identified as loops 
emerging from the wider arterioles in the background (1A, 1C-E). To assess capillary density 
the number of capillaries was determined in a visual field of 0.63 mm2 (1A). To assess capillary 
tortuosity, the number of twists per capillary in the majority of capillaries, was evaluated for each 
patient. Number of twists was stratified as 0: no twists (or pinhead capillaries) to 4: 4 or more twists 
(1B). A relatively low capillary density and tortuosity score was observed in non-diabetic controls 
(1C). In contrast, a higher capillary density and tortuosity score was observed in patients with 
diabetes (1D), often accompanied by dilation, branching and malformation of the capillaries (1E).
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100 mg) were provided 1 hour preceding the scan to achieve a heart rate <65 beats per 
minute. Initially, a non-enhanced prospective electrocardiographically gated scan, 
triggered at 75% of the R-R interval with 4 x 3.0 mm collimation was obtained to measure 
CAC score and determine the start and end position of the helical scan.
Thereafter, MSCT angiography was performed using the following parameters: 
collimation 64 x 0.5 mm, tube rotation time 400, 450 or 500 ms depending on the heart 
rate, tube current 300 or 350 mA, tube voltage 120 kV. Non-ionic contrast material 
was administered in the antecubital vein at a flow rate of 5 ml/L and the amount of 
90–105 ml (depending on the total scan time), followed by 50 ml of saline solution flush. 
Automated bolus-tracking in the aortic root was used for the timing of the scan. Images 
were acquired with simultaneous ECG registration during a single breath hold of 
approximately 10 seconds. Segmental reconstruction algorithm was applied to generate 
a single image from the data of one, two or three consecutive heartbeats. Images were 
reconstructed in the cardiac phase showing least motion artifacts. In general, the end-
diastolic phase was used. However, additional reconstructions were made throughout 
the entire cardiac cycle if necessary to improve image quality. Subsequently, the images 
were transferred to a remote workstation (Vitrea 2, Vital Images, Minnetonka, USA) for 
post-processing.
Assessment of CAD
Coronary artery calcium score
All data were evaluated with a remote workstation using dedicated software (Vitrea2, 
Vital Images, Minnetonka, USA). In each patient, coronary calcium was identified as 
a dense area in the coronary artery exceeding the threshold of 130 Hounsfield units. 
The total Agatston score was determined for each patient. Patients with a CAC score 
>100 were classified as having increased CAC.
Coronary atherosclerosis
MSCT coronary angiography images were interpreted by two experienced observers 
blinded to the patient characteristics. Discrepancies in interpretation were directly 
resolved in consensus. The presence of coronary atherosclerosis was visually evaluated 
on axial images and curved multiplanar reconstructions in at least two orthogonal 
planes. Obstructive coronary atherosclerosis was defined as the presence of luminal 
narrowing ≥50%.
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statistical analysis
Continuous variables were expressed as means ± standard deviation. Categorical 
variables were expressed as numbers (percentages).
First, for the validation of the mean labial capillary density assessment in non-diabetic 
controls, the interobserver for the first and second session, and the intraobserver for 
observer-1 as well as observer-2, were determined by calculating the Pearson coefficient 
of correlation (r). For the validation of the capillary tortuosity assessment in the 
control group, the interobserver for the first and second session, and the intraobserver 
for observer-1 as well as observer-2, were determined by calculating the agreement 
percentage and the kappa value.
Second, the mean capillary density was compared in non-diabetic controls and patients 
with type 1- and type 2 diabetes. For this purpose, the average capillary density and 
standard deviation were calculated in each group. The independent T-test was used to 
assess the difference in mean capillary density between the three groups. In addition, 
the relation between type 1 diabetes (versus non-diabetic controls as reference) and 
type 2 diabetes (versus non-diabetic controls as reference) with the capillary density was 
tested in a backward multivariate linear regression analysis, to correct for the influence 
of other cardiovascular risk factors.
Third, the distribution of capillary tortuosity was compared among healthy individuals, 
patients with type 1- and type 2 diabetes, by calculating the percentage of patients per 
tortuosity score for each group. Subsequently, the relation between type 1 diabetes (versus 
non-diabetic controls as reference) and type 2 diabetes (versus non-diabetic controls as 
reference) was also tested with the capillary tortuosity in a backward multivariate linear 
regression analysis.
Finally, in the sub-population of patients with diabetes, the relation of capillary density 
and tortuosity score with the presence of CAD was evaluated. Initially, patients with 
diabetes were stratified as having a CAC score 0-100 or as those with an elevated CAC 
score of >100. Average capillary density and standard deviation were calculated in 
each group. The independent T-test was used to assess the difference in mean capillary 
density between the two groups. A similar procedure was performed to compare the 
mean capillary density between diabetic patients with no obstructive CAD and those 
with obstructive CAD (luminal narrowing ≥50%).
To identify the potential predictors of an elevated CAC score in diabetes, a univariate 
logistic regression analysis of baseline cardiovascular risk factors, capillary density 
and capillary tortuosity was initially performed. Thereafter, all risk factors as well as 
capillary density and tortuosity were entered in a backward stepwise multiple logistic 
regression analysis model to identify the independent predictors of an elevated CAC 
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score. Results of variables with a P value ≤0.25 are illustrated. A similar procedure was 
repeated to identify the predictors of obstructive CAD in patients with diabetes.
Statistical analyses were performed using SPSS software (version 12.0.1, Inc., Chicago, 
Illinois). P values <0.05 were considered statistically significant.
REsulTs
Characteristics of non-diabetic controls and patients with diabetes
Characteristics of the sub-populations of non-diabetic controls, patients with type 1- 
and type 2 diabetes are provided in Table 1. No significant difference was observed 
among the gender distribution of patients with diabetes (type 1 and type 2) as compared 
to non-diabetic controls. Patients with type 1 diabetes were relatively younger than 
non-diabetic controls. In contrast, patients with type 2 diabetes were similar in age to 
non-diabetic controls.  Patients with type 2 diabetes had a higher mean BMI than non-
diabetic controls. As compared to non-diabetic controls, patients with diabetes (type 1 
and type 2) were more often smokers, more often had a positive family history for CAD, 
and were frequently treated with statins and anti-hypertensive medication.












Age 57 ± 14 46 ± 12 <0.001 55 ± 12 0.62
Male sex 27 (53%) 37 (61%) 0.43 33 (47%) 0.53
Diabetes duration (years) - 24 ± 14 - 10 ± 7 -
Family history of CAD 11 (22%) 28 (46%) 0.01 34 (49%) 0.004
Smoking 0 (0%) 20 (33%) <0.001 14 (20%) <0.001
Body mass index (kg/m2) 24 ± 3 25 ± 4 0.44 30 ± 7 <0.001
HbA1c (mmol/L) - 7.8 ± 1.5 - 8.3 ± 1.6 -
Micro-albuminuria - 9 (13%) - 18 (26%) -
Hypercholesterolemia - 36 (59%) - 50 (71%) -
Hypertension - 29 (48%) - 46 (66%) -
Statin use 0 (0%) 22 (36%) <0.001 38 (54%) <0.001
Anti-hypertensive 
medication
0 (0%) 19 (31%) <0.001 41 (59%) <0.001
* Difference in distribution between non-diabetic controls and patients with type 1 diabetes. 
** Difference in distribution between non-diabetic controls and patients with type 2 diabetes. CAD = 
Coronary artery disease; HbA1c = glycated haemoglobin;
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validation study
Capillary density
The interobserver correlation for the assessment of capillary density during the first 
session and second session were reasonable with a regression coefficient of 0.75 (P <0.001) 
and 0.72 (P <0.001) respectively. The intraobserver regression correlation coefficients for 







































figure 2. Mean capillary density in non-diabetic controls, versus type 1 diabetic patients, and 
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Capillary tortuosity
The interobserver values for the assessment of capillary tortuosity were excellent and 
similar for the first and second session with an agreement of 88% in tortuosity score 
(kappa 0.83). The intraobserver evaluation for tortuosity score revealed an agreement of 
90% (kappa 0.85) for observer-1 and 88% (kappa 0.83) for observer-2.
labial capillary density in patients with diabetes as compared to non-diabetic 
controls
Capillary density in type 1 diabetes
The mean capillary density in patients with type 1 diabetes (25 ± 4 per 0.63 mm2) was 
not significantly different as compared to non-diabetic controls (24 ± 3 per 0.63 mm2) 
(Figure 2). However, after correction for age and other cardiovascular risk factors in a 
backward multiple linear regression model, the presence of type 1 diabetes (with non-
diabetic controls as reference) was found to be associated with an increased capillary 
density (Exp ß 2.4, 95% CI 0.8-3.9; P = 0.003).
Capillary density in type 2 diabetes
The mean capillary density was significantly increased in patients with type 2 diabetes (27 
± 4 per 0.63 mm2) as compared to non-diabetic controls (P = 0.001) (Figure 2). Importantly, 
also after correction for age and other cardiovascular risk factors in a backward multiple 
linear regression model, the presence of type 2 diabetes (with non-diabetic controls as 
reference) maintained a significant association with capillary density (Exp ß 1.0, 95% CI 
0.3-1.6; P = 0.01).
Tortuosity Score
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figure 3. Distribution of patients according to capillary tortuosity score. A lower tortuosity 
score was observed in non-diabetic controls (3A). In type 1 diabetes, patients were rather evenly 
distributed among a tortuosity score of 1-3 (3B). In comparison, in type 2 diabetes a larger 
proportion of patients were shown to have a relatively high tortuosity score (3C).
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labial capillary tortuosity in patients with diabetes as compared to non-diabetic 
controls
Capillary tortuosity in type 1 diabetes
Whereas in non-diabetic controls a high proportion of subjects had a low tortuosity score 
of 1 (45%), with a lower proportion of subjects in the tortuosity score 2 and 3 category 
(20%) (Figure 3A); in type 1 diabetes, the patients were more evenly distributed among 
the tortuosity scores 1-3 (Figure 3B). In type 1 diabetes, a relatively higher proportion 
of patients were stratified as having a tortuosity score 2 (27%) and 3 (37%) (Figure 3B). 
Accordingly, after correction for age and other cardiovascular risk factors in a backward 
multiple linear regression model, presence of type 1 diabetes (with non-diabetic controls 
as reference) was found to be associated with capillary tortuosity (Exp ß 0.6, 95% CI 0.1-
1.0; P = 0.02).
Capillary tortuosity in type 2 diabetes
In contrast with non-diabetic controls, a minor proportion of patients with type 2 
diabetes were stratified as having a low tortuosity score of 0 (1%) or 1 (13%) (Figure 3C). 
Whereas, a relatively large proportion of these patients had a high tortuosity score 
of 4 (27%). Indeed, after correction for age and other cardiovascular risk factors in 
a  backward multiple linear regression model, the presence of type 2 diabetes (with 
non-diabetic controls as reference) was found to be a predictor of capillary tortuosity 
(Exp ß 0.5, 95% CI 0.2-0.8; P = 0.001).
CAD as assessed by MsCT in patients with diabetes
In the total sub-population of patients with diabetes, the mean CAC score was 213 ± 451. 
Overall, 39 (30%) patients with diabetes had an elevated CAC score of >100. Using MSCT 
angiography, presence of obstructive CAD (luminal narrowing ≥50%) was revealed in 31 
(24%) patients with diabetes.
Relation of labial microvascular parameters with CAD in diabetes
The mean capillary density was higher in diabetic patients with a CAC score >100 (27 
± 4 per 0.63 mm2) as compared to those with a CAC score in the range 0-100 (25 ± 4 
per 0.63 mm2) (P = 0.04) (Figure 4A). Similarly, after stratification according to MSCT 
angiography results, a higher mean capillary density was observed in diabetic patients 
with obstructive CAD (27 ± 4 per 0.63 mm2), than in those without obstructive CAD (25 
± 4 per 0.63 mm2) (P = 0.02) (Figure 4B).
As demonstrated in Figure 5A, none of the diabetic patients with a tortuosity score 0 
(pinhead capillaries) had an elevated CAC score of >100. The prevalence of an elevated 
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figure 4. Relation of mean capillary density and CAD in asymptomatic diabetic patients. Mean 
capillary density was higher in patients with an increased CAC score of >100 (4A). Similarly, mean 
capillary density was higher in diabetic patients with obstructive CAD, as compared to those with 
no obstructive CAD (4B).
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figure 5.  Relation of capillary tortuosity and CAD in asymptomatic diabetic patients. Relatively 
low prevalence of increased CAC scores of >100 were observed in patients with low tortuosity 
scores. On the contrary, the majority of patients with a high tortuosity score of 4 were revealed 
to have an increased CAC score of >100 (5A). A similar relation was observed between tortuosity 
score and the presence of obstructive CAD (5B).
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CAC score increased modestly to 11% and 14% with a tortuosity score of 1 and 2. The 
prevalence of an elevated CAC score increased further to 33% in those with a tortuosity 
score of 3. However, the most prominent increase in the prevalence of an elevated CAC 
score (74%) was observed in diabetic patients with highly tortuous capillaries (tortuosity 
score 4).
Likewise, a low tortuosity score of 0 excluded the presence of obstructive CAD in 
patients with diabetes (Figure 5B). A relatively low prevalence of obstructive CAD 
(11% and 9%) was observed in patients with a tortuosity score 1 and 2. In contrast, the 
prevalence of obstructive CAD more than doubled (26%) in patients with a tortuosity 
score 3. Importantly, a 57% majority of diabetic patients with a high tortuosity score of 4, 
were shown to have obstructive CAD.
Predictors of an elevated CAC score in diabetes
The results of binary logistic regression analysis for the evaluation of the risk factors 
associated with an elevated CAC score of >100 are provided in Table 2. Age, micro-
albuminuria, hypercholesterolemia, hypertension and both capillary density and 
tortuosity were identified as potential predictors of an elevated CAC score, in patients 
with diabetes. Of note, after correction for other cardiovascular risk factors in a backward 
Table 2. Predictors of a CAC score > 100, in patients with diabetes. Results of binary logistic 
regression analyses. 
univariate Analysis Multivariate Analysis 
(backward)*
Exp ß (95% CI) P-value Exp ß (95% CI) P-value
Age 1.12 (1.1-1.2) <0.001 1.16 (1.1-1.3) <0.001
Male sex 1.94 (0.9-4.2) 0.09 2.12 (0.6-7.7) 0.25
Diabetes duration (years) 1.02 (1.0-1.1) 0.16 - -
Family history of CAD 1.14 (0.5-2.4) 0.73 - -
Smoking 1.58 (0.7-3.6) 0.27 - -
Body mass index (kg/m2) 1.00 (0.9-1.1) 0.99 - -
HbA1c 1.14 (0.9-1.4) 0.26 - -
Micro-albuminuria 6.3 (2.4-15.4) <0.001 9.12 (1.9-43.0) 0.01
Hypercholesterolemia 2.58 (1.1-6.3) 0.04 3.79 (1.0-14.8) 0.06
Hypertension 5.52 (2.2-13.8) <0.001 - -
Type 2 diabetes (vs. Type 1 diabetes) 1.29 (0.6-2.7) 0.50 0.12 (0.0-0.5) 0.01
Capillary density (number/0.63mm2) 1.10 (1.0-1.2) 0.06 1.19 (1.0-1.4) 0.03
Capillary tortuosity (score 0-4) 2.65 (1.7-2.7) <0.001 2.58 (1.3-5.2) 0.01
* All risk factors were entered in the model. Results are displayed for risk factors with a P-value ≤0.25. 
CAD = Coronary artery disease; HbA1c = glycated haemoglobin.
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multiple logistic regression model, capillary density (Exp ß 1.2, 95% CI 1.0-1.4; P = 0.03) as 
well as capillary tortuosity (Exp ß 2.6, 95% CI 1.3-5.2; P = 0.01), were shown to maintain 
a significant association with the presence of elevated CAC.
Using receiver operating characteristic (ROC) analysis a cut-off value of 24.9 per 0.63 
mm2 was identified for capillary density. This cut-off value yielded a negative- and 
positive predictive value of respectively 84% and 39% for predicting a CAC score >100. 
Of note, the positive predictive value improved from 39% to 66% in presence of a high 
tortuosity score of 4 besides a capillary density of ³24.9 per mm2.
Predictors of obstructive CAD in diabetes
As illustrated in Table 3, age, micro-albuminuria, hypertension, capillary density and 
capillary tortuosity were found to be associated with obstructive CAD in patients with 
diabetes. Notably, analysis in a multivariate binary logistic model showed capillary 
density (Exp ß 1.3, 95% CI 1.1-1.5; P = 0.01) and capillary tortuosity (Exp ß 1.9, 95% CI 
1.0-3.6; P = 0.04) to be independently associated with the presence of obstructive CAD 
(Table 3).
Using a cut-off value of 24.9 per 0.63 mm2 for capillary density yielded a negative- and 
positive predictive value of respectively 89% and 32% for predicting obstructive CAD in 
Table 3. Predictors of obstructive CAD, in patients with diabetes. Results of binary logistic 
regression analyses. 
univariate Analysis Multivariate Analysis 
(backward)*
Exp ß (95% CI) P-value Exp ß (95% CI) P-value
Age 1.11 (1.1-1.2) <0.001 1.11 (1.0-1.2) 0.001
Male sex 1.25 (0.6-2.8) 0.59 2.71 (0.8-9.5) 0.12
Diabetes duration (years) 1.00 (0.97-1.03) 0.94 - -
Family history of CAD 1.46 (0.6-3.3) 0.36 - -
Smoking 0.78 (0.3-2.0) 0.61 - -
Body mass index (kg/m2) 0.99 (0.9-1.1) 0.85 - -
HbA1c 1.28 (1.0-1.7) 0.054 1.30 (0.9-1.9) 0.18
Micro-albuminuria 3.07 (1.2-7.9) 0.02 - -
Hypercholesterolemia 1.57 (0.6-3.9) 0.33 - -
Hypertension 2.65 (1.1-6.5) 0.03 - -
Type 2 diabetes (vs. Type 1 diabetes) 2.23 (1.0-5.2) 0.06 - -
Capillary density (number/0.63mm2) 1.13 (1.0-1.2) 0.02 1.25 (1.1-1.5) 0.01
Capillary tortuosity (score 0-4) 2.20 (1.4-3.5) 0.001 1.91 (1.0-3.6) 0.04
* All risk factors were entered in the model. Results are displayed for risk factors with a P-value ≤0.25. 
CAD = Coronary artery disease; HbA1c = glycated haemoglobin.
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diabetes. The positive predictive value improved from 32% to 60% in presence of a high 
tortuosity score of 4 in addition to a capillary density of ³24.9 per mm2.
Video clip examples of labial microcirculation as assesses by SDF are provided in the 
supplementary files (online availability via Diab Vasc Dis Res). Supplementary file 1 
shows an example of the well ordered labial capillaries in the healthy. In comparison, the 
more tortuous and malformed capillaries often observed in diabetic patients with CAD 
are shown in supplementary files 2 and 3.
DIsCussIon
The main findings of the current study were as follows: firstly, the inter-observer 
(regression coefficients per observer 0.75 and 0.72) and intraobserver (regression 
coefficients per observer 0.80 and 0.72) for the assessment of capillary density using 
SDF imaging were reasonable. Similarly, a good inter-observer (agreement per observer 
88%) and intraobserver (agreement per observer 90% and 88%) was found for the 
assessment of capillary tortuosity using SDF imaging. Secondly, after correction for age, 
gender and other cardiovascular risk factors, the presence of both type 1- and type 2 
diabetes was found to be associated with an increased capillary density and tortuosity. 
Most importantly, in the sub-population of asymptomatic patients with diabetes, the 
mean labial capillary density was significantly higher in the presence of an increased 
CAC of >100 (P = 0.04) and in obstructive CAD (P = 0.02). Moreover, after correction 
for other cardiovascular risk factors, mean capillary density was shown to be an 
independent predictor of increased CAC (P = 0.03) and obstructive CAD (P = 0.01), in 
diabetes. Likewise, the prevalence of increased CAC and obstructive CAD increased 
with capillary tortuosity. Indeed, the capillary tortuosity score was also found to be an 
independent predictor of increased CAC (P = 0.01) and obstructive CAD (P = 0.04) on 
MSCT of asymptomatic patients with diabetes.
Assessment of microcirculation by sDf
Past studies of vital microcirculation were restricted to the use of contrast microscopy and 
laser Doppler. Non-invasive imaging of the superficial skin and mucous microcirculation 
was initially implemented using the orthogonal polarization spectral (OPS) device.10 In 
OPS imaging the tissue embedding the microcirculation is illuminated with polarized 
green light. Illuminated light is absorbed by the haemoglobin in erythrocytes flowing 
through the tissue under investigation. As a result, the haemoglobin is used as the 
contrast agent, so that erythrocytes are imaged as dark globules in motion, against 
a white background. Consequently, the intravascular erythrocytes of perfused 
microvessels, rather than the microvessel walls are visualized. The imaging technique 
has been further modified in the SDF device to provide better visualization of the 
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microcirculation at capillary level.15 In SDF, stroboscopic imaging partially prevents 
smearing of moving features such as the flowing red blood cells due to short illumination 
intervals. The microcirculatory image is more restricted from contamination by tissue 
surface reflection. Also, as compared to OPS, imaging by SDF has a shallower focusing 
depth. Therefore, the structures underlying the microcirculatory image field interfere to 
a lower extent.
The OPS and SDF imaging devices have been previously validated10,16,17 and used to 
assess the functional anatomy of the sublingual, and nail fold microcirculation in critical 
care, and in patients with heart failure, sepsis and rheumatic diseases.12,13 In the present 
study the assessment of the quantity (capillary density) and structure (tortuosity) of the 
labial capillaries using the SDF was validated. Evaluation of the labial microvascular 
network in non-diabetic controls and patients with diabetes, showed the capillary 
density and tortuosity to increase with the presence of diabetes. The increased labial 
capillary density and tortuosity may be a maker of microvascular disease.
Microvascular disease in diabetes
In diabetes, abnormal microvascular patterns have been described in nephropathy, 
retinopathy, and the myocardial capillaries.18,19 Early morphological changes in the 
kidney of humans and animals with diabetic nephropathy include an increase in the 
number of glomerular capillaries as well as elongation and intermittent dilation and 
occlusion of the microvessels.20-23 Alternatively, diabetic retinopathy can be classified as 
the early non-proliferative stage with microaneurysms and haemorrhages, or the later 
proliferative stage with formation of neovessels.24 Furthermore, a study showed increased 
tortuosity of retinal vessels in presence of gestational diabetes.25 Less information is 
available on the architecture of the myocardial microvessels in humans. However, in 
animal models, higher spatial capillary density and tortuosity have been observed in 
the myocardium in presence of diabetes.26,27
Various mechanisms have been proposed for the distortion of the microvascular 
network and the subsequent microvascular complications in patients with diabetes.28,29 
Hyperglycaemia is shown to promote exposure of endothelial cells to AGEs, resulting in 
protein kinase C activation, abnormal endothelial nitric oxide synthase expression and 
induction of Angiotensin-2 and vascular endothelial growth factor (VEGF).30-32 
Experimental studies suggest that VEGF may in turn stimulate the expression of 
adhesion molecules by endothelial cells and promote vascular inflammation, causing 
more adverse endothelial perturbations.33,34 The overall molecular and functional 
changes result in the final sequelae of increased permeability of the microvessels and 
finally ischemia that drives unregulated angiogenesis.
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Relation of microvascular disease and CAD
Micro- and macrovascular complications of diabetes share a number of pathogenic 
mechanisms.8,30 Primarily, both processes include components of endothelial 
dysfunction and inflammation.35-36 In addition, hypoxia induced angiogenesis is also 
increased in the vasa vasorum of the coronary arteries of patients with diabetes.36 
The corresponding neovasculature microangiopathy is suggested to accelerate 
atherosclerosis and predispose plaque rupture.36 Thus, microvascular disease and CAD 
may be interconnected, with microvascular disease prompting atherosclerosis through 
hypoxia and changes in the vasa vasorum.
Accordingly, the majority of follow-up studies in patients with diabetes have found the 
presence of microvascular disease to increase risk of CAD irrespective of traditional 
cardiovascular risk factors.5-7 During 5 years follow-up, Gall and colleagues found 
albuminuria to be a strong predictor cardiovascular mortality in patients with diabetes 
type 2 diabetes (HR 2.5 (1.1-5.8)).5 Similarly, in the EURODIAB Prospective Cohort Study 
of 2,787 patients with type 1 diabetes, both albuminuria and peripheral neuropathy were 
shown to predict cardiovascular mortality, whereas retinopathy did not.7 In contrast, in 
the Atherosclerosis Risk in Communities Study of patients with type 2 diabetes, the 
presence of diabetic retinopathy was found to be associated with a twofold risk of incident 
CAD and a threefold risk of fatal CAD, during an average follow-up of 7.8 years.6 In line 
with these findings, we found a significant and independent relation between the labial 
parameters of microvascular disease, comprising of the capillary density and tortuosity, 
with increased CAC and obstructive CAD in patients with diabetes. In particular, a low 
capillary density of <24.9 per 0.63 mm2 yielded a good negative predictive value for 
an increased CAC (84%) and obstructive CAD (89%). Also, labial capillary tortuosity 
score of 0 to 2, was associated with a low prevalence of an increased CAC (0 -14%) or 
obstructive CAD (0-11%). In contrast, in diabetic patients with a capillary tortuosity score 
of 4, a relatively high prevalence of increased CAC (74%) and obstructive CAD (57%) was 
observed.
study limitations
A number of limitations must be acknowledged. First, the parameters of the 
microcirculation as assessed by SDF imaging only reflect characteristics of perfused 
capillaries. In the current study, influence of external factors on capillary recruitment 
was limited by standardizing the study environment. Also, flow alterations in the 
microcirculation due to external pressure were prevented by minimizing probe 
contact with the labial tissue during image acquisition. Herewith a good inter-session 
reproducibility of parameters of the microcirculation was observed in healthy non-
diabetic controls. However, perfusion of capillaries may be less consistent in diabetes 
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as a consequence of functional and morphological changes. Secondly, the relation 
of labial capillary density and tortuosity with CAD could not be verified in the non-
diabetic control group. As MSCT coronary angiography is accompanied with radiation 
exposure, it is not feasible to perform a similar assessment in asymptomatic subjects free 
of cardiovascular risk. Finally, the analysis was restricted to evaluation of the association 
between labial capillary density and tortuosity as assessed by SDF with traditional risk 
factors, as well as with the presence of CAD. However, the proatherogenic process which 
relates these microvascular parameters with CAD was not investigated.
Conclusion and future perspectives
The assessment of the labial capillary density and tortuosity, as markers of microvascular 
disease, is feasible and reproducible using the SDF imaging device. The labial capillary 
density and tortuosity increased with several traditional cardiovascular risk factors, 
micro-albuminuria and the presence of diabetes. A yet further increase in the labial 
capillary density and tortuosity was observed in diabetic patients with CAD. Assessment 
of the labial microvascular parameters using the non-invasive SDF handheld device 
may convey the potential to estimate the degree of vascular morbidity in patients with 
diabetes at bedside.
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The general introduction (Chapter 1) of this thesis firstly outlines the concepts underlying 
atherosclerosis in diabetes. An overview of the dilemmas in risk stratification for 
coronary artery disease (CAD) in diabetes is provided. The clinical protocol that forms 
the basis for the studies presented in the thesis is described. Finally, the objective and 
outline of the thesis are explained.
PART 1
The first part of the thesis focuses on the nature of CAD in diabetes, and its presentation 
with different imaging modalities.
In Chapter 2, the relation of epicardial adipose tissue with CAD was assessed using CT 
angiography (CTA) in 190 patients. The study population comprised both non-diabetic 
and diabetic patients. The quantity of epicardial adipose tissue was an especially 
good predictor of any CAD. The relationship remained significant after correcting for 
diabetic status and other conventional CAD risk factors. An epicardial adipose tissue 
volume of 73 ml or more was shown to have a sensitivity and specificity of 77% and 70% 
for predicting a calcium score of >10, and 72% and 70% for presence of CAD on CTA. 
However, the quantity of epicardial adipose tissue did not significantly increase with 
the extent or severity of CAD.
The relation between the adipose tissue product adiponectin with parameters of CAD on 
CTA was explored in Chapter 3. Anomalous low and more variable adiponectin plasma 
levels are anticipated especially in patients with type 2 diabetes. The study was therefore 
conducted specifically in a type 2 diabetes subpopulation. Low plasma adiponectin 
was related with the presence of any atherosclerosis, obstructive atherosclerosis and 
atherosclerotic plaque burden.  A plasma adiponectin of <4.5 mcg/ml resulted in a 
sensitivity and specificity of 80% and 71% for predicting obstructive atherosclerosis. 
Interestingly, analysis of plaque phenotype showed a predominant relation between 
low plasma adiponectin and the quantity of non-calcified plaques, which have been 
implicated in unstable CAD.
In Chapter 4, the nature of coronary atherosclerosis as assessed by CTA was compared 
in asymptomatic patients with type 1 and type 2 diabetes. No difference was observed 
in the average CAC score. However, the prevalence of obstructive atherosclerosis was 
higher in patients with type 2 diabetes. Also a higher mean number of atherosclerotic 
and obstructive plaques was observed in patients with type 2 diabetes. In addition, the 
percentage of noncalcified plaques was higher in patients with type 2 (66%) versus type 
1 diabetes (27%). Consequently, in type 2 diabetes, a higher plaque burden was observed 
for each CAC score category.
Chapter 5 compared the diagnostic information obtained using CTA of the coronary 
arteries with functional data acquired using SPECT perfusion imaging, in 130 patients 
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with diabetes (type 1 and type 2). Thirty-five patients (27%) were shown to have 
obstructive epicardial CAD on CTA. Notably, in the remaining 95 patients free of 
obstructive epicardial CAD, abnormal myocardial perfusion was observed in yet 
30 patients (32%). The endothelial function was assessed by the flow-mediated dilation 
of the brachial artery and compared in patients with normal and abnormal myocardial 
perfusion who were free of epicardial CAD. Flow-mediated dilatation was significantly 
lower in patients with abnormal myocardial perfusion (3.6% +/- 2.4%) as compared to 
those with normal myocardial perfusion (6.4% +/- 2.6%). This finding reflects abnormal 
myocardial perfusion as a consequence of reduced endothelial function in absence of 
obstructive CAD in a substantial proportion if asymptomatic patients with diabetes.
PART 2
In the second part of the thesis the value of non-invasive vascular measurements and 
cardiac imaging techniques was evaluated for risk stratification of CAD in diabetes.
Chapter 6 firstly reviews published data on the implementation of non-invasive 
vascular tools (carotid intima media thickness (CIMT), arterial stiffness and flow-
mediated dilation) for risk stratification. Based on this overview it was concluded 
that CIMT and arterial stiffness as assessed by pulse wave velocity (PWV) show good 
reproducibility in diabetes, and are both increased in presence of clinically manifest 
CAD. However, limited data were available on the relation of these parameters with 
asymptomatic CAD in diabetic patients. Therefore, the value of CIMT and arterial 
stiffness for risk stratification of CAD in asymptomatic patients with diabetes remained 
to be examined. The use of flow-mediated dilation in clinical practice is limited due to 
poor reproducibility under variable external and physical circumstances. Secondly, the 
implementation of non-invasive cardiac imaging in patients with diabetes was reviewed. 
Previous studied showed CAC scores to be increased in presence of CAD. However, as 
compared to the general population, CAC scoring could possibly underestimate risk of 
future coronary events in diabetes. Anatomic imaging by CTA and functional testing by 
SPECT myocardial perfusion imaging had superior sensitivity and negative predictive 
value for presence of CAD in diabetes. However, risk stratification of all diabetic patients 
with CTA and/or SPECT myocardial perfusion imaging does not seem cost-effective 
and comprises radiation exposure. Therefore, we proposed an algorithm wherein the 
truly non-invasive and radiation free vascular measurements (CIMT and PWV) could 
serve as a primary risk stratification tool to select patients with type 2 diabetes who 
should undergo further assessment with CTA or SPECT.
Accordingly, Chapters 7-9 focus on the value of CIMT and PWV as a primary risk 
stratification test in asymptomatic patients with diabetes.
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In Chapter 7, assessment of CIMT in 150 asymptomatic patients with diabetes (type 1 
and type 2) showed a significant relation with the presence and severity of CAD on CTA. 
The mean CIMT increased significantly from 0.58 +/- 0.08 mm in presence of normal 
coronary arteries to 0.67 +/- 0.12 mm in non-obstructive atherosclerosis and further to 
0.75 +/- 0.12 mm in obstructive atherosclerosis. Receiver operating characteristics curve 
analysis yielded a sensitivity and specificity of 85% and 72%, with a CIMT cut-off value 
of 0.67 mm, for predicting obstructive CAD.
Chapter 8 evaluated the relation of CIMT with abnormal myocardial perfusion on SPECT, 
specifically in type 2 diabetes. Herein, increased CIMT emerged as an independent 
predictor of the presence and extent of abnormal myocardial perfusion. Importantly, 
only 3% of asymptomatic diabetic patients with normal CIMT values had severe 
myocardial perfusion abnormalities. Assessment of CIMT may therefore be useful to 
identify asymptomatic patients with diabetes at higher risk for CAD in need of further 
diagnostic testing using non-invasive cardiac imaging.
In Chapter 9, we evluated the value of the parameters of arterial stiffness as a primary 
risk stratification test in asymptomatic patients with diabetes. For this purpose the 
relation of the two non-invasive parameters of arterial stiffness, the PWV and the 
augmentation index, with the severity of myocardial perfusion abnormalities on SPECT 
was studied in 160 patients (type 1 and type 2). Both PWV and the augmentation index, 
were shown to increase with the severity of myocardial perfusion abnormalities on 
SPECT. However, after adjustment for age and other cardiovascular risk factors, PWV 
remained a significant predictor of severe myocardial perfusion abnormalities, whereas 
the augmentation index lost significance. This result suggests a potential for risk 
stratification for CAD through non-invasive assessment of arterial stiffness by PWV.
Subsequently, in Chapter 10, we compared the performance of the Framingham risk 
score, CIMT, PWV and CAC scoring as a primary risk stratification tool to identify the 
asymptomatic type 2 diabetes patients with functionally relevant CAD. Functionally 
relevant CAD defined as obstructive CAD on CTA and abnormal myocardial perfusion 
on SPECT was observed in 24% of patients. The Framingham risk score did not increase 
the AUC for predicting functionally relevant CAD (AUC 0.61, P=0.18). In contrast, the 
AUC increased significantly for PWV (AUC 0.68, P=0.03), CIMT (AUC 0.81, P<0.001) and 
CAC scoring (AUC 0.84, P<0.001). An excellent sensitivity and negative predictive value 
were observed with increased CIMT (83% and 95%) and a CAC score >100 (85% and 97%) 
for predicting functionally relevant CAD. As a consequence, CIMT and CAC scoring 
may be the preferred primary risk stratification tools for identification of asymptomatic 
patients with type 2 diabetes requiring further testing.
Chapter 11 describes a study exclusively in asymptomatic patients with type 1 diabetes. 
The presence and degree of myocardial perfusion abnormalities on SPECT were assessed. 
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Thereafter, we focused on the issue of risk stratification in this population. We observed 
abnormal myocardial perfusion in 41% of the patients, with 14% having severe defects. 
Significant predictors of extent of perfusion defects were age, micro-albuminuria and a 
CAC score >100. Severe perfusion defects were observed in yet 9% of patients without 
micro-albuminuria. On the other hand a CAC score <100 excluded severe perfusion 
defects. Additionally, CAC scoring was shown to have incremental value for predicting 
severe perfusion defects over age and the presence of micro-albuminuria (P=0.01). 
Consequently, abnormal myocardial perfusion is observed in a substantial number of 
asymptomatic patients with type 1 diabetes. CAC score assessment seems as the superior 
strategy to exclude the presence of silent severe CAD in type 1 diabetes.
PART 3
The third part of the thesis describes a novel technique, sidestream dark field imaging, 
for the assessment of the microcirculation at capillary level.
First, the technique was validated in Chapter 12. The reproducibility of labial capillary 
density and capillary tortuosity assessment was tested in 50 healthy volunteers. The 
interobserver correlation for the assessment of capillary density during the first session 
and second session were reasonable with a regression coefficient of 0.75 (P <0.001) and 
0.72 (P <0.001) respectively. The intraobserver regression correlation coefficients for the 
assessment of capillary density were 0.80 (P <0.001) and 0.72 (P <0.001) for observer-1 and 
observer-2. The interobserver correlation for the assessment of capillary density during 
the first session and second session were reasonable with a regression coefficient of 
0.75 (P <0.001) and 0.72 (P <0.001) respectively. The intraobserver regression correlation 
coefficients for the assessment of capillary density were 0.80 (P <0.001) and 0.72 (P <0.001) 
for observer-1 and observer-2. Therefore, we concluded that the assessment of the labial 
capillary density and tortuosity, as parameters of the microcirculation, is feasible and 
reproducible using the SDF imaging device.
In Chapter 13, we proceeded to study the parameters of labial microcirculation in 
patients with type 1- and type 2 diabetes as compared to healthy controls. Both type 1- 
and type 2 diabetes were associated with increased capillary density and tortuosity. 
The second part of the study was performed specifically in the diabetic population and 
evaluated the parameters of microcirculation in relation to CAD. In diabetic patients, 
the mean capillary density was an independent predictor of elevated CAC (P=0.03) and 
obstructive CAD on CTA (P=0.01). Using a cut-off mean capillary density of 24.9 (per 0.63 
mm2) the negative predictive value was 84% and 89% for elevated CAC and obstructive 
CAD. Likewise, capillary tortuosity was an independent predictor of increased CAC 
(P=0.01) and obstructive CAD (P=0.04). Therefore, it seems that the assessment of labial 
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microcirculation parameters using SDF conveys the potential to estimate vascular 
morbidity in patients with diabetes at bedside.
ConClusIons
The primary objective of the thesis was to evaluate and compare various techniques and 
strategies for risk stratification of CAD in asymptomatic patients with diabetes.
The pathophysiologic pathway from obesity to CAD in diabetes is not fully understood. 
However, several markers of central adiposity show a relation with the degree of CAD. In 
this line, increased epicardial adipose tissue volume predisposes CAD. More specifically, 
the adipose tissue product adiponectin seems to be inversely related with the presence 
and degree of CAD in type 2 diabetes. A better understanding and employment of such 
markers could offer the possibility to distinguish the high risk diabetic patient at an 
early stage, prior to onset of vascular disease.
Dysfunction of the endothelium seems to occur in early stages of vascular disease. 
The consequent insufficient vasomotor response in the microvasculature may result 
in relative hypoperfusion. Therefore, in diabetic patients, myocardial perfusion defects 
prompted by endothelial dysfunction are sometimes observed in absence of obstructive 
CAD. In line with this observation, follow up studies have shown inducible myocardial 
perfusion defects to resolve in a majority of diabetic patients treated with antiatherogenic 
therapy. On the other hand, peristent hypoperfusion may result in morphological changes 
distinguished by proliferative neovascularization and distortion of the microvascular 
pattern. The SDF imaging device is validated for the non-invasive evaluation of these 
characteristics of the microvasculature. Using this novel technique, the assessment of 
capillary density and tortuosity, as markers of microvascular disease, is shown to be 
feasible and reproducible. Moreover, the presence of microvascular disease as assessed 
by SDF is associated with CAD in asymptomatic patients with diabetes.
In diabetic patients with atherosclerosis, CTA is able to define the extent, severity 
and composition of atherosclerotic lesions in the coronary arteries. Due to distinct 
pathophysiology and distinct patient profile, the nature of CAD as assessed by CTA 
differs in type 1- and type 2 diabetes. A relatively high proportion of calcified plaques 
is present in type 1 diabetes. Consequently, CAC score assessment seems the superior 
strategy to exclude the presence of severe CAD in asymptomatic patients with type 
1 diabetes. Indeed, CAC scoring has incremental value over clinical risk factors for 
predicting severe CAD in type 1 diabetes. In type 2 diabetes, a higher plaque burden 
is observed for each CAC score category. Nevertheless, also in type 2 diabetes, a low 
CAC score performs well in excluding the presence of severe CAD accompanied with 
abnormal myocardial perfusion. However, risk stratification using the truly non-invasive 
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and radiation free CIMT performs equally well in predicting severe CAD accompanied 
with abnormal myocardial perfusion in type 2 diabetes.
A sequential approach comprising of CIMT or CAC scoring as a first step, followed by 
further diagnostic imaging if indicated, may possibly provide the most feasible and 
cost-effective approach for risk stratification of CAD in asymptomatic patients with 
diabetes. Thereby, a more patient tailored approach could be accomplished in patient 
management. However, prospective follow-up studies assessing the clinical outcome 
and cost-effectiveness of such algorithms are necessary to further define the role of non-
invasive vascular tools and cardiac imaging techniques in management of patients with 
diabetes.
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In de algemene inleiding (Hoofdstuk 1) van dit proefschrift wordt eerst een overzicht 
gegeven van onderliggende principes van atherosclerose vorming bij diabetes. Een 
overzicht van de dilemma’s in risicostratificatie voor CAD bij diabetes wordt verstrekt. 
Het klinisch protocol dat de basis vormt voor de studies in dit proefschrift wordt 
beschreven. Tot slot worden de doelstelling en de opzet van het proefschrift toegelicht.
DEEl 1
Het eerste deel van het proefschrift richt zich op de aard van CAD bij diabetes, en de 
wijze waarop dit zich manifesteert bij verschillende beeldvormende modaliteiten. In 
Hoofdstuk 2 werd de relatie tussen epicardiaal vetweefsel met CAD (beoordeeld met 
behulp van CTA) beschreven in 190 patiënten. De studiepopulatie bestond uit zowel 
niet-diabetische als diabetespatiënten. De hoeveelheid epicardiaal vetweefsel was 
een bijzonder goede voorspeller voor CAD. Het verband bleef significant na correctie 
voor diabetische status en andere conventionele CAD risicofactoren. Een epicardiaal 
vetweefsel volume van 73 ml of meer toonde een sensitiviteit en specificiteit van 77% 
en 70% voor het voorspellen van een calcium score van >10, en 72% en 70% voor de 
aanwezigheid van CAD op CTA. Echter, de hoeveelheid epicardiaal vetweefsel was niet 
significant gerelateerd aan de mate of ernst van CAD.
De relatie tussen het vetweefsel product adiponectine met parameters van CAD op CTA 
werd geëvalueerd in Hoofdstuk 3. Abnormaal lage en meer variabele adiponectine 
plasmaspiegels worden vooral bij patiënten met type 2 diabetes verwacht. De 
studie werd daarom specifiek in een type 2 diabetes subpopulatie uitgevoerd. Lage 
adiponectine spiegels waren gerelateerd aan de aanwezigheid van atherosclerose, 
obstructieve atherosclerose en hoeveelheid atherosclerotische plaque. Een adiponectine 
plasmaspiegel van <4,5 mcg/ml resulteerde in een sensitiviteit en specificiteit van 80% 
en 71% voor het voorspellen van obstructieve atherosclerose. Aanvullende analyse 
van plaque fenotype toonde een relatie tussen lage adiponectine spiegels met de 
aanwezigheid van niet-gecalcificeerde plaques welke vermoedelijk vaker bij instabiele 
CAD betrokken zijn.
In Hoofdstuk 4 werd de uitgebreidheid, ernst en samenstelling van coronair 
atherosclerose zoals beoordeeld op CTA vergeleken tussen asymptomatische patiënten 
met type 1 en type 2 diabetes. Er werd geen verschil waargenomen in de gemiddelde 
calcium score. De prevalentie van obstructief atherosclerose was hoger bij patiënten met 
type 2 diabetes. Bij patiënten met type 2 diabetes werd ook een hoger gemiddeld aantal 
atherosclerotische plaques en obstructieve plaques waargenomen. Bovendien was het 
percentage niet-gecalcificeerde plaques hoger bij patiënten met type 2 (66%) diabetes 
in vergelijking met type 1 diabetes (27%). Derhalve werd bij type 2 diabetes een hogere 
plaque last waargenomen voor elke CAC score categorie.
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In Hoofdstuk 5 werd in 130 patiënten met diabetes (type 1 en type 2) de diagnostische 
anatomische informatie verkregen middels CTA van de coronairen met de functionele 
data verkregen middels SPECT myocardperfusie. Vijfendertig patiënten (27%) bleken 
obstructief epicardiaal CAD te hebben op CTA. In de overige 95 patiënten zonder 
obstructief epicardiaal CAD, werd abnormale myocardperfusie waargenomen bij een 
opvallend hoog aantal patiënten (n=30, 32%). De endotheelfunctie werd beoordeeld 
middels FMD van de a. brachialis. Deze werd vergeleken in patiënten met normale- 
en abnormale myocardperfusie bij wie epicardiaal obstructief CAD uitgesloten was. 
FMD was significant lager bij patiënten met abnormale myocardperfusie (3,6% +/- 
2,4%) in vergelijking met patiënten met normale myocardperfusie (6,4% +/- 2,6%). Deze 
bevindingen wijzen op frequent voorkomen van abnormale myocardperfusie als gevolg 
van verminderde endotheelfunctie bij asymptomatische patiënten met diabetes zonder 
obstructief epicardiaal CAD.
DEEl 2
In deel 2 van het proefschrift wordt de waarde van de niet-invasieve vasculaire metingen 
en beeldvormingstechnieken geëvalueerd voor risicostratificatie van CAD bij diabetes.
In Hoofdstuk 6 werd een overzicht gegeven van artikelen die gepubliceerd zijn over 
de implementatie van niet-invasieve vasculaire metingen (CIMT, arteriële vaatstijfheid 
parameters en de FMD) voor risicostratificatie. Op basis van dit literatuuronderzoek werd 
geconcludeerd dat CIMT en arteriële vaatstijfheid zoals beoordeeld door PWV goede 
reproduceerbaarheid vertonen bij diabetes. De CIMT en PWV zijn beide verhoogd bij 
aanwezigheid van klinisch manifeste CAD bij diabetespatiënten. Er zijn echter beperkte 
gegevens beschikbaar over de relatie van deze parameters met asymptomatisch CAD 
bij diabetespatiënten. Daarom dient de waarde van CIMT en arteriële vaatstijfheid 
parameters voor CAD risicostratificatie bij asymptomatische diabetespatiënten nog te 
worden onderzocht. Het gebruik van FMD in de klinische praktijk bleek beperkt vanwege 
de slechte reproduceerbaarheid onder variërende externe en fysieke omstandigheden.
Tevens werd in dit hoofdstuk een overzicht gegeven over de implementatie van niet-
invasieve cardiale beeldvormingstechnieken bij diabetespatiënten. Eerdere studies 
tonen in deze studiepopulaties verhoogde CAC scores in aanwezigheid van CAD. 
In vergelijking met de algemene bevolking onderschat de CAC score bij diabetes 
mogelijk het risico op toekomstige cardiale events als gevolg van CAD. Anatomische 
beeldvorming van de coronairen middels CTA en functionele beeldvorming middels 
SPECT myocard perfusiescintigrafie hebben een superieure sensitiviteit en negatief 
voorspellende waarde voor de aanwezigheid van CAD bij diabetes. Risicostratificatie 
bij alle diabetespatiënten met CTA en/of SPECT myocardperfusie lijkt echter niet 
kosteneffectief en stelt patiënten bloot aan ioniserende straling. Daarom hebben we een 
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algoritme voorgesteld waarin de werkelijk niet-invasieve en stralingsvrije vasculaire 
metingen (CIMT en PWV) als primaire sleutel dienen voor selectie van patiënten met 
type 2 diabetes die nader analyse dienen te ondergaan middels CTA of SPECT.
Om die reden wordt in de Hoofdstukken 7-9 de waarde van CIMT en PWV als een 
primaire risicostratificatie test voor CAD beoordeeld bij asymptomatische patiënten met 
diabetes.
In Hoofdstuk 7 werd bij 150 asymptomatische patiënten met diabetes (type 1 en type 
2) een CIMT meting verricht. Deze toonde een significante relatie met de aanwezigheid 
en de ernst van CAD op CTA. De gemiddelde CIMT steeg substantieel van 0,58 +/- 0,08 
mm bij patiënten met normale coronairen naar 0,67 +/- 0,12 mm in aanwezigheid van 
niet-obstructieve atherosclerose en verder naar 0,75 +/- 0,12 mm in aanwezigheid van 
obstructieve atherosclerose. ROC analyse leverde een sensitiviteit en specificiteit van 
85% en 72% voor het voorspellen van obstructieve CAD bij een CIMT cut-off waarde 
van 0.67 mm.
In Hoofdstuk 8 werd de relatie tussen CIMT met abnormale myocardperfusie op 
SPECT beoordeeld in een patiëntenpopulatie met enkel type 2 diabetes. Hierbij bleek 
een verhoogde CIMT een onafhankelijke voorspeller te zijn voor de aanwezigheid 
en uitgebreidheid van abnormale myocardperfusie. Van belang is dat ernstige 
myocardperfusie afwijkingen in slechts 3% van diabetespatiënten met een normale 
CIMT waard voorkwamen. Beoordelen van het CIMT kan daarom nuttig zijn om 
asymptomatische patiënten met diabetes te identificeren die een hoger risico op CAD 
lopen. Bij een verhoogd CIMT zou dan aanvullend diagnostisch onderzoek met behulp 
van niet-invasieve cardiale beeldvorming overwogen kunnen worden.
In Hoofdstuk 9 werd de potentie van verschillende parameters van arteriële vaatstijfheid 
in de rol van een primaire risicostratificatietest in asymptomatische patiënten met 
diabetes onderzocht. Hiertoe werd de verhouding tussen de niet-invasief gemeten 
PWV en augmentatie index met de uitgebreidheid van myocardperfusie afwijkingen bij 
SPECT bestudeerd in 160 patiënten (type 1 en type 2). Zowel PWV als de augmentatie 
index bleken toe te nemen met de uitgebreidheid van myocardperfusie afwijkingen. Na 
correctie voor leeftijd en andere cardiovasculaire risicofactoren bleek alleen de PWV 
een significante voorspeller van ernstige myocardperfusie afwijkingen te zijn, terwijl de 
augmentatie index geen significante voorspellende waarde meer toonde. Dit resultaat 
suggereert een potentiële rol voor risicostratificatie voor CAD via een niet-invasieve 
bepaling van arteriële stijfheid middels PWV.
Vervolgens werden in Hoofdstuk 10 de prestaties van de Framingham risicoscore, 
CIMT, PWV en CAC score als een primair instrument getoetst voor het herkennen van 
asymptomatische hoogrisico type 2 diabetes patiënten met functioneel relevant CAD. 
Functioneel relevant CAD werd gedefinieerd als aanwezigheid van zowel obstructief 
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CAD op CTA als abnormale myocardperfusie op SPECT. Dit werd waargenomen in 24% 
van de patiënten. De Framingham risicoscore toonde daarbij geen verhoging van de AUC 
voor het voorspellen van functioneel relevante CAD (AUC 0,61, p = 0,18). Daarentegen 
toonde de AUC wel significante stijging voor PWV (AUC 0,68, P = 0,03), CIMT (AUC 0,81, 
p <0,001) en CAC score (AUC 0,84, p <0,001). Een uitstekende sensitiviteit en negatief 
voorspellende waarde voor het voorspellen van functioneel relevante CAD werd 
waargenomen met een verhoogde CIMT (83% en 95%) en een CAC score >100 (85% en 
97%). Daarom lijkt het verrichten van een CIMT meting of CAC score de geprefereerde 
primaire risicostratificatie methode voor identificatie van hoogrisico asymptomatische 
patiënten met type 2 diabetes.
Hoofdstuk 11 beschrijft een studie die uitsluitend bij asymptomatische patiënten 
met type 1 diabetes verricht is. De aanwezigheid en mate van myocardperfusie 
afwijkingen bij SPECT werd beoordeeld. Daarna hebben we ons gericht op de kwestie 
van de risicoanalyse bij deze populatie. Een abnormale myocardperfusie werd in 41% 
van de patiënten waargenomen, met in 14% van patiënten ernstige perfusiedefecten. 
Significante voorspellers van de mate van perfusiedefecten waren leeftijd, micro-
albuminurie en een CAC score >100. In 9% van patiënten zonder micro-albuminurie 
werden alsnog ernstige perfusiedefecten waargenomen. Anderzijds kan bij een CAC 
score van <100 de aanwezigheid van ernstige perfusiedefecten volledig uitgesloten 
worden. Bovendien toonde de CAC score incrementele waarde boven de risicofactoren 
leeftijd en de aanwezigheid van micro-albuminurie in het voorspellen van ernstige 
perfusiedefecten (P = 0,01). Concluderend werd een abnormale myocardperfusie in een 
groot aantal asymptomatische patiënten met type 1 diabetes waargenomen. CAC score 
bepaling blijkt superieur te zijn in het uitsluiten van asymptomatische ernstige CAD bij 
type 1 diabetes.
DEEl 3
Het derde gedeelte van het proefschrift beschrijft een nieuwe techniek, SDF imaging, 
voor de beoordeling van de microcirculatie op capillair niveau.
Eerst werd de validatie van deze techniek beschreven in Hoofdstuk 12. De 
reproduceerbaarheid van de labiale capillairdichtheid en capillairtortuositeit middels SDF 
imaging werd getest in 50 gezonde vrijwilligers. De inter-correlatie voor de beoordeling 
van de capillairdichtheid tijdens de eerste sessie en de tweede sessie waren redelijk met 
een regressie coëfficiënt van respectievelijk 0,75 (P<0,001) en 0,72 (p<0,001). De intra-
observer regressie correlatiecoëfficiënten voor de beoordeling van de capillairdichtheid 
waren 0,80 (p <0,001) en 0,72 (p <0,001) voor waarnemer-1 en waarnemer-2. De inter-
correlatie voor de beoordeling van de capillairdichtheid tijdens de eerste sessie en 
de tweede sessie waren redelijk met een regressie coëfficiënt van respectievelijk 0,75 
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(P <0,001) en 0,72 (p <0,001). De intra-observer regressie correlatiecoëfficiënten voor 
de beoordeling van de capillairdichtheid waren 0,80 (p <0,001) en 0,72 (p <0,001) voor 
waarnemer-1 en waarnemer-2. Er werd geconcludeerd dat de beoordeling van de labiale 
capillairdichtheid en capillairtortuositeit met SDF, als parameters van de microcirculatie, 
haalbaar en reproduceerbaar lijkt.
In Hoofdstuk 13 werden de parameters van de labiale microcirculatie bij patiënten met 
type 1 - en type 2 diabetes in vergelijking met gezonde controles bestudeerd. Zowel 
type 1 - als type 2 diabetes bleken geassocieerd te zijn met verhoogde capillairdichtheid 
en capillairtortuositeit. Het tweede deel van de studie werd uitgevoerd bij in de 
subpopulatie van patiënten met diabetes. De relatie tussen CAD met de parameters 
van de microcirculatie bij diabetespatiënten werd onderzocht. Bij diabetespatiënten 
bleek de gemiddelde capillairdichtheid een onafhankelijke voorspeller van zowel 
verhoogde CAC score (P=0,03) als obstructief CAD op CTA (P = 0.01). Op basis van een 
capillairdichtheid cut-off waarde van 24,9 (per 0.63 mm2) werden negatief voorspellende 
waarden van respectievelijk 84% en 89% berekend voor een verhoogde CAC score en 
voor obstructief CAD. Ook bleek de capillairtortuositeit een onafhankelijke voorspeller 
voor verhoogde CAC (P = 0.01) en obstructief CAD (P = 0.04). Deze waarnemingen 
suggereren dat analyse van de labiale microcirculatie parameters met behulp van SDF 
een potentieel klinisch toepasbaar instrument vormt voor het in schatten van vasculaire 
morbiditeit bij patiënten met diabetes.
ConClusIEs
De primaire doelstelling van het proefschrift was om verschillende technieken en 
strategieën voor risicostratificatie van CAD bij asymptomatische patiënten met diabetes 
te evalueren en te vergelijken.
De pathofysiologische weg van overgewicht naar CAD bij diabetespatiënten is niet 
volledig begrepen. De verschillende markers van centrale adipositas lijken echter een 
relatie te tonen met de uitgebreidheid van CAD. Een verhoogde epicardiaal vetweefsel 
volume toont dan ook een predispositie voor CAD. Daarnaast toont het vetweefsel 
product adiponectine juist een omgekeerd evenredig relatie met de aanwezigheid en de 
mate van CAD in type 2 diabetes. Een beter begrip en toepassing van dergelijke markers 
zou het herkennen van een hoogrisico diabetespatiënt in een vroeg stadium en vóór 
aanvang van vaatziekte mogelijk kunnen maken.
Endotheeldysfunctie lijkt al in een vroeg stadium van vaatziekte plaats te vinden. De 
daaruit voortvloeiende ontoereikende vasomotorische respons in de microvasculatuur 
kan resulteren in relatieve hypoperfusie. Bij diabetespatiënten lijken derhalve in 
afwezigheid van obstructief CAD myocard perfusiedefecten waargenomen te worden 
als gevolg van endotheeldysfunctie. Eerdere follow-up studies bij diabetespatiënten 
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hebben dan ook herstel van myocard perfusie defecten aangetoond na behandeling 
met medicamenteuze anti-atherogene therapie. Anderzijds kan persisterende 
hypoperfusie ook tot morfologische veranderingen leiden die gekenmerkt worden door 
proliferatieve neovascularisatie en vervorming van de microvasculaire patroon. De SDF 
beeldvorming is gevalideerd voor de niet-invasieve evaluatie van deze eigenschappen 
van de microvasculatuur. Toepassing van deze nieuwe techniek blijkt haalbaar en 
reproduceerbaar voor de beoordeling van capillaire dichtheid en tortuositeit als 
kenmerken van microvasculaire aantasting. Bovendien wordt de aanwezigheid van 
microvasculaire kenmerken zoals beoordeeld door SDF geassocieerd met CAD bij 
asymptomatische diabetes patiënten.
Bij diabetische patiënten met atherosclerose kan CTA de uitgebreidheid, de ernst en 
samenstelling van atherosclerotische laesies in de coronairen definiëren. Wegens 
verschillen in pathofysiologie en risicoprofiel, verschilt ook de aard van CAD zoals 
beoordeeld door CTA in type 1 - en type 2 diabetes. Een relatief groot aandeel van 
CAD bestaat uit gecalcificeerde plaques bij type 1 diabetes. Hierdoor lijkt evaluatie 
middels CAC score de superieure strategie om de aanwezigheid van ernstige CAD 
bij asymptomatische patiënten met type 1 diabetes uit te sluiten. Een CAC score 
verrichting heeft dan ook incrementele waarde over klinische risicofactoren voor het 
voorspellen van ernstige CAD bij type 1 diabetes. Bij type 2 diabetes is een hogere 
plaque last waargenomen voor elke CAC score categorie. Een lage CAC score sluit van 
de aanwezigheid van ernstig CAD gepaard met abnormale myocardperfusie ook bij 
type 2 diabetes uit. Evenwel presteert risicostratificatie met behulp van de niet-invasieve 
en stralingsvrije CIMT even goed in het voorspellen van ernstige CAD gepaard met 
abnormale myocardperfusie bij type 2 diabetes.
Een sequentiële aanpak bestaande uit CIMT of CAC score als een eerste stap, gevolgd door 
verdere diagnostische beeldvorming op indicatie, kan zorgen voor de meest haalbare 
en kosteneffectieve aanpak voor risicostratificatie van CAD bij asymptomatische 
patiënten met diabetes. Daardoor zou een meer patiënt gerichte benadering kunnen 
worden bereikt in het beheer van patiëntenzorg. Prospectieve follow-up trials voor het 
beoordelen van de klinische uitkomst en de kosteneffectiviteit van dergelijke algoritmen 
zijn noodzakelijk om de rol van niet-invasieve vasculaire instrumenten en cardiale 
beeldvormingstechnieken in het kader van behandeling van patiënten met diabetes 
verder te definiëren.
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